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Before the discovery of antibiotics, bacterial infections were a major cause of 
human death and suffering. The latter half of the 20th saw the the ‘Golden Era’ of 
antibiotic discovery, where a large number of new drugs were introduced for routine 
clinical use, leading to countless lives saved. However, the widespread use (and misuse) 
of antibiotics has led to an alarming increase in human pathogenic bacteria that have 
become resistant to many, and in some cases all, antibiotic treatments. Antimicrobial 
resistance (AMR) is now widely recognised as one of the preeminent challenges facing 
humanity in the 21st century. Central to our ability to counter AMR is the discovery and 
development of new antibiotic compounds that act via novel molecular mechanisms. 
This PhD thesis describes synthetic and medicinal chemistry studies into some new 
classes of antibacterials that show promising activity against the human pathogens 
Staphylococcus aureus (Thesis Part A; Chapters 1-4) and Mycobacterium tuberculosis 
(Thesis Part B; Chapters 5-7). 
	
Summary of HMPC 1 analogues targeted for structure-activity studies as anti-MRSA 
agents. 
 
High-throughput screening conducted by collaborators at Brown University 
(Rhode Is., USA) identified several new chemotypes that are able to rescue 
Caenorhabditis elegans worms from a methicillin-resistant S. aureus (MRSA) infection. 
 vii 
One of the hit compounds, 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate 
(HMPC) 1, was the focus of my studies, which aimed to understand the structural 
requirements for anti-MRSA activity (Chapter 2). Three key areas of the molecule were 
investigated: (1) the carbodithioate appendage, (2) the pyrazole-N-aryl substituent and 
(3) the group attached at the pyrazole 3-position. A combination of new and established 
literature chemistry was used to create a diverse library of analogues carrying structural 
variations at these positions. Key conclusions were that the carbodithioate moiety is 
essential for activity and that eukaryotic cell cytotoxicity will be a challenge to the 
development of a new drug from this class. Mechanism of action studies carried out by 
collaborators with HMPC 1 revealed a central role for MgrA, an oxidation-sensing 
protein used by MRSA to counter challenges of reactive oxygen and nitrogen species. 
 A second hit compound from the C. elegans/MRSA screening program was 3-
(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC 15). Chapter 3 explored some 
preliminary structure-activity questions around the anti-MRSA activity of PSPC 15. 
Sulfide and sulfoxide analogues of 15 were synthesised and shown to have vastly 
differing activities, thus supporting the likely involvement of discrete molecular 
target(s) in MRSA (and other Gram-positive bacteria) rather than a non-specific 
mechanism of action for the class. The findings support more detailed structure-activity 
explorations with this interesting class of low molecular weight antibacterials. 
 
Summary of 6-substituted amiloride analogues targeted for structure-activity studies as 
anti-tuberculosis agents. 
 
 With the increasing global incidence of multidrug-resistant (MDR) and totally 
drug-resistant (TDR) tuberculosis (TB,) there is an urgent need to identify new drugs 
 viii 
against this major human pathogen. Part B of the thesis explored the synthesis and 
structure-activity relationships of 6-substituted amiloride derivatives as anti-TB agents. 
Preliminary screening efforts carried out by Prof Gregory Cook (University of Otago, 
NZ) identified 6-benzofuran-2-yl amiloride (HM2-16F 20) as showing potent activity 
(minimum inhibitory concentration 4 µM) against TB. Based on this early lead, new 
Suzuki-Miyaura coupling chemistry was developed to access a series of derivatives that 
replaced the benzofuran with other aromatic heterocycles. None of these compounds we 
found to show improved activity against TB. A series of substituted benzofuran 
analogues were next prepared using analagous Suzuki-Miyaura chemistry, however, 
substitution was found to reduce activity. Finally, new Sonogashira-tandem benzofuran 
cyclisation chemistry was developed to provide access to additional substituted 
benzofuran analogues. Unfortunately, these compounds also showed lower activity than 
the parent HM2-16F 20. 
In summary, my PhD studies led to the discovery and implementation of novel 
chemistry that enabled access to many new analogues of lead antibacterials against 
MRSA and TB. The insights gained from the work have contributed to a better 
understanding of the structural requirements for activity within these classes and will be 
used to guide future drug development efforts. 
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1.1 History of methicillin resistant Staphylococcus aureus (MRSA) infections 
Staphylococcus aureus is a highly adaptive Gram-positive bacterial pathogen 
and the causative agent of a variety of serious infections, including bacteraemia, 
endocarditis, pneumonia and osteomyelitis.2 In 1878, Robert Koch was the first to 
discover that multiple diseases are caused by S. aureus. Alexander Ogston was to later 
discover that S. aureus is responsible for intra-abdominal sepsis and abscesses.3 Before 
the introduction of penicillin, S. aureus was a significant cause of mortality, with more 
than 80% of patients with S. aureus bacteremia dying. The use of penicillin eliminated 
many deaths by this organism but it wasn’t long before strains were identified that 
exhibited resistance to the drug. This led to creation of modified derivatives, including 
methicillin and oxacillin. However, in 1961 and only a year after its introduction, the 
first methicillin-resistant Staphylococuus aureus (MRSA) strains started to emerge.4,5  
The incidence of MRSA infections has increased significantly over the past few 
decades, especially in the USA.6 In 1968, many deaths occurred in patients infected 
with S. aureus at Boston City Hospital and long-term care facilities in Massachusetts. 
According to a report from the National Nosocomial Infections Surveillance System 
(NNISS), MRSA infections increased in large U.S. hospitals from 4% in the 1980s to 
50% in the1990s. In some hospitals, MRSA accounted for up to 80% of all S. aureus 
infections.7,8 In the past few decades, MRSA infections outside of healthcare settings, 
known as community-associated MRSA (CA-MRSA),9 have been on the rise. In 2005 it 
was estimated that more than one million people worldwide were infected per year with 
MRSA.10 Compared to infections caused by methicillin susceptible S. aureus (MSSA), 
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MRSA infections are more difficult to treat, lead to increased rates of morbidity and 
mortality and can greatly increase medical costs.4       
 
1.2 Risk factors 
1.2.1 Healthcare-associated MRSA (HA-MRSA) infections   
When MRSA initially emerged it was considered a nosocomial pathogen that 
only infected people exposed to healthcare facilities and patients with other risk factors, 
such as drug abuse.11 This type of MRSA, later named HA-MRSA, is now a major 
pathogen that has spread across the globe and holds a strong prevalence in North and 
South America, Europe and Asia.12 The Centres for Disease Control and Prevention 
(CDC) estimated that the number of HA-MRSA infections in U.S hospitals increased 
from 2.4% in 1975 to 29% in 1991 and to 64% (1.7 million people) in 2002.9  
 
1.2.2 Community-associated MRSA (CA-MRSA) infections 
From when MRSA emerged in 1961 through until the 1990’s, MRSA infections 
were thought to be rare outside of healthcare facilities.5 However, upon closer scrutiny, 
MRSA infections that had been acquired from outside hospital environments, so-called 
community-associated MRSA, were identified in both paediatric and adult 
populations.13,14 The first confirmed cases of CA-MRSA in Australia involved 
individuals who developed infections despite having no exposure to healthcare facilities 
or other risk factors.15 CA-MRSA infections were described in two reports in the USA 
from Children’s hospitals, where several children who had no prior exposure to 
healthcare facilitates were treated for bloodstream infections.16,17 CA-MRSA has been 
noted as the cause of morbidity in Australian aboriginal communities, USA, New 
Zealand, Malaysia and elsewhere. The most at-risk groups are military personnel, 
 4 
prisoners, athletes and intravenous drug users. One common factor risk linked to the 
disease is poor hand hygiene.18  
Fundamental differences exist between HA-MRSA and CA-MRSA genetics that 
impact risk factors and prevalence. The main genetic differences involve the 
staphylococcal chromosomal cassette mec (SCCmec).11 HA-MRSA strains can carry the 
mecA gene on the larger SCCmec types I, II, or III, while CA-MRSA strains can carry 
SCCmec types harbouring resistance to classes of antibiotics other than β-lactams (i.e. 
penicillins, cephalosporins and carbapenems).11,12 
 
1.3 Antibiotic treatment of MRSA infections 
There are four principal classes of β-lactam antibiotics: penicillins, 
cephalosporins, carbapenems and monobactams.19 Due to the high incidence of 
resistance, the effectiveness of β-lactams for treating MRSA infections has been 
declining. The non- β-lactam antibiotic vancomycin was introduced for MRSA 
treatment in 1958 and although it has been used for over 50 years, controversies still 
exist around how best to use it. The drug is routinely given to patients with active 
MRSA as only a few MRSA isolates in the USA have been confirmed as resistant.20 
Vancomycin is not always the most appropriate treatment as the drug has several 
important limitations; for example, it is not bactericidal, it does not penetrate well into 
lung tissues and it can sometimes cause serious adverse effects, including 
nephrotoxicity and red man syndrome.21 
Telavancin is a semi-synthetic derivative of vancomycin that shares a similar 
mode of action, i.e. inhibition of cell wall synthesis,22 but is additionally capable of 
depolarizing bacterial membranes and disrupting barrier function. Telavancin is 
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Figure 1.1 Chemical structures of vancomycin, linezolid, daptomycin and tigecycline. 
  
Linezolid is sometimes used in the treatment of MRSA infections and works via 
a mechanism that involves inhibition of protein synthesis through binding to bacterial 
50S ribosomes. Linezolid achieves high concentrations in the lung epithelium, making it 
suitable for treating MRSA respiratory infections.24 Linezolid was compared to 
vancomycin in a randomized study in 1,184 patients with hospital-associated MRSA 
pneumonia. Clinical success was observed with linezolid but mortality rates were 
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similar for the two drugs.25 Nephrotoxicity was observed at nearly twice the rate among 
patients treated with vancomycin (18.2%) compared to linezolid (8.4%).25  
Daptomycin is a cyclic lipopeptide antibiotic that acts to disrupt cell membrane 
function via calcium-dependent binding, leading to inhibition of bacterial protein 
synthesis. It is active against both methicillin- and vancomycin-resistant staphylococci26 
and is indicated for use in the treatment of chronic MRSA infections, except 
pneumonia, due to its effects on the respiratory system.27 The drug is bactericidal at 
high concentrations but can induce myopathy at high doses.28 Recent studies showed 
that optimal dosing of daptomycin requires further evaluation in order to limit adverse 
effects.29 
Tigecycline is indicated for the treatment of complicated skin and skin structure 
infections and for intra-abdominal infections. Its mode of action involves inhibition of 
protein synthesis.30 The drug was originally considered effective for the treatment of 
serious MRSA infections,30  however, analysis of 7400 patients in clinical trials 
indicated a higher risk of mortality with serious infections. This led to a warning by the 
US FDA that recommended use of alternative agents.31 
Tetracyclines are similar in structure to tigecycline and include doxycycline and 
minocycline derivatives, which function as bacteriostatic agents by inhibiting protein 
synthesis.32 Minocycline appears to be better than other tetracyclines for overcoming 
resistance mechanisms of MRSA due to its longer half-life and better absorption.32 In 
addition, minocycline is more active against MRSA isolates in biofilms compared to 
vancomycin, daptomycin, linezolid and tigecycline.32 Several other antibiotics have 
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1.4 Discovery of Propyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-
carbodithioate (HMPC) as a new antibacterial with a novel mechanism of action 
against MRSA 
 The growing resistance of the major human pathogen S. aureus to many 
antibiotics (vancomycin, and more recently daptomycin and linezolid) has led to this 
organism being placed on the World Health Organization’s (WHO) list of high priority 
antibiotic-resistant bacteria for which there is an urgent need to develop effective new 
therapeutics.46 The following sections describe the discovery and properties of propyl 5-
hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) 1 (Figure 1.2), a 
new lead antibacterial against S. aureus that appears to act via a novel mechanism. This 
discovery was made in a collaboration between the laboratories of Associate Professor 
Michael Kelso at the University of Wollongong, Australia and Professor Eleftherios 
Mylonakis at Brown University (Providence, Rhode Island, USA). All data presented 
below were produced by the Mylonakis Lab and Professor Mike Gilmore’s Lab at the 
Harvard Medical School (Boston, Massachusetts, USA). 
 
 
Figure 1.2 Structure of propyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-
carbodithioate (HMPC) 1, a new lead antibacterial against MRSA. 
 
1.4.1 Antibacterial activity of HMPC 1 against MRSA 
Screening of the Maybridge 5 Library (Maybridge, Thermo Fisher Scientific) 
identified HMPC 1 as showing direct antibacterial activity against S. aureus MW2 (a 
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lab strain of MRSA) (Minimum inhibitory concentration: MIC = 4 µg/mL)47 and an 
ability to rescue  Caenorhabditis elegans from S. aureus MW2 infection.48-51 The 
fraction of C. elegans worms that survived an infection in the presence of HMPC 1 
ranged between 93-100%, compared to 40% for untreated controls (Figure 1.3). HMPC 
1 appeared not to affect the viability of C. elegans at the test concentration (7 µg/mL). 
The compound was subsequently shown to be equipotent across a panel of recent 
clinical MRSA isolates from the Mylonakis Laboratory collection, with all tested 
isolates displaying MIC = 4 µg/mL (Table 1.2). 
 
 
Figure 1.3 HMPC 1 rescues C. elegans from MRSA infection. A 384-well assay plate 
was co-inoculated with C. elegans, S. aureus MW2 and either 7 µg/mL HMPC (A), 10 
µg/mL vancomycin (B, positive control), or 1% DMSO vehicle (C, negative control; 
40% survival). Representative Sytox Orange-stained (right) and bright field (left) 




Table 1.2 Activity (MIC) of HMPC 1 against six MRSA clinical isolates. MIC values 









BFSA25 4 32 2 
BFSA30 4 32 1 
BFSA31 4 64 2 
BFSA32 4 64 2 
BFSA33 4 64 2 
BFSA48 4 >64 1 
 
The spectrum of activity of HMPC 1 was evaluated against a panel of ESKAPE 
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).52,53 In 
addition to S. aureus, HMPC 1 was active against Enterococcus faecium (MIC = 16 
µg/mL) but the compound showed no activity against any Gram-negative strains (Table 
1.3). 
 
Table 1.3 Activity of HMPC 1 against a panel of ESKAPE pathogens. MIC values for 
control antibiotics vancomycin (Gram-positive) and gentamicin (Gram-negative) are 
included for comparison. 






Enterococcus faecium E007 16 1-2  
Staphylococcus aureus MW2 4 1  
Klebsiella pneumoniae WGLW2 > 64  0.5 
Acinetobacter baumannii ATCC > 64  1 
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17978 
Pseudomonas aeruginosa PA14 > 64  2-4 
Enterobacter aerogenes Hormaeche 
and Edwards ATCC 13048 
> 64  1 
 
Growth curves of S. aureus MW2 in the presence of HMPC 1 indicated that the 
compound inhibits growth in a concentration-dependent manner over the range 1-4 
µg/mL (Figure 1.4(A)). Time-kill assays using a higher concentration of HMPC 1 (16 
µg/mL, 4x MIC) comparing its killing kinetics to daptomycin (Figure 1.4(B)) showed 
that HMPC 1 does not cause a reduction in bacterial viability until eight hours post-
treatment, in contrast to the rapidly bactericidal daptomycin, indicating that the 










Figure 1.4 (A) S. aureus MW2 growth inhibition in the presence of 1-4 µg/mL HMPC 
1. (B) Time-kill assay comparing HMPC 1 (16 µg/mL; 4x MIC) and daptomycin (DAP; 
10 µg/mL). 
 
1.4.2 Screening of a S. aureus promoter-lux clone array   
Antibiotic-activated promoter-lux clone arrays in S. aureus provide 
characteristic transcriptional activation light signatures that can be used to classify 
antibiotic classes based on their mechanism(s) of action.54 A promoter-lux array was 
screened to investigate whether HMPC 1 induces transcriptional changes in S. aureus 
similar to known antibiotics. HMPC 1 was shown to activate promoter-lux clones C, E, 
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F, G, K, L and M (Figure 1.5(A)), which represents a unique profile bearing some 
similarities to DNA-damaging agents and/or DNA replication inhibitors.54,55  
 
 
Figure 1.5 (A) Response of S. aureus promoter-lux array to HMPC 1 exposure. The 
name of each reporter clone is shown in the upper left corner of each picture. A clear 
zone around the disc indicates inhibition of growth in the presence of higher 
concentrations of HMPC 1. At the periphery of the inhibition zone where sub-MIC 
levels of HMPC 1 are present, changes in luminescence indicate altered transcription. 
The disc on the left of each panel is HMPC 1 and on the right DMSO (vehicle control). 
(B) Zones of S. aureus growth inhibition produced by HMPC 1 in the presence/absence 
of calf thymus DNA. (C) Disc diffusion assay with varying concentrations of HMPC 1 
in the presence/absence of S. aureus genomic DNA. 
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With the above evidence suggesting DNA binding might be a contributor to the 
HMPC 1 mechanism, the compound was tested to see whether it interacts directly with 
DNA. First, the UV visible spectrum of HMPC 1 was recorded in the presence/absence 
of excess calf thymus DNA. No DNA hyperchroism or hypochromism was observed, 
nor were shifts in the positions of absorption bands in the region 290-360 nm (data not 
shown), suggesting that HMPC 1 does not bind to eukaryotic DNA. Support for this 
conclusion was obtained by measuring zones of S. aureus growth inhibition produced 
by different concentrations of the compound in the presence/absence of calf thymus 
DNA (Figure 1.5(B)). Only insignificant (3 mm) reductions were observed, further 
supporting that HMPC 1 does not bind to eukaryotic DNA. 
To test whether the compound binds to S. aureus DNA, disc diffusion assays 
were conducted using varying concentrations of HMPC 1 with/without S. aureus MW2 
genomic DNA present (Figure 1.5(C)). No significant decreases in zones were observed 
across all HMPC 1 concentrations. Finally, electrophoretic mobility shift assays 
(EMSA) on S. aureus genomic DNA incubated with HMPC 1 did not show any 
evidence of direct DNA binding (Figure 1.6). The above findings, together with the 
unique promoter-lux profile, indicate that DNA is not the target of HMPC 1 and that the 
compound appears as the prototypical member of a new antibacterial class that acts via 




Figure 1.6 Electrophoretic mobility shift assay showing no binding of HMPC 1 to S. 
aureus MW2 genomic DNA.  
 
1.4.3 Isolation and whole-genome sequencing of S. aureus mutants resistant to 
HMPC 
Single-step resistance selection where S. aureus MW2 was plated onto agar 
containing 2x and 4x MIC concentrations of HMPC 1 yielded no resistant bacteria (data 
not shown). Sequential passaging in liquid medium with increasing concentrations of 
HMPC, however, allowed isolation of low-level resistant mutants.56 Mutant populations 

































independent resistance selections were conducted and whole genome sequences 
obtained from the controls and mutants showing MIC 8 or 16 µg/mL (a total of 9 
populations were sequenced). A summary of the mutations observed in the resistant 
clones is provided in Table 1.4. 
 











1      8 731157 MNV 17 MgrA 46.8 G108fs 
  
731244 SNV 1 MgrA 51.9 R84H 
        
2      8 731332 SNV 1 MgrA 100 V55F 
        
3      8 731158 Deletion 12 MgrA 52.9 L109del4 
  
731283 SNV 1 MgrA 28.9 P71N 
  
731470 SNV 1 MgrA 10.5 E9* 
        
1 16 731244 SNV 1 MgrA 100 R84H 
  
1366975 Deletion 4 FmtC 93.5 I461fs 
        
2 16 731295 SNV 1 MgrA 20.9 G67A 
  
731332 SNV 1 MgrA 77.4 V55F 
  
1366139 Deletion 7 FmtC 28 I181fs 
        
3 16 731283 SNV 1 MgrA 100 P71N 
  





1366760 Deletion 684 FmtC 100 N386del228 
aMNV, Multi-nucleotide variant; SNV, Single Nucleotide Variant; bfs, frame-shift; 
*stop codon 
 
Analysis of high-frequency mutations identified two genes that were repeatedly 
and independently mutated across multiple selections: (1) the transcriptional regulator 
mgrA (MW0648) and (2) phosphatidylglycerol lysyltransferase fmtC/mprF (MW1247). 
Close analysis of low-frequency mutants in all selected strains revealed additional 
mutations in both mgrA and fmtC (Table 1.4). One strain also acquired a mutation in a 
hypothetical protein (MW0910) containing a YdiL-like membrane protease domain. 
Experiments next looked at how the observed mutations might impact HMPC 1 
activity and resistance. The most often mutated gene, mgrA, is a transcriptional 
regulator master switch that controls expression of a large number of S. aureus 
genes.57,58 The dominant mutations were all located within the winged helix DNA-
binding domain of the MgrA protein (Val55Phe is at the start of a-helix 3, Pro71Gln is 
at the start of a-helix 4 and Arg84His is in a b-strand of the wing region (PDB: 2PV6) 
(Figure 1.7). Two resistant mutants contained a single mutation in mgrA, while the 
remaining strains carried subpopulations of different mutants, all of which would be 
predicted to disrupt protein function based on their location within the protein (Figure 
1.7 and Table 1.4). 
To test whether MgrA disruption directly impacts susceptibility to HMPC 1, two 
S. aureus MW2 mutants lacking a functional mgrA (AH3456 and AH4322) were tested 
for susceptibility.59,60 No difference in the MIC was observed in either mutant relative 
to the wild type MW2 strain AH843 but both mutants were able to grow to higher cell 




Figure 1.7 HMPC 1 resistance-associated mutations in MgrA mapped to the DNA-
binding domain. The MgrA dimer (PDB: 2BV6) is shown with the two equivalent 
subunits coloured light blue and white/grey. Missense variants at Val55, Pro71, and 
Arg84 (shown in red) all mapped to the winged-helix DNA-binding domain (left, 
bottom half), including the DNA recognition helix. 
 
All three HMPC-resistant populations developed mutations in the 
phosphatidylglycerol lysyltransferase fmtC/mprF (MW1247) gene and these mutations 
correlated with higher resistance to the compound (MIC=16µg/mL; Table 1.4). No fmtC 
deletion mutant existed in the MW2 strain background, but a readily available fmtC 
mutant strain was found in the Nebraska Transposon Mutant Library (NTML, mutant 
NE1360, SAUSA300_1255). The fmtC transposon mutant showed a 2-fold increase in 
MIC towards HMPC 1 compared to the wild type USA300 JE2 strain (MIC = 4 µg/mL). 
One resistant mutant also carried a mutation in MW0910, a hypothetical protein that 
contains a domain similar to the YdiL membrane protease. The corresponding NTML 
mutant (NE841, SAUSA300_0932) showed no change in MIC compared to the wild 
type (MIC = 4 µg/mL). 
The changes that occur in the transcriptional profile of S. aureus upon 
inactivation or overexpression of MgrA are well characterized.58 As a transcriptional 
regulator, MgrA can mediate autolysis in S. aureus.61,62 Testing of MgrA mutants for 
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autolytic activity showed that the Val55Phe mutant behaved similarly to the wild type, 
whereas the Arg84His mutant showed increased sensitivity to treatment with Triton X-
100 but was less sensitive than the mgrA null mutants (Data not shown). 
 
1.4.4 Mammalian cell toxicity assays 
Hemolysis assays with human red blood cells were performed as a preliminary 
assessment of the selectivity of HMPC 1 for bacterial cells over mammalian cells. No 
hemolytic activity was observed over the concentration range 0.125-64 µg/mL (Figure 
1.8(A)). Cytotoxicity testing of HMPC 1 in HKC-8 kidney cells (Figure 1.8(B)) 
revealed that the compound produced a ~50% reduction in cell viability at 
concentrations close to its MIC against S. aureus MW2. HepG2 liver cells were less 
sensitive, showing 94% survival at 4 µg/mL and approximately 50% survival at 16 




Figure 1.8 (A) Hemolytic activity of HMPC 1. (B) Cytotoxicity of HMPC 1 towards 
HKC-8 cells.  (C) Cytotoxicity of HMPC 1 towards HepG2 cells. 
 
1.4.5 Overview and Summary of Thesis Aims for Part A 
New antibiotics are urgently needed to combat the growing threat posed by 
multidrug-resistant strains of S. aureus. HMPC 1 was identified by our collaborators as 
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a novel antibacterial that inhibits S. aureus growth and is capable of rescuing C. elegans 
from an MRSA infection.48 Screening of a promoter-lux array revealed a novel 
transcriptional activation profile for the compound, where it activated promoter-lux 
clones C, E, F, G, K, L and M. While unique, this profile did show some overlap with 
DNA-damaging agents (i.e. overlapping activation of C, E, F, K, L, M and non-
activation of J) and/or DNA replication inhibitors (overlapping activation of C, G, K, L, 
M and non-activation of J). This observation led to testing of whether HMPC 1 directly 
binds to DNA. However, binding to calf thymus DNA or genomic DNA from S. aureus 
MW2 was shown to not occur by UV-visible spectroscopy, disc diffusion assays and 
electrophoretic mobility shift assays. The promoter-lux clones C, and E and to a lesser 
extent clone F, all of which were activated by HMPC, encode recA-lux. A recA mutant 
strain show altered susceptibility to HMPC 1, however, the MIC remained unchanged 
(MIC = 4 µg/mL) against the S. aureus JE2 strain and isogenic mutant lacking a 
functional RecA protein (NTML, NE805, SAUSA300_1178).63,64 The absence of a 
difference in MIC suggests that the SOS response being produced is not due to DNA 
damage but is triggered by a different stressor. It is known, for example, that β-lactam 
antibiotics trigger SOS responses by compromising the integrity of bacterial 
membranes, and that SOS induction promotes the appearance of mutations needed for 
development of resistance.65  
Sub-MIC concentrations of HMPC 1 were shown to increase the frequency of 
spontaneous mutations that give rise to rifampicin resistance, however, no difference 
was observed between HMPC-treated and untreated bacteria (0.309´1011 untreated 
versus 0.324´1011 treated). Therefore, despite its lux-array profile showing some 
similarities to DNA-damaging and SOS-inducing agents, HMPC 1 appears to act via a 
distinct mechanism(s). 
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Whole-genome sequencing of HMPC-resistant mutants identified two genes that 
mutated in response to HMPC 1: the transcriptional regulator mgrA (MW0648) and the 
phosphatidylglycerol lysyltransferase fmtC/mprF (MW1247). MgrA is a global 
transcription regulator that belongs to the MarR (multiple antibiotic resistance 
regulator)/SarA (staphylococcal accessory regulator A) family of proteins, which 
respond to various environmental stressors and play a key role in the development of 
drug resistance.66-70 MgrA affects the expression of approximately 350 genes that 
control multiple properties of S. aureus, including expression of virulence factors, 
regulation of autolysis and antibiotic resistance, as well as other global regulatory 
genes.57,58,61,71-73 MgrA also regulates the multidrug-resistance (MDR) efflux pumps 
NorA, NorB and NorC, the non-MDR efflux pump Tet38 and the ABC transporter 
AbcA in S. aureus. These pumps typically provide the first line of bacterial defense 
against antibiotics until more efficient resistance mechanisms emerge.74,75 MIC assays 
conducted in the presence of the efflux pump inhibitor thioridazine74,76 showed no 
difference in S. aureus susceptibility to HMPC 1, suggesting that drug efflux is not a 
major contributor to HMPC resistance. 
Clues as to the molecular consequences of the MgrA mutations that emerged in 
the HMPC-resistant populations were obtained by assessing their location in the 
protein’s reported X-ray crystal structure.77 The Val55Phe and Arg84His variants 
clearly introduce steric clashes in the ß-strands near wing 1, a DNA-binding region of 
the canonical winged-helix domain, which could not be accommodated without 
changing the overall protein structure (Figure 1.7). The Pro71Gln mutation mapped to 
the beginning of DNA-recognition helix 4, which would cause an extension of the helix 
and alter the structure of the DNA-binding domain. It is predicted that the resistance-
associated mutations identified would affect the DNA-binding winged-helix domain and 
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thus alter the affinity of MgrA for specific DNA-binding sites, leading to transcriptional 
changes in resistant bacteria. The precise nature of these transcriptional changes remains 
to be identified. 
Based on the above studies, it was concluded that mutations in MgrA alter the 
expression of MgrA-regulated genes in response to HMPC 1, leading to adaptive 
responses that affect the susceptibility of S. aureus and allow other more stable 
resistance mutations to appear. This was supported by the appearance of secondary 
mutations in fmtC (MW1247) during the course of the resistance selection experiment. 
FmtC, also referred to as multiple peptide resistance factor (MprF),78 catalyzes 
formation of lysyl-phosphatidylglycerol during lipid biosynthesis, a modification that 
increases cell surface positive charge and confers protection against cationic 
antimicrobials.79-83 It has been suggested that MprF plays a biophysical role in 
membrane stability and organization and that this can modify S. aureus susceptibility to 
antibiotics.80,84 A change in membrane organization that reduces HMPC 1 entry into 
cells would explain the increased resistance observed in the S. aureus JE2 fmtC mutant 
strain. 
Neither of the resistance-associated genes identified in the above resistance 
studies is likely to be the cellular target of HMPC 1. Thus, while the mechanism of 
action of HMPC 1 remains unknown, it appears that the compound acts on targets 
within S. aureus cells to induce a stress response that can be mitigated by transcription 
changes driven by mutations in MgrA. These changes are followed by a rise in more 
specific mutations affecting the cell membrane and possibly entry of HMPC 1 into S. 
aureus cells.  
The overarching aim of Chapter 2 was to use synthetic organic and medicinal 
chemistry to explore structure-activity relationships (SAR) around analogues of HMPC 
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1 as anti-MRSA agents, with the goal of identifying more potent compounds that also 
show lower activity against eukaryotic cells (i.e. higher bacterial selectivity). Three 
main areas of the molecule to be were explored: (1) the carbodithioate and its alkyl 
substituent R1, (2) the N-phenyl group on the pyrazole (R2) and (3) the substituent at the 
pyrazole C3 position (R3).  
 
 

















Synthesis and structure-activity relationships of 
HMPC 1 analogues as antibacterials against 
MRSA 
 
2.1 Synthetic strategy overview 
The major goal of this chapter was to use organic synthesis to systematically 
explore the structural requirements for anti-MRSA activity and reduced eukaryotic cell 
cytotoxicity within 5-hydroxypyrazole-4-carbodithioates, the class to which HMPC 1 
belongs. The general synthetic strategy towards HMPC 1 analogues involved first 
preparing N-aryl-pyrazoline-5-one precursors and then reacting them with carbon 
disulfide and an appropriate alkyl halide. There are several procedures reported for the 
formation of 5-hydroxypyrazole-4-carbodithioates in this way that employ various bases 
(e.g. alkoxides, lithium diisopropylamide (LDA), and n-butyllithium), depending on the 
pKa of the pyrazoline-5-one active methylene group.19 The methods generally involve 
generating stabilised ketone enolates and then reacting these with electrophilic carbon 
disulfide. Quenching of the intermediate carbodithioate anion with the appropriate alkyl 
halide then installs the alkyl chain. The final compounds tend to exist almost 
exclusively in the aromatic 5-hydroxypyrazole form as opposed to the a-substituted 
pyrazoline-5-one tautomer (Scheme 2.1).85 
 
Scheme 2.1 General strategy for the synthesis of HMPC 1 analogues. 
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2.2 Replacement of the 4-carbodithioate group of HMPC 1: Analogues 2-6 
Initial efforts focused on establishing the importance of the 4-carbodithioate 
function for activity against MRSA. Target analogues sought to replace the 4-
carbodithioate group with amide, thioamide or ester isosteres and other functionality. 
The chemistry used in the synthesis of these analogues is summarised in Scheme 2.2. 
 
 
Scheme 2.2 Summary of chemistry used to synthesise HMPC 1 analogues that replaced 
the 4-carbodithioate group. Reagents and conditions: a. K2CO3, n-propyl isocyanate, 
DMF/benzene, rt, 59%; b. K2CO3, n-propyl isothiocyanate, DMF/benzene, 50 °C, 83% 
c. K2CO3, CS2, CH3I, DMF/benzene, 0 °C, 66%; d. n-BuLi, CS2, n-bromopropane, 
THF, 0-25 °C, 52%,85 e. Na(s), n-PrOH, 80 °C, 90%;86 f. K2CO3, CH3I, DMF 0-25 °C, 
90%. 
 
 At the outset of the study, HMPC 1 was resynthesized to confirm that an 
independently prepared sample shows the same activity against MRSA as the 
commercially acquired material tested previously by our collaborators at Brown 
University. HMPC 1 was synthesized by a-deprotonation of the commercially available 
N-phenyl-3-methylpyrazolin-5-one 7 with n-butyllithium in THF at 0 oC. Quenching the 
enolate with carbon disulfide and adding n-bromopropane to alkylate the carbodithioate 
anion gave 1 in 52% yield. This procedure was based on the method reported by 
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Maurelia et al,87 who obtained 1 in 48% yield. A mechanism for the formation of 1 is 
proposed in Scheme 2.3. The re-synthesised sample of 1 was found to show identical 
activity towards MRSA (MIC 4 µg/mL) as the previously tested commercial sample. 
 
 
Scheme 2.3 Proposed mechanism for the formation of HMPC 1 from 7. 
 
Amide 2 and thioamide 3 were formed by reacting the enolate of 7, this time 
generated using K2CO3 in a DMF/benzene, with n-propyl isocyanate (1.5 eq) and n-
propyl isothiocyanate (1.5 eq), respectively. Both reactions proceeded after stirring for 
~5 h at room temperature, or by gentle heating, to give 2 and 3 in 59% and 83% yields, 
respectively (Scheme 2.2). The procedures were based on literature precedents reported 
by Cadieux et al88 and Bagdatli et al,89 who showed that reaction of related 
pyrazolinones with aryl isocyanates under a basic conditions (Et3N) gave 4-
amidopyrazoles. The latter report showed that 4-thioamidopyrazoles could be formed 
from pyrazolinones using KOH in DMF.   
The 1H NMR spectrum (CDCl3) showed a broad singlet with an integration of 
1H at 5.23 ppm for amide 2 and at 7.09 ppm (NH) for thioamide 3. This signal 
corresponded to the newly introduced amide and thioamide NH groups, respectively. 
Three signals with integration 2H (x2) and 3H were also observed, corresponding to the 
2 x methylene and one methyl group in the propyl chains. The mass spectra of 2 and 3 
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showed base peaks corresponding to the expected m/z for C14H18N3O2+ at 260.1394 and 
C14H18N3OS+ 276.1165, respectively. A likely mechanism for the formation of 2 and 3 
by the above methods is outlined in Scheme 2.4. 
 
 
Scheme 2.4 Proposed mechanism for the formation of amide 2 and thioamide 3 by 
reacting 7 with n-propyl isocyanate and n-propyl isothiocyanate, respectively. 
 
The carboxylic ester isostere 5 was obtained using the reported method.90 This 
involved first generating ketene dimethyldithioacetal 4 in 66% yield from 7 using 
K2CO3, CS2 and excess CH3I. A mechanism for this reaction is proposed in Scheme 2.5. 
 
 
Scheme 2.5 Proposed mechanism for the formation of ketene dimethyldithioacetal 4 
from 7 using excess K2CO2 and excess CH3I. 
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Ketene dimethyldithioacetal 4 was subsequently advanced to the n-propyl ester 
5 in 90% yield by alcoholysis with sodium in n-PrOH at 80 °C. A mechanism for this 
reaction is proposed in Scheme 2.6. Here, the nucleophilic sodium n-propoxide 
generated in situ attacks the electrophilic ketene dimethyldithioacetal of 4 triggering a 
conjugate addition reaction that pushes electrons into the carbonyl oxygen sink. Ensuing 
loss of the gas MeSH by conjugate elimination then gives an intermediate ketene 
thioacetal, which subsequently undergoes conjugate addition with a second equivalent 
of sodium propoxide to provide the dipropylketene acetal following elimination of a 
second equivalent of MeSH. Hydrolysis upon workup then delivers 5. 
 
 
Scheme 2.6 Proposed mechanism for the formation of n-propyl ester 5 from ketene 
dimethyldithioacetal 4 by reaction with sodium n-propoxide. 
 
In the 1H NMR spectrum of 4, the pyrazolin-5-one CH2 signal that was formerly 
present in 7 at 2.67 ppm had disappeared and was replaced by two new 3H singlets at 
2.78 and 2.71 ppm, corresponding to the ketene dithioacetal methyl groups. The 1H 
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NMR spectrum of 5 indicated the presence of a propyl group, showing two triplet 
signals at 1.03 and 4.27 ppm, corresponding to the terminal CH3 group and the CH2 
group immediately adjacent to the ester, respectively. The high-resolution mass 
spectrum of 5 showed a peak at m/z 261.1234 corresponding to the expected 
C14H17N2O3+ [M+H] molecular ion.    
Amide 2, thioamide 3, ester 5 and ketene dimethyldithioacetal intermediate 4 
were all tested by collaborators at Brown University and shown to be devoid of anti-
MRSA activity (MIC > 64 µg/mL), thus establishing the critical importance of the 4-
carbodithioate group. 
The role of the 5-OH substituent on the pyrazole ring was explored next. 
Originally the intention was to prepare the pyrazole-OMe ether of 1 to establish the 
requirement, or otherwise, of the 5-OH group for anti-MRSA activity. However, 
treatment of 1 under standard aryl-OH alkylation conditions using K2CO3 and excess 
CH3I at room temperature in DMF instead delivered the mixed methylpropyl ketene 
dithioacetal 6 in 90% yield. Formation of 6 and not the pyrazole-OMe derivative was 
supported by NMR data. Firstly, the spectrum clearly showed the peaks expected for a 
propyl group (S-CH2: 3.20 ppm, (2H, t); CH2: 1.74 ppm, (2H, m); CH3: 1.04 ppm, (3H, 
t), along with an additional 3H singlet at 2.71 ppm. Zhong P. et al91 reported that the S-
CH3 of a related pyrazole appears at δ 2.30 ppm (Scheme 2.7), while Polkam N. et al92 
reported that pyrazole-5-OCH3 groups appear at 3.62 ppm. The chemical shift of the 
CH3 group in 6 at 2.71 ppm is therefore more consistent with S-methylation rather than 
O-methylation. In addition, the 13C APT NMR spectrum of 6 showed a far downfield 
signal for a carbon that did not correlate to a proton at δ 174.3 ppm, consistent with a 
carbonyl (amide) carbon as opposed to an aromatic pyrazole C5 with an OCH3 attached. 
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A peak at m/z 307.0933 was observed in the high-resolution mass spectrum of 6 
corresponding to the expected C15H19N2OS2+ molecular ion. 
 
Scheme 2.7 Structure of an N-phenylpyrazole91 related to 6 showing that the chemical 
shift of an S-CH3 group (δ 2.30 ppm) is similar to the S-CH3 signal in 6 (δ 2.71 ppm). 
 
The preference for methylation of 1 on sulfur rather than oxygen can be 
explained using hard/soft acid base theory,86,93 where the soft alkyl iodide electrophile 
reacts preferentially with the soft sulfur nucleophile rather than the harder oxyanion. A 
mechanism for the reaction is proposed in Scheme 2.8. When tested against MRSA, 
compound 6 was found to be inactive (MIC > 128 µg/mL), thus supporting the 
importance of both the 5-OH group and the 4-carbodithioate function. 
 
 
Scheme 2.8 Proposed mechanism for the formation of mixed methylpropyl dithioketene 
acetal 6 following treatment of 1 with excess K2CO3 and methyl iodide. 
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2.3 Modifications at the n-propyl chain of HMPC 1: Analogues 8a-8f2.3.1
 Synthesis 
Replacement of the carbodithioate n-propyl chain of HMPC 1 with Me, Et, allyl, 
n-Bu, Bn and 3-pyridyl groups was explored next. These analogues were obtained by 
forming the enolate of 7 and successively quenching with CS2 and the appropriate alkyl 
iodides. The structures of the compounds were all confirmed by 1H/13C NMR, HRESI-
MS and IR spectroscopy (see Chapter 4 for experimental details). 
The procedures implemented were analogous to those employed in the synthesis 
of HMPC 1, where commercially available N-phenyl-3-methylpyrazolin-5-one 7 was 
initially deprotonated with n-butyllithium in THF at 0 oC, followed by successive 
quenching of the enolate with carbon disulfide and the requisite alkyl iodides. The 
reaction mixtures were all stirred at room temperature for 16 h and gave target 
analogues 8a-8f as yellow powders. The quantities of analogues produced (mg) and the 
individual reaction yields are provided in Table 2.1. Introduction of the Me 8a and Et 
8b groups using alkyl iodides gave excellent yields (85% and 86%, respectively), 
whereas use of alkyl bromides to get n-propyl 1 and allyl 8c derivatives gave lower 
yields (52% and 55%, respectively). Introduction of the benzyl and 3-pyridyl groups 
using benzylic bromides gave 8e and 8f in intermediate yields (77% and 60%). These 
trends suggest that alkyl halide reactivity is determining the reaction outcome. Higher 
yields might be obtainable through use of alkyl iodides in all of these reactions. An 
alternative could be to add catalytic sodium/potassium iodide or the more soluble 
tetrabutylammonium iodide to the reactions containing alkyl bromides to effect in situ 
Finkelstein conversion to the iodides. 
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Table 2.1 Synthesis of HMPC 1 analogues 8a-8f carrying variations in the 4-
carbodithioate alkyl chain. 
 
 
As a representative example, the 1H NMR spectrum of the ethyl-substituted 8b 
(Figure 2.1, top) showed a singlet at d 13.77 ppm with an integration of 1H, 
corresponding to 5-OH group on the pyrazole. A doublet at d 7.81 ppm (J = 7.9 Hz) 
corresponded to the H7 and H11 phenyl ring protons. Two triplets at d 7.45 ppm (1H) 
and d 7.30 ppm (2H) with the same coupling constant (J = 7.4 Hz) were assigned to the 
H9 and H8/10 protons on the phenyl ring, respectively. Signals at d 1.43 and 3.38 ppm 
 34 
integrating for 5H corresponded to the methylene and methyl groups of the ethyl chain. 
A sharp singlet at d 1.43 ppm integrating for 3H corresponded to the pyrazole C3 
methyl group. Signals for the phenyl ring and pyrazole methyl groups were similarly 
observed in the 1H spectra of all analogues 8a-8f, showing only small variations in 
chemical shift. The 5-OH signal was observed in the 1H spectrum of analogues 8a-8d 
but not in 8e and 8f, perhaps due to greater exchange with solvent deuterons, although 
reasons for this are not clear. 
The 13C APT spectrum of 8b was referenced to CDCl3 at δ 77 ppm and phased 
with CH3 and CH carbon signals positive (up) and CH2’s and carbons with no protons 
attached negative (down, Figure 2.1, bottom). The carbodithioate signal appeared far 
downfield at δ 213.7 ppm. The C5 of the pyrazole ring was de-shielded due to the 
attached hydroxyl group having carbonyl-like character, appearing at δ 157.8. The C3 
signal of the pyrazole ring appeared downfield at δ 146.9 due to the attached 
electronegative nitrogen atom. The negative peak at δ 137.3 ppm was assigned to the C6 
of the phenyl ring. An intense positive peak in the aromatic region (δ 129.2 ppm) was 
assigned to chemically equivalent C7 and C11 ring carbons. The less intense CH peak 
was assigned to C9 of the aromatic ring. A second large positive peak in the aromatic 
region (δ 121.7 ppm) was assigned to the chemically equivalent C8 and C10 carbons. 
The small negative signal at δ 111.3 ppm was assigned to the substituted C4 carbon of 
the pyrazole ring. A negative peak at δ 28.3 ppm was assigned to the C14 methylene 
and the two positive peaks at δ 18.2 and δ 12.8 ppm were assigned to the C12 and C15 











2.4.2 Biological activity of 8a-8f 
Testing for anti-MRSA activity by our Brown University collaborators showed 
that shortening the n-propylcarbodithioate chain of HMPC 1 to one carbon 8a led to a 4-
fold drop in potency, while the slightly longer Et derivative 8b gave only a 2-fold loss 
(Table 2.2). Introduction of an alkene 8c maintained or slightly reduced potency and 
extension by 1 carbon 8d increased potency 2-fold. Addition of steric bulk and 
hydrophobicity with a benzyl group 8e resulted in a 2-fold increase in potency, 
however, a significant drop in potency occurred when a polar nitrogen atom was 
introduced into the aryl ring 8f (MIC 16-32 µg/mL). 
HMPC 1 and analogs 8a-8e were also tested by our Brown University 
collaborators for eukaryotic cell cytotoxicity using the immortalized human renal 
proximal tubular epithelial cell line HKC-8 and selectivity indices were calculated (SI = 
HKC-8 IC50/MRSA-MW2 MIC, Table 2.2). No MRSA-selective activity was observed 
for 1 or derivatives 8a, 8b or 8d and only modest selectivity (2-4 fold) was seen with 
allyl derivative 8c. Benzylic derivative 8e showed the highest selectivity for MRSA (8-
16 fold) in this series. Cytotoxicity testing was not performed on the less active 3-









Table 2.2 Antibacterial activity (MIC) of HMPC 1 and analogues 8a-8f against MRSA. 
Cytotoxicity towards eukaryotic HKC-8 cells (IC50) and selectivity indices (SI) are 
shown. n.d = not determined. 
 
 
2.5 Addition of para-substituents to the N-phenyl ring of HMPC 1: Analogues 11a-
11g 
Analogues 11a-11g carrying a selection of halo, electron donating and electron 
withdrawing substituents at the para-position of the pyrazole N-phenyl group of HMPC 
1 were explored next. These compounds were targeted to establish whether para-
substituents in this ring can modulate activity against MRSA and/or lower eukaryotic 
cell cytotoxicity. The pyrazole 3-Me group and the 4-carbodithioate propyl chain were 
kept unchanged to simplify interpretation of the structure-activity data; i.e. so that the 
observed changes in the biological activity could be unambiguously attributed to the 
structural changes introduced on the N-aryl ring. Relevant literature precedents and the 




2.5.1 Synthesis of intermediate p-substituted N-arylpyrazol-5-ones 10a-10g 
The chemistry described above for the synthesis of HMPC 1 (Section 2.2) 
indicated that para-substituted derivatives of N-phenyl-3-methylpyrazolin-5-one 7 (i.e. 
10a-10g) were required for the synthesis of carbodithioates 11a-11g. N-arylpyrazolin-5-
ones are variants of pyrazoles that contain a ketone function adjacent to the nitrogen 
atom bearing the aryl ring. The enol tautomer of the ketone confers these compounds 
with significant aromatic 5-hydroxypyrazole-like character.94 N-arylpyrazolin-5-one 
derivatives have been shown to exhibit a wide variety of biological effects, such as anti-
inflammatory, anticancer, antidiabetic, cytotoxic, antibacterial and antiviral 
activities.95,96 For example, 4,4-dichloropyrazolin-5-one derivatives are potent inhibitors 
of human telomerase and 4,4-dibromopyrazolin-5-one (Figure 2.2), shows antifungal 
activity against Helminthosporium oryzae.97  
 
 
Figure 2.2 Chemical structures of 4,4-dichloropyrazolin-5-one and 4,4-
dibromopyrazolin-5-one. 
 
The first synthesis of  N-arylpyrazol-5-ones by Ludwig Knorr in 1883 described 
the reaction of phenyl hydrazine with an acetoacetate ester.98 This reaction, commonly 
referred to as the Knorr synthesis, has stood the test of time and since been used to 
prepare many N-arylpyrazolin-5-ones from substituted aryl hydrazines and β-
ketoesters.99,100 The reliability and generality of the reaction demonstrated over more 
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than a century suggested the Knorr reaction as the obvious choice for accessing N-
arylpyrazolin-5-ones 10a-10g (Scheme 2.9) 
 
 
Scheme 2.9 The Knorr synthesis for accessing N-arylpyrazol-5-ones 10a-10g. 
 
A mechanism for the Knorr reaction is depicted in Scheme 2.10. In the first step, 
the more nucleophilic terminal nitrogen of the aryl hydrazine attacks the more 
electrophilic ketone carbonyl group of ethyl acetoacetate (as opposed to the ester 
carbonyl) to form an arylhydrazone after loss of a water molecule. The internal nitrogen 
of the newly formed aryl hydrazone then attacks the ester carbonyl, leading to loss of 
ethoxide as a leaving group to deliver the N-arylpyrazolin-5-one.  
 
 
Scheme 2.10 Mechanism for the Knorr synthesis of N-arylpyrazolin-5-ones from aryl 
hydrazines and ethylacetoacetate. 
 
The Knorr reactions were carried out in 90% EtOH:10% CH3CO2H at room 
temperature or with gentle heating at 50 °C for 1 h (Method A), or by stirring at room 
temperature overnight in absolute ethanol (Method B). The cheap and commercially 
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available aryl hydrazine hydrochloride salts 9a-9g were used in place of the free 
hydrazines. Choice of Method A or B for preparative scale reactions was based on 
results from preliminary small scale trials comparing the product yields. Purification on 
preparative scale was carried out using silica gel column chromatography affording 
yields ranging from 25-87%. The quantities of N-arylpyrazolin-5-ones synthesised (mg) 
and the yields of the reactions are provided in Table 2.3. 
 
Table 2.3 Synthesis of N-arylpyrazolin-5-ones 10a-10g. 
 
 
The 1H NMR spectrum of representative analogue 10a (Figure 2.3) showed two 
doublet signals with integration 2H at d 7.02 (J = 7.7 Hz) and d 6.48 (J = 7.1 Hz) ppm, 
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corresponding to the p-substituted phenyl ring protons. A 2H singlet at d 3.36 was 
assigned to the CH2 of the pyrazolin-5-one ring. Two 3H singlets at d 2.32 and d 2.13 
ppm corresponded to the pyrazolin-5-one 3-CH3 group and aryl p-CH3 substituent, 
respectively. 
The 13C NMR spectrum of 10a (Figure 2.3) showed a signal at d 20.9 ppm 
corresponding to the methyl group on the aryl ring. Signals at d 170.3 and d 156.1 ppm 
(negative in the 13C APT spectrum; not presented) were assigned to the non-hydrogen 
bearing C5 and C3 carbons of the pyrazolin-5-one ring. Two signals at d 135.9 and d 
134.8 ppm (negative in the 13C APT spectrum) corresponded to the substituted carbons 
C9 and C6 in the aryl ring, respectively. Signals observed at d 156.1 ppm and d170.3 
ppm corresponded to the imino and carbonyl carbons. A signal at d 43.3 ppm, which 




Figure 2.3 1H (300 MHz, CDCl3) and 13C NMR spectra (75 MHz, CDCl3) for 10a. 
 
2.5.2 Conversion of 10a-10g to 5-hydroxypyrazole-4-carbodithioates 11a-11g 
The strategy of treating N-arylpyrazolin-5-ones 10a-g with a strong base and 
quenching the enolates with CS2 followed by n-bromopropane was used to produce 
11a-g. In this one-pot procedure, the N-arylpyrazolin-5-ones were first treated with n-
butyllithium in THF at 0 oC and stirred for 1.5 h. After formation of the carbanion, CS2 
was added to the reactions and stirring continued for further 1 h at 0 oC. Final 
conversion to 11a-g was then achieved by adding n-bromopropane and stirring at room 
temperature for another 16 h. The compounds were all purified by silica gel column 
chromatography to give the targets in 32-75% yields (Table 2.4). These procedures were 








The 1H NMR spectrum of representative analogue 11a (Figure 2.4) showed the 
expected signals. Addition of a carbodithioate and n-propyl chain to 10a to give 11a 
was evidenced by loss of the methylene signal of 10a at d 2.67 ppm and the appearance 
of three new signals at d 3.38, d 1.82 and d 1.10 ppm, corresponding to the 2 x CH2 and 
1 x CH3 groups of the n-propyl chain. A heavily de-shielded signal at d 13.70 ppm was 
consistent with the presence of the hydroxyl group at the pyrazole C5. 
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Analysis of the 13C APT NMR spectrum of 11a supported the above 
assignments (Figure 2.4). As expected, additional peaks (relative to 10a) appeared at d 
35.8, d 21.5 and d 13.8 ppm, corresponding to the newly introduced n-propyl group, 
along with a diagnostic carbodithioate carbon signal at d 213.8 ppm. A negative signal 
(i.e. no hydrogens attached) at d 157.6 ppm was assigned to the C5, which in compound 
10a appeared at d 170.3. A negative peak at d 111.5 ppm corresponded to the C4 of the 
pyrazole ring in 11a, which for pyrazolin-5-one 10a appeared as a negative CH2 signal 




Figure 2.4 1H (500 MHz, CDCl3) and 13C APT spectra (125 MHz, CDCl3) for 11a. 
 
2.5.3 Biological activity of 11a-11g 
 Testing of 11a-11g for anti-MRSA activity showed that addition of a Me group 
11a gave no change (relative to 1), whilst introducing an electron donating methoxy 
group 11b produced a 2-fold drop in potency. Halogen substituents 11c-e gave increases 
in potency (2–4 fold) and introduction of electron withdrawing cyano 11f and NO2 11g 
groups gave the highest activity (MIC 0.5–2 µg/mL). Testing of the most potent 
analogue 11g against eukaryotic HKC-8 cells showed that the increased potency against 
MRSA was unfortunately accompanied by an increase in cytotoxicity, as indicated by 




Table 2.5 Antibacterial activity (MIC) of analogues 11a-11g against MRSA. 
Cytotoxicity towards eukaryotic HKC-8 cells (IC50) and selectivity indices (SI) are 
shown for the most active compound 11g only. 
 
 
2.6 Replacement of the 3-Me group of HMPC 1 with p-substituted phenyl rings: 
Analogues 14a-14i 
The target analogues 14a-14i replaced the 3-Me group of HMPC 1 with aryl 
rings bearing the same halo, electron donating and electron withdrawing substituents at 
the para-position as used in 11a-11g. An additional p-CF3 substituent was also 
explored. As with the other analogues investigated up to this point, the modifications 
aimed to show whether tangible structure-activity relationships exist around the 3-
position, which would support a target-specific mechanism of antibacterial action as 
opposed to a general, non-specific mechanism (e.g. effects on membranes). It was also 
hoped that compounds with increased anti-MRSA activity and lower eukaryotic cell 
cytotoxicity might be identified. 
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2.6.1 Synthesis of intermediate 3-aryl-N-phenylpyrazolin-5-ones 13a-13i 
Access to the target carbodithioates 14a-14i using the above chemistry required 
use of the Knorr reaction to prepare the requisite 3-p-substituted aryl-N-
phenylpyrazolin-5-one precursors 13a-13i. It was anticipated that modifying the Knorr 
reaction to deliver these intermediates would simply involve replacing ethyl 
acetoacetate with commercially available p-substituted 3-aryl-b-ketoesters (also known 
as ethyl benzoylacetates, 12a-12i). Wang, X. et al99 demonstrated that 3-aryl-b-
ketoesters can undergo the Knorr reaction with aryl hydrazines when they prepared a 
series of N-arylpyrazolin-5-ones for investigation as anti-analgesic, anti-bacterial, anti-
fungal, anti-inflammatory, anti-microbial, anti-diabetic, anti-hyperglycemic and 
anxiolytic agents.101 Several other studies similarly reported Knorr syntheses using 
benzoylacetates.100,102-104  
The reactions were carried out by stirring the p-substituted ethyl benzoylacetates 
12a-12i with phenylhydrazine in absolute ethanol at room temperature overnight. 
Moderate to good yields (21-81%) were obtained and, depending on the substrate, use 











Table 2.6 Synthesis of 3-p-substituted aryl-N-phenylpyrazolin-5-ones 13a-13i using the 
Knorr reaction of phenylhydrazine (or hydrochloride salt) with ethyl benzoylacetates.  
 
 
The 1H NMR spectrum of a representative example 3-p-nitrophenyl-N-
phenylpyrazolin-5-one 13i in DMSO-d6 (Figure 2.5) revealed an interesting feature 
about pyrazolin-5-ones, where in this solvent the compounds exist exclusively in their 
5-hydroxypyrazole enol tautomeric form. This was in contrast to the spectra of 
pyazolin-5-ones recorded in CDCl3, which showed exclusively the 5-keto form (see 
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Figure 2.3, compound 10a above). In DMSO-d6, compound 13i showed two doublets, 
each with an integration of 2H at d 8.28 (J = 8.8 Hz) and d 8.10 (J = 8.8 Hz) ppm, 
corresponding to the 7¢/11¢ and 8¢/10¢ p-NO2-aryl ring protons. A 2H doublet at d 7.83 
(J = 8.5 Hz) was assigned to the 7/11 aromatic ring protons and a 2H triplet at d 7.51 (J 
= 8.5 Hz) to the 8/10 protons. A triplet with an integration of 1H (J = 8.4 Hz) at d 7.34 
was assigned to H9 of the pyrazole N-phenyl ring. A singlet at d 6.23 with an 
integration of 1H was assigned to the proton at C4. This provided the first indication 
that DMSO-d6 causes the compounds to exist in the 5-hydroxypyrazole enolic tautomer 
because in the 1H NMR spectrum of 10a (CDCl3, Figure 2.3), the equivalent signal 
showed an integration of 2H and appeared much further upfield at 2.67 ppm. 
The furthest downfield negative signal in the 13C APT spectrum of 13i (in d6-
DMSO) appeared at δ 154.7 ppm, corresponding to the substituted C9¢ carbon; i.e. 
carbon directly attached to the highly electron withdrawing (therefore de-shielding) 
nitro group. A negative signal at δ 147.9 ppm was assigned to C6¢, corresponding to the 
other substituted carbon of the pyrazole C3 aryl ring. Two negative signals at 147.0 
ppm and 140.2 ppm corresponded to the C5 and C3, respectively. A negative signal at δ 
139.0 ppm was assigned to the C6 substituted carbon; i.e. carbon directly attached to the 
N1. The positive aromatic peaks at δ 129.4, δ 126.7, δ 126.3, δ 124.4 and δ 121.9 ppm 
corresponded to C8¢/10¢, C9, C8/10, C7¢/11¢ and C7/11. A diagnostic signal indicating 
the presence of the 5-hydroxypyrazole enolic tautomer of 13i (in DMSO-d6) was a 
positive peak (i.e. CH) at δ 86.6 ppm, corresponding to C4. For pyazol-5-one 10a (in 
CDCl3), this appeared as a negative signal (i.e. CH2) much further upfield at 43 ppm. 
The same diagnostic 1H and 13C signals indicative of enolic tautomers were observed 
for 10d-f, 13f and 13h in DMSO-d6. It is postulated that the weak acidity of CDCl3 
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allows for facile proton exchange that favours the keto tautomer, whereas the non-acidic 
DMSO-d6 shifts the tautomeric equilibrium towards the 5-hydroxypyrazole enolic form. 
It is also possible that DMSO acts a H-bond acceptor that stabilises the enolic pyrazole 




Figure 2.5 1H (400 MHz, DMSO-d6) and 13C APT spectra (100 MHz, DMSO-d6) for 
representative analogue 3-p-nitrophenyl-N-phenylpyrazolin-5-one 13i. 
 
2.6.2 Conversion of 13a-13i to 5-hydroxypyrazole-4-carbodithioates 14a-14i 
Treating 3-aryl-N-phenylpyrazol-5-ones 13a-13i with n-butyllithium and 
quenching the respective enolates with CS2 followed by n-bromopropane afforded 14a-
14g in useable yields (10-60%, Table 2.7). In each case, 1.0 eq of n-butyllithium was 
added first to the pyrazolin-5-one and stirred for 1.5 h at 0 oC. Carbon disulfide was 
added to generate carbodithioate anion, followed by n-bromopropane and the reactions 






Table 2.7 Synthesis of HMPC 1 analogues 14a-i carrying p-substituted aryl rings (R2) 
in place of the methyl group at C3. 
 
 
The 1H NMR spectrum of representative analogue 14i confirmed addition of the 
n-propyl chain, where the key signal at d 6.23 in the precursor pyrazolin-5-one was 
absent and replaced by three new signals at d 3.22, d 1.66 and d 0.96 ppm, 
corresponding to the n-propyl group. A heavily de-shielded signal was also observed at 
d 13.59 ppm corresponding to the pyrazole C5 OH group. Similar signals were observed 
for all other analogues with variations in chemical shift generally <1.0 ppm. 
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Analysis of the 13C APT spectrum of 14i supported the structure (Figure 2.6).  
As expected, new peaks at d 36.4, d 21.2 and d 13.7 were observed for the n-propyl 
chain and a peak at d 215.0 was observed for the carbodithioate carbon. A negative 
signal at d 110.1 corresponding to the substituted C4 of the pyrazole ring in 14i was also 
present. This signal occurred at d 86.6 in the precursor pyrolazin-5-one 13i (although as 




Figure 2.6 1H (400 MHz, CDCl3) and 13C APT spectra (100 MHz, CDCl3) for 
representative analogue 14i. 
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2.6.3 Biological activity of 14a-14i 
Compound 14a showed a 2-fold increase in anti-MRSA activity and a 16-fold 
increase in selectivity relative to 1 (Table 2.8). The increased potency and selectivity 
observed with 14a was an early finding in the work and acted as the catalyst to pursue 
the more detailed SAR studies described here with para-substituted analogues 14b-14i. 
Addition of the p-Me group 14b led to a slight increase in potency (MIC = 1-2 µg/mL) 
relative to 14a but the change also reduced selectivity. The methoxy group 14c did not 
change activity against MRSA but it lowered selectivity. Larger increases in 
antibacterial potency were seen with halo groups 14d-f (MIC = 0.5-1 µg/mL) but no 
improvements in selectivity were seen. A significant drop in potency was observed with 
the CF3 group 14g (MIC = 32-64 µg/mL), which differed from other strongly electron 
withdrawing cyano 14h and nitro 14i substituents that maintained potency but showed 













Table 2.8 Antibacterial activity (MIC) of analogues 14a-14i against MRSA. 
Cytotoxicity towards eukaryotic HKC-8 cells (IC50) and selectivity indices (SI) are also 
shown. n.d = not determined 
 
 
2.7 Summary and Concluding Remarks 
In Chapter 1.4.2 it was discussed how treatment of a S. aureus promoter-lux 
array with HMPC 1 produced a unique luminescence profile, suggestive of a novel 
mechanism of action against MRSA. However, some similarities to DNA-damaging 
agents and/or DNA replication inhibitors were noted.106 This led to speculation that the 
anti-MRSA and cytotoxicity of 1 might arise from DNA binding. However, UV/vis 
experiments measuring the binding of 1 to calf thymus DNA and zone of growth 
inhibition disk measurements performed with 1 in the presence/absence of calf thymus 
or S. aureus genomic DNA (Chapter 1.4.2) appeared to rule this out. Nevertheless, the 
similar levels of HKC-8 toxicity observed in the current study with the majority of 
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analogs of 1, combined with the absolute requirement for a carbodithioate function to 
elicit anti-MRSA activity, led to further examination of whether 1 might exert 
antibacterial and cytotoxic effects through non-specific nucleic acid and/or protein 
reactivity. The DNA-reactivity of 1 was probed by electrospray ionization mass 
spectrometry (ESI-MS) using a panel of single stranded, double stranded and G-
quadruplex DNA oligonucleotides. When incubated with up to 10-fold excesses of 
HMPC 1 under a variety of conditions, no evidence of any DNA:1 adducts was 
observed (data not shown. See reference107). Similarly, no adducts were observed by 
ESI-MS when 1 was incubated with RNA oligonucleotides. 
The effects of HMPC 1 on DNA replication in vitro was also explored using as 
assay where all of the enzymes, ancillary proteins, nucleotide precursors, DNA template 
and other molecular components required for duplication of bacterial DNA are present 
and able to effect replication in a cell-free environment.108 Covalent reactivity with any 
of these reaction components would be expected to read out as inhibition of replication 
in the assay. Only slight inhibition of replication was observed with 1 at 
concentrations >160 μM, i.e. well above the MIC against MRSA and IC50 towards 
HKC-8 cells (data not shown. See reference107). In vitro RNA transcription assays 
similarly showed no inhibition by 1 at relevant concentrations. Thus the absence of any 
effects for 1 in this comprehensive battery of assays rules out non-specific nucleic acid 
or protein reactivity as a contributor to the anti-MRSA mechanism of the pyrazole-4-
carbodithioate class, or their eukaryotic cell cytotoxicity. 
This work has shown that 5-hydroxypyrazole-4-carbodithioates are an 
interesting new class of anti-MRSA agents that require the 4-carbodithioate function for 
activity. While non-specific DNA and protein covalent reactivity has been ruled out as 
part of the mechanism, it is possible that intrinsic reactivity of the 4-carbodithioate may 
 57 
still play a role. It was shown that MgrA-mediated defence responses are triggered in 
MRSA by 1.106 MgrA is an oxidation-sensing protein used by MRSA to counter 
challenges of reactive oxygen and nitrogen species. Upon detecting these species, a 
unique cysteine residue (Cys12) located at the dimer interface of the protein is oxidized 
to cysteine sulfenic acid, causing dissociation of MgrA from DNA and initiation of 
signalling pathways that switch on antibiotic resistance.77 It is speculated that 
intracellular redox reactivity of the 4-carbodithioate function (aided by the neighbouring 
OH group) causes oxidative stress that triggers MgrA activation and its downstream 
consequences. For example, the carbodithioate could trigger MgrA activation through 
oxidation of its key Cys-SH to Cys-SOH. It is not yet known whether this signalling 
pathway is responsible for the MRSA growth inhibitory properties of the class. 
Alternatively, it is possible that metal chelation by the 4-carbodithioate and 
neighbouring OH group may play a role.109 
 While limited selectivity (maximum 16-fold) for MRSA over eukaryotic HKC-8 
cells was achieved with the analogues explored here, further increases might be possible 
with a larger analogue set. Studies to fully elucidate the anti-MRSA mechanism and 
identify the discrete cellular targets of the compounds using more selective analogues 
would be worth pursuing. Many novel analogues could be prepared using the chemistry 
developed in this project. A vast selection of alkyl halides, alkyl- and (het)aryl-
hydrazines and alky/(het)aryl-b-ketoesters are commercially available, allowing for 
large numbers of analogues to be prepared and detailed structure-activity relationships 
established. Choice of analogues for synthesis could be governed by standard medicinal 
chemistry principles (i.e. Lipinski and membrane penetration rules; e.g. polar surface 
area < 90 Å2, logP 2-4, aqueous solubility > 20 µg/mL) and synthetic tractability. 
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The library of 5-hydroxypyrazole-4-carbodithioates prepared here and analogues 
prepared in the future could be screened for biological activity against a range of other 
anti-inflammatory, anticancer, antidiabetic, antibacterial and antiviral targets. In recent 
collaborative work between the Kelso Lab and Prof Heath Eckroyd’s lab at the 
University of Wollongong, HMPC 1 and several analogues were shown to activate the 
transcription factor heat shock factor 1 (HSF1), a master regulator of the heat shock 
stress response pathway in humans. These preliminary findings have triggered a 
program to further explore these compounds for their ability to inhibit the pathological 
mechanisms underpinning development and progression of the devastating disease 
amylotrophic lateral sclerosis (ALS).110 Curiously, as observed with MRSA, only 
analogues bearing the 4-carbodithioate function were active. It will be very interesting 
to explore this exciting recent finding, both from a chemical biology perspective and 















Synthesis and preliminary structure-activity 
evaluation of 3-(phenylsulfonyl)-2-
pyrazinecarbonitrile and analogues as a new 
antibacterials against MRSA 
 
3.1 Introduction  
Chapter 1 discussed how a Caenorhabditis elegans-based whole animal 
infection model can be used for simultaneous high-throughput in vivo screening for 
compounds that show both efficacy against MRSA and potentially low toxicity.111 The 
chapter went on to describe the antibacterial properties of hit compound HMPC 1 that 
was identified from the screen and Chapter 2 detailed the anti-MRSA structure-activity 
relationships around the HMPC class. In this Chapter, the discovery and antibacterial 
properties of a second hit compound from the C. elegans-MRSA screen performed by 
collaborators at Brown University (USA), 3-(phenylsulfonyl)-2-pyrazinecarbonitrile 
(PSPC 15), are presented along with a small-scale preliminary structure-activity study 
that I contributed as part of my PhD studies. 
PSPC 15 was chosen for follow up study because the compound is a novel, low 
molecular weight scaffold that had not previously been reported to show antibacterial 
activity. Two analogues of PSPC 15, the phenyl sulfide 16 and sulfoxide 17, were 
designed and synthesized as a way of providing a simple assessment of whether the 
antibacterial activities of PSPC 15 are likely to be target-based; i.e. as opposed to acting 
via non-specific mechanisms (e.g. membrane effects). We rationalized that such a 
conclusion could be drawn if significant changes in activity were observed between the 
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three closely related structures, and this could then justify a larger medicinal chemistry 
effort (beyond the scope of this work). Resynthesis and testing of PSPC 15 in the C. 
elegans-MRSA assay (in non-high-throughput format) was undertaken first to confirm 
the anti-MRSA activity of the compound. 
 
 
Figure 3.1 Structure of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC 15), a second 
anti-MRSA hit compound identified in a C. elegans-MRSA high-throughput screen. 
The structures of the target sulfide (PSPC-1S 16) and sulfoxide (PSPC-6S 17) 
derivatives required for preliminary investigation of anti-MRSA structure-activity 
relationships are also shown. 
 
3.2 Synthetic chemistry  
3.2.1 Synthesis of phenyl sulfide PSPC-1S 16 
At the outset of this study, it was envisaged that sulfone PSPC 15 and the 
sulfoxide derivative PSPC-6S 17 could be accessed from the common sulfide precursor, 
i.e. corresponding to PSPC-1S 16, by full and partial oxidation of the sulfur atom, 
respectively. A previous report showed that reaction of commercially available 2-cyano-
6-chloropyrazine (CCP) 18 with mercaptans in the presence of sodium metal in 
anhydrous dioxane provided the requisite sulfide PSPC-1S 16. For example, 2-cyano-6-
ethylthiopyrazine was obtained in 40% yield using this method from ethyl mercaptan, 
while our target phenyl sulfide PSPC-1S 16 was reportedly obtained in only 30% yield 
using thiophenol (Scheme 3.1 A).112 
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Before attempting the synthesis of PSPC-1S 16 using this method, I postulated 
that the reaction might be simplified and the yield improved by using commercially 
available sodium thiophenoxide in place of Na/thiophenol. This modification would 
have the advantage of abolishing the need to handle pyrophoric sodium metal. To this 
end, when commercial 2-cyano-6-chloropyrazine 18 (1 eq) was heated at reflux with 
sodium thiophenoxide (1.1 eq) in THF, complete reaction occurred after only 1 h, as 
evidenced by consumption of the starting 18 by TLC and ESI-MS analysis. 
Concentration of the reaction mixture and purification of the crude by silica gel column 
chromatography afforded PSPC-1S 16 in 82% yield (Scheme 3.1 B). 
 
 
Scheme 3.1 (A) Literature method for synthesising PSPC-1S from commercially 
available 2-cyano-6-chloropyrazine 16113 (B) Improved synthesis of PSPC-1S 16 using 
commercial sodium thiophenoxide developed in this work. 
 
The 1H NMR spectrum of PSPC-1S 16 (Figure 3.2) showed two doublets, each 
with an integration of 1H at d 8.40 (J = 1.6 Hz) and d 8.34 (J = 1.6 Hz), corresponding 
to the protons at the 6 and 5 positions on the pyrazine ring, respectively. A doublet with 
an integration of 2H at d 7.58 (J = 6.6 Hz) was assigned to the chemically equivalent 
H11 and H15 ortho protons on the phenyl ring. This signal was de-shielded by inductive 
electron withdrawal from the pyrazinyl sulfide group. An apparent triplet with an 
integration of 3H at d 7.48 (J = 7.5 Hz) was assigned to the H12, H13 and H14 phenyl 
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ring protons. Signals observed at δ 0.88, δ 1.26 and δ 1.63 corresponded to ‘grease’ and 
a small amount of residual EtOAc. 
The 13C NMR spectrum (Scheme 3.2) showed a downfield signal at d 161.5 
corresponding to the de-shielded C2 carbon on the pyrazine directly attached to the 
sulfide function. The next furthest downfield signal at d 146.4 was assigned to the 
carbon at position-6 of the pyrazine ring, as this signal would be de-shielded by the 
para-positioned nitrile group and the adjacent pyrazine nitrogen. The signal at d 140.6 
was assigned to the carbon at position-5 of the pyrazine ring, as this signal would be 
slightly less de-shielded by the meta- positioned nitrile. The large peak in the aromatic 
region at δ 135.7 was assigned to the chemically equivalent C12, C14 carbons of the 
phenyl ring. The slightly smaller signal at d 130.3 was assigned to the C13 of the 
aromatic ring, and the larger peak at δ 129.8 ppm was assigned to the chemically 
equivalent C11 and C15 carbons. The small peak at δ 127.6 was assigned to the 
substituted C10 of the phenyl ring. The singlet peak at δ 126.6 corresponded to the C3 
of the pyrazole that is linked to carbonitrile group and the nitrile carbon was the most 
upfield signal at δ 114.4. 
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3.2.2 Synthesis of PSPC 15 and PSPC-6S 17 
Oxidation of sulfides is typically carried out with, for example, m-
chloroperbenzoic acid (m-CPBA), NaBrO2, H2O2 or KMnO4, and produces either (or 
both) the sulfoxide and/or sulfone depending on the reaction conditions.113-115 In this 
work, m-CPBA was chosen as the electrophilic oxygen source for the oxidation.116 In 
the first attempt, treatment of sulfide PSPC-1S 16 with 1.2 eq of m-CPBA in CH2Cl2 at 
room temperature for 24 h produced sulfoxide PSPC-6S 17 in 66% yield (Scheme 3.2). 
Subsequently repeating the reaction with 2.5 eq of m-CPBA under the same conditions 
provided 36% of the sulfone PSPC 15 and 25% of PSPC-6S 17.  
 
 
Scheme 3.2 Synthesis of sulfoxide PSPC-6S 17 and sulfone PSPC 15 from sulfide 
PSPC-1S 16. 
 
A mechanism for the m-CPBA-promoted oxidation of sulfide PSPC-1S 16 is 
outlined in Scheme 3.3. The nucleophilic lone pair of electrons on the sulfur atom 
attacks the electrophilic peroxy atom of the m-CPBA reagent. Loss of m-chlorobenzoic 
acid as the leaving group then delivers the sulfoxide PSPC-6S 17. The remaining lone 
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pair on the sulfur atom of the sulfoxide can then repeat the process when a sufficient 
excess of m-CPBA is present to deliver the sulfone PSPC 15. 
 
 
Scheme 3.3 Mechanism for the oxidation of sulfide PSPC-1S 16 to the corresponding 
sulfoxide 17 and sulfone 15 using m-CPBA. 
 
The 1H NMR spectrum of PSPC-6S 17 (Figure 3.3) showed two doublets, each 
with an integration of 1H at d 8.86 (J = 2.2 Hz) and d 8.77 (J = 2.2 Hz), corresponding 
to the protons at the 6 and 5 positions on the pyrazine ring, respectively. These signals 
were shifted further downfield relative to those in the sulfide 16 by the electron 
withdrawing effect of the sulfoxide group. A triplet with an integration of 2H at d 7.93 
was assigned to the chemically equivalent H11 and H15 ortho protons on the phenyl 
ring. An apparent triplet with an integration of 3H at d 7.55 (J = 6.6 Hz) was assigned to 
the H12, H13 and H14 phenyl ring protons.  
The 13C NMR spectrum (Scheme 3.3) showed a downfield signal at d 164.1 
ppm, corresponding to the de-shielded C2 carbon on the pyrazine. This signal was more 
downfield relative to PSPC-1S 16 because of the electron withdrawing sulfoxide. The 
signal at d 147.2 ppm was assigned to the carbon at position-6 of the pyrazine ring. The 
signal at d 146 ppm was assigned to the carbon at position-5 of the pyrazine ring as this 
signal is slightly more de-shielded by the para-positioned SO group. The quaternary 
aromatic (C10) signal was observed in the expected region at d 141.6 ppm. The slightly 
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smaller signal at d 132.6 ppm was assigned to the C13 of the phenyl ring. The large 
peak in the aromatic region at δ 129.9 ppm was assigned to the chemically equivalent 
C12, C13 carbons of the phenyl ring. This signal was de-shielded by ortho-inductive 
electron withdrawl by the SO group. The larger peak at δ 125.1 ppm was assigned to the 
chemically equivalent C11 and C15 carbons. The signal at δ 127.6 ppm corresponded to 
the C3 of the pyrazine linked to the carbonitrile group and the nitrile carbon was the 
most upfield signal at δ 113 ppm. 
 




A peak at m/z 252.0202 in the high-resolution electrospray ionisation mass 
spectrum corresponded to the expected C11H7N3NaOS [M + Na]+ molecular ion for 
PSPC-1S 17.  
The 1H NMR spectrum of PSPC 15 (Figure 3.4) showed two doublets, each with 
integration of 1H at d 8.88 (J = 2.2 Hz) and d 8.84 (J = 2.2 Hz) ppm, which were 
assigned to the H6 and H5 protons of the pyrazine ring, respectively. These signals were 
shifted downfield by the de-shielding effects of the SO2 group. A doublet with an 
integration of 2H at d 8.16 (J = 7.4 Hz) ppm was assigned to the chemically equivalent 
H11 and H15 phenyl ring protons. Two triplets were evident, one with an integration of 
1H at d 7.74 (J = 7.5 Hz) ppm for H13 and the other with integration 2H at d 7.63 (J = 
7.8 Hz), corresponding to the H12 and H14 phenyl ring protons.  
The 13C NMR spectrum of PSPC 15 (Figure 3.4) showed the C2 of the pyrazine 
in the expected region at d 157.2 ppm. This signal was shifted slightly upfield relative to 
the same carbon in the sulfoxide. A signal at d 147.3 ppm was assigned to the carbon at 
position-6 of the pyrazine ring as it was de-shielded by a para-CN group. A signal at d 
146.1 ppm was assigned to the carbon at position-5 on the pyrazine ring as it was 
slightly less de-shielded by the para-SO2 group. The peak appearing d 137.1 ppm was 
assigned to C10 as this signal would be more de-shielded by the SO2 group than the SO 
group. The signal at d 135.4 ppm was assigned to the C13 of the phenyl ring. This 
signal was slightly more de-shielded than in the sulfoxide. The two high intensity 
singles at δ 129.84 and δ 129.81 ppm were assigned to the symmetrically-opposed C11, 
C15 and C12, C14 phenyl ring carbons, respectively. The signal at δ 128.4 ppm 
corresponded to the C3 of the pyrazine linked to carbonitrile group and the nitrile 
carbon was the most upfield signal at δ 113.2. 
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Figure 3.4 1H (500 MHz, CDCl3) and 13C APT spectra (125 MHz, CDCl3) for PSPC 15. 
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A peak at m/z 268.0151 in the high-resolution electrospray ionisation mass 
spectrum corresponded to the expected C11H7N3NaO2S [M + Na]+ molecular ion for 
PSPC 15.  
 
3.3 Biological Results and Discussion  
3.3.1 Screening of resynthesized PSPC 15 in the C. elegans-MRSA infection assay 
The C. elegans-MRSA liquid infection assay is a well-established high 
throughput screening platform that allows simultaneous assessment of both the toxicity 
and antibacterial efficacy of test compounds in 384-well formats.111,117 The endpoint of 
the assay is the number of MRSA-infected worms that survive the infection after 
treatment with test compounds. This liquid infection assay was used by our collaborator 
at Brown University (USA) Prof Eleftherios Mylonakis to identify antibacterial hits 
from a library of 21,472 pre-selected compounds provided by Boehringer-Ingelheim 
GmbH (BI). The compounds were pin-transferred to 384-well plates to a final assay 
concentration of 20 µg/mL. Each sample plate contained 16 wells each of positive 
control (vancomycin at 10 µg/mL in 1% DMSO) and negative control (1% DMSO). 
The percent survival of infected worms treated with library compounds was determined 
at the end of the assay and a Z score was calculated for each well to identify hits. Of the 
21,472 compounds tested, 318 (1.4% hit rate) protected worms from MRSA-mediated 
killing. 
To measure the activity of my independently synthesized sample of PSPC 15, 
the C. elegans-MRSA assay was repeated (in non-HTS mode) using serial dilutions in 
the range of 0.78-100 µg/mL and the activity of the compound was compared to 
vancomycin over the same concentration range. At the lowest concentration, both 
resynthesized PSPC 15 and vancomycin were effective in prolonging survival of more 
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than 90% of the infected worms (Figure 3.5). However, at the higher concentrations of 
50 and 100 µg/mL, worms treated with PSPC 15 showed only 46% and 16% survival, 
respectively, whereas vancomycin-treated worms showed >97% survival. These 
findings suggest that although PSPC 15 ameliorates MRSA-associated lethality in 
worms at low concentration, the compound appears to be toxic to the worms at higher 
concentrations. These findings were all in agreement with the results that had been 
obtained previously in the original HTS run, thus confirming that PSPC 15 is indeed the 








Figure 3.5 Re-synthesised PSPC 15 prolonged survival of C. elegans infected with 
MRSA. A. 384-well assay plates were co-inoculated with young adult stage C. elegans 
glp-4(bn2);sek-1(km4) animals, MRSA strain MW2, and either DMSO (negative 
control), or 2-fold serial dilutions (0.78-100 μg/mL) of vancomycin (positive control) or 
resynthesized PSPC 15. Sytox Orange-stained images of assay wells containing serial 
dilutions of the drugs are shown, where only dead worms take up the Sytox Orange dye 
and fluoresce. B. The percent survival of infected worms was calculated from the ratio 
of fluorescent worm areas to the total area occupied by worms in a well. 
 
3.3.2 In vitro antibacterial activity of PSPC 15, PSPC-1S 16, PSPC-6S 17 
Compounds identified in chemical screens that prevent a pathogen from killing 
C. elegans can inhibit the growth of the pathogen, block its virulence, and/or enhance C. 
elegans immunity.118,119  To help distinguish between these possibilities, the 
resynthesized sample of PSPC 15 was tested for direct effects on MRSA growth. The 
compound was found to inhibit the growth of MRSA (strain MW2) in Müller-Hinton 
broth, showing MIC 4 µg/mL, which was comparable to vancomycin (MIC 2 µg/mL, 
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Table 3.1). A time-kill assay at 10x MIC (40µg/mL) showed that PSCP 15 is 
bactericidal, killing 100% of MRSA cells after a 4-hour exposure period (Figure 3.6). 
The minimum bactericidal concentration of PSPC 15 against MRSA was 16 µg/mL 
(data not shown); i.e. 4 x MIC. These data confirmed that PSPC 15 functions directly as 
an antibacterial that both blocks the growth of and kills MRSA.   
 
 
Figure 3.6 Time-kill kinetics of PSPC 15 against MRSA. Survival of MRSA in broth 
culture (CFU/mL) is shown after treatment with DMSO (control) or PSPC 15 at 10 x 
MIC (40 μg/mL). 
 
The broader antibacterial activity of PSPC 15 was explored against a panel of 
the ESKAPE pathogens: E. faecium, K. pneumoniae, A. baumannii, P. aeruginosa and 
Enterobacter spp. The six ESKAPE pathogens are the main causes of nosocomial 
infections that are difficult to treat due to antimicrobial resistance.52 Similar to MRSA, 
the MIC of PSPC 15 against the Gram-positive species E. faecium was 8 µg/mL (Table 
3.1), however, PSPC displayed much higher MICs against the Gram-negative pathogens 
K. pneumoniae (64 µg/mL), A. baumannii (32 µg/mL), P. aeruginosa (>64 µg/mL) and 
Enterobacter spp. (>64 µg/mL). 
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Table 3.1 Antibacterial activity of PSPC 15, PSPC-6S 16 and PSPC-1S 17 against 













E. faecium (E007) 4 ND 8 >64 8 
MRSA (MW2) 2 ND 4 >64 4 
K. pneumoniae (77326) ND 16 64 >64 64 
A. baumannii (ATCC 
17978) 
ND 0.5 32 >64 32 
P. aeruginosa (PA14) ND 2 >64 >64 >64 
Enterobacter spp. 
(KCTC 2625) 
ND 32 >64 >64 >64 
*ND = Not determined 
 
The sulfide and sulfoxide analogues of PSPC were also tested for antibacterial 
activity against MRSA and the ESKAPE pathogens (Table 3.1). The sulfide analogue 
PSPC-1S 16 was found to be inactive across all species (MICs > 64 µg/mL). In contrast, 
the sulfoxide analogue PSPC-6S 17 showed identical potency to PSPC 15 against all of 
the species tested. These findings suggest that the activity of PSPC 15 is highly 
structure-dependent as a single atom change was able to totally abrogate activity. The 
dramatic changes in activity observed here are consistent with the compound class 
acting via modulation of a specific antibacterial target and not via a general (e.g. 
membrane-based) mechanism. Further experiments performed with the PSPC 15 sample 
I synthesized by our collaborators at Brown University are described below for 




3.3.3 Efflux pump inhibitor PAβN potentiates the activity of PSPC 15 against 
Gram-negative bacteria 
The peptidomimetic compound phenylalanine arginyl β-naphthylamide (PAβN) 
is a broad spectrum efflux pump inhibitor that is active against 
resistance/nodulation/division (RND) pumps in various Gram-negative bacteria, where 
it can restore antibiotic susceptibility of many strains.120 The activity of PSPC 15 
against Gram-negative ESKAPE pathogens was measured in the presence of PAβN at a 
fixed concentration of 64 µg/mL to establish whether the pump inhibitor potentiates 
PSPC 15 activity. At this concentration PaβN on its own showed no growth inhibition 
against any of the strains (data not shown). In the presence of PAβN, the MIC of PSPC 
15 against K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp. all 
decreased more than 4-fold (Table 3.2), indicating the compound it likely a substrate for 
pumps inhibited by this compound. 
 
Table 3.2 PAβN potentiates the antibacterial activity of PSPC 15 against Gram-





Fold change PSPC 15 
PSPC 15 +  
PAβN (64 
µg/mL) 
K. pneumoniae (ATCC 77326)  64 8 8 
A. baumannii (ATCC 17978)  32 4 8 
P. aeruginosa (PA14)  >64 16 >4 
Enterobacter spp. (KCTC 2625) >64 8 >8 
 
 75 
3.3.4 PSPC 15 acts synergistically with polymyxin B against K. pneumoniae and A. 
baumannii 
Polymyxin B is a lipopeptide antibiotic that is effective against a variety of 
Gram-negative bacteria. The ability of polymyxin B to act synergistically with PSPC 15 
against K. pneumoniae and A. baumannii was explored. A microplate checkerboard 
assay was used to test for growth inhibition of the strains in the presence of PSPC 15 
adjusted to final concentrations in the range of 1-64 μg/mL and polymyxin B adjusted to 
final concentrations of 0.063-64 μg/mL. The minimum concentrations at which the two 
compounds inhibited bacterial growth, both alone and in combination, were determined 
in order to calculate the Fractional Inhibitory Concentration (FIC) index.121 The FIC 
indices of polymyxin B/PSPC 15 against K. pneumoniae and A. baumannii were found 
to be 0.141 and 0.375, respectively (Table 3.3). FIC indices <0.5 indicate that 
polymyxin B exhibits synergistic activity with PSPC 15 against both pathogens. 
 
Table 3.3 MIC data for PSPC and polymyxin B alone and in combination against K. 




PSPC 15 Polymyxin B 





64 16 1 and 2 0.141 
A. baumannii 
(ATCC 17978) 




3.3.5 Cytotoxicity and hemolytic activity of PSPC 15 
PSPC 15 was found to be toxic to worms at high concentrations (Figure 3.7), 
suggesting that the compound might be toxic to eukaryotic cells. In vitro cytotoxicity of 
PSPC 15 was thus evaluated against HEK-293 cells. The cells were treated with serial 
dilutions of PSPC 15 over the concentration range 1-64 μg/mL and cell viability 
determined. The mitochondrial toxin rotenone, which interferes with the electron 
transport chain in mitochondria, was included as a positive control. At concentrations 
up to 2 μg/mL PSPC 15, almost 90% of treated cells survived (Figure 3.7 A). Higher 
concentrations of PSPC 15 caused a dose dependent increase in toxicity to HEK-293 
cells, culminating in a survival rate of only 8.5% at 64 μg/mL.  
PSPC 15 was also tested for its ability to cause hemolysis of red blood cells 
(RBCs). Sheep erythrocytes were treated with serial dilutions (0.063-64 μg/ml) of PSPC 
15 for 1 hour. Cells treated with serial dilutions of the membrane-damaging detergent 
Triton X-100 (0.001-1%) were included as the positive control. PSPC 15 exposure did 
not trigger visible RBC hemolysis at the maximum concentration tested (Figure 3.7 B). 
Triton X-100 caused hemolysis at all concentrations above 0.008%. These findings 
suggest that PSPC 15 does not cause damage to mammalian cell membranes, but 





Figure 3.7 Cytotoxicity and hemolytic activity of PSPC 15. A. Viability of mammalian 
HEK-293 cells was measured after treatment with serially diluted concentrations (1-64 
μg/ml) of PSPC 15 or the mitochondrial toxin rotenone (positive control). Cell viability 
was measured spectrophotometrically by detecting degradation of WST-1 dye into 
formazan by viable cells, which produces a measurable color change. B. Sheep 
erythrocytes were treated with serial dilutions of Triton X-100 (0.001-1%) or PSPC 15 
(0.063-64 μg/mL). Formation of colour indicates hemolysis. 
 
3.4 Summary and Concluding Remarks 
PSPC 15 was identified as a hit compound in a high throughput C. elegans-
MRSA liquid infection assay. The first step in confirming the validity of this result was 
to independently synthesise a sample of the compound and retest its activity in the C. 
elegans assay, and others. In pursuit of this goal, I developed a simple two step 
synthesis of PSPC 15 starting from the commercially available 2-cyano-6-
 78 
chloropyrazine 18. In the first step, a modification to the literature procedure was 
introduced where sodium thiophenolate was used in place of Na/thiophenol mixtures 
and the solvent was switched from 1,4-dioxane to THF. These simple changes made the 
reaction easier to perform, avoided the use of pyrophoric sodium metal and increased 
the yield of the desired sulfide PSPC-1S 16 from 30% to 82%, it is possibility due to 
high solubility of thiophenol in THF and it makes high yields. m-CPBA oxidation of 
PSPC-1S 16 was then able to deliver practical quantities of the sulfoxide PSPC-6S 17 
and the sulfone PSPC 15. Thus, in addition to providing a pure sample of resynthesized 
PSPC 15, this synthesis was able to deliver two new closely related analogues of the 
parent hit compound that could be used to probe whether anti-MRSA activity in the 
class shows structure-dependent activity, consistent with a target-based mechanism of 
action. 
When tested for antibacterial effects against MRSA and a panel of ESKAPE 
pathogens, the resynthesized sulfone PSPC 15 and sulfoxide PSPC-6S 17 showed 
identical activities across all tested strains, whereas the sulfide PSPC-1S 16 was totally 
inactive. The close structural similarity between these three compounds and the large 
difference in antibacterial activity that was observed despite this is evidence that the 
compound class acts by a specific (target-based) mechanism and not through a more 
general non-specific action. Further studies are required to confirm this assertion. These 
could involve a much broader medicinal chemistry program and more detailed 
exploration of the structure-activity relationships. The low molecular weight and 
promising activity of the compounds described here supports such a study. Given that 
the active sulfoxide PSPC-6S 17 is chiral, it would be interesting to isolate and test both 
enantiomers to see whether they differ in activity, which would provide further support 
for the compounds acting on discrete molecular targets. 
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PSPC 15 and PSPC-6S 17 both showed greatly reduced activity against Gram-
negative bacteria compared to Gram-positives. The action of efflux pumps in 
transporting the compounds out of Gram-negative bacteria may have contributed to the 
higher MICs. Efflux pumps have been implicated in resistance of P. aeruginosa to 
tetracycline, chloramphenicol and norfloxacin,122 agents that remain effective against 
Gram-positive bacteria, including S. aureus. Among the several categories of efflux 
pump systems in Gram-negative bacteria, the RND system is constitutively active and 
plays a major role in resistance to many antibiotics, including β-lactams, 
fluoroquinolones, and aminoglycosides.123 It is likely that PAβN potentiated the activity 
of PSPC 15 against the Gram-negative bacteria through inhibition of efflux pumps. 
Interestingly, a recent study showed that PAβN is also capable of permeabilizing 
bacterial membranes at a concentration of 50 µg/mL, leading to increased uptake of 
small molecules into bacteria from the surrounding environment.124 This suggests that 
there may be multiple ways by which PAβN potentiates the activity of PSPC 15, 
including efflux pump inhibition and by enhancing uptake. Further studies are needed to 
tease out these details. 
Polymyxin B was found to potentiate the activity of PSPC 15 against K. 
pneumoniae and A. baumannii. Polymyxin B, which was discovered more than 50 years 
ago, is effective against a wide range of Gram-negative bacteria, but was rarely used 
clinically until recently due to nephrotoxicity and neurotoxicity concerns.125 The 
rationale for testing polymyxin B in combination with PSPC 15 was that if they 
functioned synergistically, relatively low concentrations of each drug could potentially 
be used when treating infections, potentially reducing toxicity risks. Having observed 
this synergy supports further examination of other antibiotic combinations with PSPC 
15 and its analogues. 
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Chapter 4 
Part A: Experimental and references  
4.1 Experimental Procedures 
4.1.1 Chemistry – General  
All reactions were performed under an argon atmosphere in oven-dried 
glassware with magnetic stirring unless otherwise stated. Reagents and solvents were 
used without further purification unless otherwise noted. Toluene, benzene, 
dimethylformamide (DMF) and dichloromethane (DCM) were used directly from a 
Puresolve® solvent purification system. MeOH and isopropanol (iPrOH) were distilled 
from barium oxide and stored over 4 Å molecular sieves under nitrogen. THF was dried 
by distillation from sodium benzophenone ketyl under nitrogen. Reagents and starting 
materials were weighed using a Sartorius Extend 220g balance. Solvents were removed 
under reduced pressure (in vacuo) at (25-40 °C) with a Büchi rotary evaporator 70 
attached to a vacuubrand CVC2 pump (Vacuubrand GmbH, Wertheim, Germany). 
Solvent residues were removed in vacuo using a Javac Vector RD-90 double stage high 
vacuum pump. Analytical thin layer chromatography (TLC) monitoring of reactions and 
product purity was performed using aluminum-backed plates coated with silica gel 
(Merck 60 F254). Compounds on TLC plates were visualised by UV light (l 254 nm). 
Flash column chromatography was performed using Merck silica gel 60 (0.04-0.063 
mm, 230-400 mesh). 
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4.1.2 Compound characterisation and data collection 
Melting points were determined using a Buchi digital M-560 melting point 
apparatus and are uncorrected. Infrared spectra were obtained on neat samples using an 
Avator ESP spectrometer. Low resolution electron impact (EI+) mass spectra were 
obtained using a Shimadzu QP- 5000 mass spectrometer by direct insertion with a 70-
eV electron beam. Low resolution electrospray ionisation (ES+) mass spectra were 
obtained on a micromass Z-path (LCZ) platform spectrometer. EI High Resolution 
Mass Spectra (HRMS) were obtained on a Fisons/VG Autospec spectrometer using 
perfluorokerosene as internal standard. ES HRMS were obtained on a Waters QTof 
Ultima spectrometer using polyethylene glycol or polypropylene glycol as internal 
standard.  
1H, 13C and 2D-NMR experiments were performed using Varian Mercury 300 
MHz, Varian Inova 500 MHz, Varian Premium Shielded 500 MHz and Ascent 400 
MHz spectrometers at 25 °C. Spectra were referenced internally using the chemical 
shifts of solvent residual proton resonances relative to TMS (0 ppm). The abbreviations 
Ar = aryl, s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet and bs = 
broad singlet are used throughout. 
 
4.2 Replacement of the 4-carbodithioate group of HMPC 1: Analogues 2-6 
Synthesis of 5-hydroxy-3-methyl-1-phenyl-N-propyl-1H-pyrazole-4-carboxamide 2 
Pyrazol-5-one 7 (200 mg, 1.1 mmol) and K2CO3 (158 mg, 1.1 
mmol) were added to dry DMF/benzene 2:1 (18 mL) in a 50 mL 
round bottom flask and the mixture was stirred at 0 °C for 1 h 
before adding dropwise a solution containing n-propyl isocyanate 
(0.1 mL, 1.7 mmol) in dry benzene (1 mL). Stirring was 
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continued at room temperature for a further 2 h while monitoring by TLC (Pet. 
spirit:EtOAc, 60:40). The reaction was quenched by addition of 1 N HCl (10 mL) 
causing a precipitate to form. The mixture was extracted with CHCl3 (20 mL) and the 
organic fraction was washed with water and brine, dried over anhydrous MgSO4 and 
concentrated. The residue was purified by silica gel column chromatography (Pet. 
spirit:EtOAc, 85:15) to yield 2 (168 mg, 59%) as a white solid. TLC Rf (Pet. 
spirit:EtOAc, 60:40) = 0.84;  Mp 88-90 °C. 1H NMR (500 MHz, CDCl3) δ 7.51 
(apparent doublet, J = 7.7 Hz, 2H, H7, H11), 7.40 (apparent triplet, J = 7.8 Hz, 2H, H8, 
H10), 7.29 (t, J = 7.4 Hz, 1H, H9), 5.23 (s, 1H, NH), 3.16 (q, 6.7Hz, 2H, H14), 2.3 (s, 
3H, H12), 1.52 (m, 2H, H15), 0.9 (t, J = 7.4 Hz, 3H, H16); 13C NMR (125 MHz, 
CDCl3) δ 151.6 (C13), 148.9 (C5), 145.0 (C3), 138.2 (C6), 128.9 (C8, C10), 127.0 (C9), 
123.2 (C7, C11), 95.6 (C4), 43.1 (C14), 22.8 (C15), 14.5 (C12), 11.1 (C16); IR (neat) ν 
2915, 1653, 1472, 808, 755 cm-1; HRESI-MS: m/z calculated for C14H18N3O2 [M + H]+  
260.1394, found 260.1399. 
 
Synthesis of 5-hydroxy-3-methyl-1-phenyl-N-propyl-1H-pyrazole-4-carbothio 
amide 3  
Pyrazol-5-one 7 (200 mg, 1.1 mmol) and K2CO3 (158 mg, 1.1 
mmol) were added to dry DMF (3 mL) and benzene (1 mL) in a 
25 mL round bottom flask and the mixture was stirred at 0 °C for 
1 h before adding dropwise a solution containing n-propyl 
isothiocyanate (0.1 mL, 1.7 mmol) in dry benzene (1 mL). 
Stirring was continued at 50 °C for a further 5 h while monitoring by TLC (Pet. 
spirit:EtOAc, 80:20). The reaction was quenched by addition of 6 N HCl (10 mL) and 
extracted with EtOAc (2 x 15 mL). The combined organic fractions were washed with 
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water and brine, dried over anhydrous MgSO4 and concentrated. The residue was 
purified by silica gel column chromatography (Pet. spirit:EtOAc, 80:20) to yield 3 (252 
mg, 83 %) as a white solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.68; Mp 126-128 °C. 
1H NMR (500 MHz, CDCl3) δ 13.43 (s, 1H, OH), 7.78 (apparent doublet, J = 7.8 Hz, 
2H, H7, H11), 7.44 (apparent triplet, J = 7.6 Hz, 2H, H8, H10), 7.29 (t, J = 7.2 Hz, 1H, 
H9), 7.09 (s, 1H, NH), 3.75 (dd, J = 12.5, 6.5 Hz, 2H, H14), 2.53 (s, 3H, H12), 1.77 (m, 
2H, H15), 1.05 (t, J = 7.3 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 188.3 (C13), 
158.1 (C5), 142.7 (C3), 137.6 (C6), 129.1 (C8, C10), 126.9 (C9), 121.7 (C7, C11), 99.9 
(C4), 46.1 (C14), 21.8 (C15), 16.4 (C12), 11.6 (C16); IR (neat) ν 3229, 3057, 2957, 





To a 100-mL round-bottom flask was added K2CO3 (1.4 g, 10 mmol), 
DMF (7.5 mL) and benzene (15 mL) and the mixture was stirred at 
0 °C for 1 h. A separate 100 mL round bottom flask was charged with 
pyrazol-5-one 7 (700 mg, 4.0 mmol) and DMF (15 mL) and stirred for 
15 min before adding carbon disulfide (240 µL, 3.4 mmol) and stirring 
at 0 °C for 1 h. The contents of the first flask were added to the second flask and stirring 
continued at 0 °C for 6 h. Methyl iodide (620 µL, 10 mmol) in benzene (5 mL) was then 
added dropwise and the reaction stirred at 0 °C for 1 h while monitoring by TLC (Pet. 
spirit:EtOAc, 80:20). The reaction was quenched by addition of H2O (15 mL) and the 
mixture was diluted with CHCl3 (25 mL). The organic fraction was separated and 
washed with brine, dried over anhydrous MgSO4 and concentrated. The residue was 
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purified by silica gel column chromatography (20% EtOAc in hexane) to yield 4 (738 
mg, 66%) as a red solid. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.21; Mp 78-80 °C; 1H 
NMR (500 MHz, CDCl3) δ 8.00 (apparent doublet, J = 7.9 Hz, 2H, H7, H11), 7.41 
(apparent triplet, J = 7.9 Hz, 2H, H8, H10), 7.17 (t, J = 7.4 Hz, 1H, H9), 2.78 & 2.71 (s, 
2 ´ 3H, H14, H15), 2.54 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 175.4 (C13), 
160.3 (C5), 146.8 (C3), 138.7 (C6), 128.6 (C4), 124.5 (C8, C10), 121.3 (C9), 118.9 (C7, 
C11), 21.4 & 19.6 (C14, C15), 17.7 (C12); IR (neat) ν 2915, 1653, 1472, 808, 755 cm-1;  
HRESI-MS: m/z calculated for C13H15N2O S2 [M + H]+  279.0620, found 279.0626. 
 
Synthesis of Propyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate 5 
Sodium (330 mg, 1.4 mmol) was carefully added in portions to 
anhydrous n-propanol (2 mL) and the mixture was stirred until 
complete dissolution of the metal. Bis(methylthio)-methylene 
pyrazol-5-one 4 (200 mg, 0.72 mmol) was added and the reaction 
temperature was raised to 80 °C and stirred for 6 h while 
monitoring by TLC (Pet. spirit:EtOAc, 80:20). The reaction was quenched by addition 
of 6 N HCl (10 mL) causing the reaction mixture to change from orange to light yellow. 
The mixture was diluted with excess H2O and the layers separated. The aqueous layer 
was extracted with EtOAc (2 x 20 mL) and the combined organic fractions were washed 
with water and brine, dried over anhydrous MgSO4 and concentrated. The residue was 
purified by silica gel column chromatography (Pet. spirit:EtOAc, 85:15) to yield 5 (170 
mg, 90%) as a white solid. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.27;  Mp 42-44 C°;  1H 
NMR (500 MHz, CDCl3) δ 7.78 (apparent doublet, J = 7.8 Hz, 2H, H7, H11), 7.43 
(apparent triplet, J = 7.9 Hz, 2H, H9), 7.28 (t, J = 7.5 Hz, 2H, H8, H10), 4.27 (t, J = 6.5 
Hz, 1H, H14), 2.41 (s, 3H, H12), 1.78 (multiplet, 2H, H15), 1.03 (t, J = 7.4 Hz, 3H, 
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H16) 13C NMR (125 MHz, CDCl3) δ 167.5 (C13), 157.6 (C5), 148.5 (C3), 137.6 (C6), 
129.2 (C8, C10), 126.8 (C9), 121.25 (C7, C11), 93.8 (C4), 66.3 (C14), 22.2 (C15), 
14.62 (C12), 10.7 (C16); IR (neat) ν 2970, 2931, 1653, 1575, 1218, 786, 687 cm-1; 
HRESI-MS: m/z calculated for C14H17N2O3 [M + H]+  261.1234, found 261.1239. 
 
Synthesis of (Z)-3-methyl-4-((methylthio)(propylthio)methylene)-1-phenyl-1,4-
dihydro-5H-pyrazol-5-one 6  
HMPC 1 (292 mg, 1.0 mmol) and K2CO3 (138 mg, 1.0 mmol) in 
DMF (10 mL) were stirred at 0 °C for 1h before adding dropwise 
a solution of methyl iodide (0.3 mL, 5.0 mmol). The reaction was 
stirred overnight at room temperature with monitoring by TLC 
(Pet. spirit:EtOAc, 80:20). After quenching with H2O (15 mL) the 
mixture was diluted with CHCl3 (3×15 mL) and the organic 
fraction was washed with brine, dried over anhydrous MgSO4 and concentrated. The 
residue was purified by silica gel column chromatography (10% EtOAc in hexane) to 
yield 6 (277 mg, 90%) as a red liquid. TLC Rf (Pet. Spirit:EtOAc, 80:20) = 0.58; M.p 
122-124 °C; 1H NMR (400 MHz, CDCl3) δ 7.98 (apparent doublet, J = 9.9 Hz, 2H, H7, 
H11), 7.38 (apparent triplet, J = 7.4 Hz, 2H, H8, H10), 7.14 (t, J = 7.4 Hz, 1H, H9), 
3.20 (t, J = 7.4 Hz, 2H, H14), 2.71 (s, 3H, H17), 2.52 (s, 3H, H12), 1.74 (multiplet, 2H, 
H15), 1.04 (t, J = 7.4 Hz, 3H, H16), Note: the cis stereochemistry of the double bond is 
assumed based on literature126; 13C NMR (100 MHz, CDCl3) δ 174.3 (C13), 160.4 (C5), 
147.1 (C3), 138.8 (C6), 128.8 (C8, C10), 124.5 (C9), 122.4 (C4), 119.0 (C7, C11), 40.9 
(C14), 23.7 (C15), 21.2 (C17), 17.9 (C16), 13.3 (C12); IR (neat) ν 2963, 2927, 2871, 
1663, 1480, 809, 757, 644 cm-1; HRESI-MS: m/z calculated for C15H19N2OS2 [M + H]+ 
307.0933, found 307.0939. 
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4.3 Synthesis of substituted pyrazol-5-ones 10a-g & 13a-i 
General Method A: The phenylhydrazine (or hydrochloride salt) and b-keto ester (i.e. 
ethylacetoacetate or benzoylacetoacetate, 1 eq) were dissolved in glacial acetic 
acid:EtOH (10:90) and stirred at 45-50 C° overnight while monitoring by TLC (Pet. 
spirit:EtOAc, 60:40). The solvent was removed in vacuo and the crude residue was 
purified by silica gel column chromatography.  
 
General Method B: The phenyhydrazine (or hydrochloride salt) and b-keto ester (i.e. 
ethylacetoacetate or benzoylacetoacetate, 1 eq), were dissolved in EtOH and stirred at 
room temperature overnight. The solvent was removed in vacuo and the crude residue 
was purified by column chromatography.  
  
Synthesis of 3-methyl-1-(p-tolyl)-1,4-dihydro-5H-pyrazolin-5-one 10a  
 The compound was produced by General Method 
A using of p-tolylhydrazine hydrochloride 9a (1.0 
g, 6.3 mmol). The reaction mixture was diluted 
with EtOAc (50 mL) and the organic layer 
washed twice with 5% sodium bicarbonate (50 
mL) and brine, dried over anhydrous MgSO4 and concentrated. The crude residue was 
purified by silica gel column chromatography using a gradient (Pet. spirit:EtOAc, 0 → 
20%) to afford 10a (440 mg, 37%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 
80:20) = 0.37; Mp 128-130 °C; 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H, 
H7, H11), 7.17 (d, J = 8.2 Hz, 2H, H8, H10), 3.36 (s, 2H, H4), 2.32 (s, 3H, H13), 2.13 
(s, 3H, H12).; 13C NMR (75 MHz, CDCl3) δ 170.3 (C5), 156.1 (C6), 135.9 (C9), 134.8 


























3120, 3072, 2952, 2921, 2852, 1622, 1567, 1509, 776 cm-1; HRESI-MS: m/z calculated 
for C11H11N2O [M - H]- 187.0877, found 187.0871. 
 
Synthesis of 1-(4-methoxyphenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-one 10b  
 The compound was produced by General Method 
B using (4-methoxyphenyl)hydrazine 
hydrochloride 9b (1.0 g, 5.7 mmol). The crude 
residue was purified by silica gel column 
chromatography using a gradient (Pet. 
spirit:EtOAc, 0 → 5%) to afford 10b (417 mg, 35%) as a yellow powder. TLC Rf  (Pet. 
Spirit:EtOAc, 80:20) = 0.1; Mp 122-124 °C; 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 
8.0 Hz, 2H, H7, H11), 6.91 (d, J = 8.1 Hz, 2H, H8, H10), 3.80 (s, 2H, H4), 3.39 (s, 3H, 
H14), 2.17 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 170.2 (C5), 157.0 (C9), 156.0 
(C6), 131.8 (C3), 120.8 (C8, C10), 114.4 (C7, C11), 55.4 (C14), 43.0 (C4), 17.0 (C12); 
IR (neat) ν 3119, 3072, 3014, 2954, 2928, 2836, 1596, 1510, 1254, 825 cm-1; HRESI-
MS: m/z calculated for C11H11N2O2 [M - H]- 203.0826, found 203.0821. 
 
Synthesis of 1-(4-fluorophenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-one 10c  
 The compound was produced by General Method 
B using (4-fluorophenyl)hydrazine hydrochloride 
9c (1.0 g, 6.2 mmol). The crude residuewas 
purified by silica gel column chromatography 
using a gradient (Pet. spirit:EtOAc, 0 → 20%) to 
afford 10c (301 mg, 25%) as yellow powder. TLC 



















































7.83 (dd, J = 8.9, 4.8 Hz, 2H, H8, H10), 7.07 (t, J = 8.6 Hz, 2H, H7, H11), 3.43 (s, 2H, 
H4), 2.19 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 170.5 (C5), 161.0 (C9), 156.5 
(C6), 134.3 (C3), 120.8 (d, J = 7.5 Hz, C7, C11), 115.7 (d, J = 22.5 Hz, C8, C10), 43.1 
(C4), 17.1 (C12); IR (neat) ν 3054, 2922, 1597, 1509, 779 cm-1; HRESI-MS: m/z 
calculated for C10H8FN2O [M - H]- 1910626, found 191.0621. 
 
Synthesis of 1-(4-chlorophenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-ol 10d  
 The compound was produced by General Method B 
using (4-chlorophenyl)hydrazine hydrochloride 9d 
(1.0 g, 5.5 mmol). The crude residue was purified by 
recrystallization from ethanol (20 mL) to afford 10d 
(441 mg, 37%) as a yellow powder. TLC Rf (Pet. 
spirit:EtOAc, 80:20) = 0.14; Mp 163-164 °C; 1H NMR (500 MHz, d6-DMSO) δ 7.75 
(d, J = 8.6 Hz, 2H, H7, H11), 7.47 (d, J = 8.6 Hz, 2H ,H8, H10), 5.37 (s, 1H, H4), 2.11 
(s, 3H, H12); 13C NMR (125 MHz, d6-DMSO) δ 158.7 (C5), 149.1 (C3), 137.7 (C6), 
128.8 (C8, C10), 128.1 (C9) 121.4 (C7, C11), 89.1 (C4), 14.0 (C12); IR (neat) ν 3107, 
3042, 2924, 1493, 761 cm-1; HRESI-MS: m/z calculated for C10H8ClN2O [M - H]- 
207.0331, found 207.0325. 
 
Synthesis of 1-(4-bromophenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-ol 10e  
The compound was produced by General Method B 
using (4-bromophenyl)hydrazine hydrochloride 9e 
(1.0 g, 4.4 mmol). The crude residue was purified by 
recrystallization from ethanol (20 mL) to afford 10e 


















































spirit:EtOAc, 80:20) = 0.16; Mp 191-193 °C; 1H NMR (400 MHz, d6-DMSO) δ 7.69 
(m, 2H, H7, H11), 7.64 (m, 2H, H8, H10), 5.49 (s, 1H, H4), 2.16 (s, 3H, H12); 13C 
NMR (100 MHz, d6-DMSO) δ 155.7 (C5), 149.2 (C3), 137.3 (C6), 132.3 (C8, C10), 
123.0 (C7, C11), 118.3 (C9), 89.8 (C4), 13.9 (C12); IR (neat) ν 3087, 1593, 1484, 798 
cm-1; HRESI-MS: m/z calculated for C10H8BrN2 [M - H]- 250.9825, 
 
Synthesis of 1-(4-cyanophenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-ol 10f 
The compound was produced by General Method B 
using (4-cyanophenyl)hydrazine hydrochloride 9f (1.0 
g, 5.9 mmol). The crude residue was purified by 
recrystallization from ethanol (20 mL) to afford 10f 
(522 mg, 44%) as a yellow powder. TLC Rf (Pet. 
spirit:EtOAc, 80:20) = 0.42; Mp 167-169 °C; 1H NMR (500 MHz, d6-DMSO) δ 7.96 
(d, J = 8.4 Hz, 2H, H7,H11), 7.86 (d, J = 8.4 Hz, 2H, H8, H10), 5.40 (s, 1H, H4), 2.13 
(s, 3H, H12); 13C NMR (125 MHz, d6-DMSO) δ 160.4 (C5), 142.2 (C3), 133.9 (C8, 
C10), 119.99 (C9), 119.4 (C6), 118.1 (C7, C11), 107.0 (C13), 89.2 (C4), 17.4 (C12); IR 
(neat) ν 3137, 3110, 2961, 2223, 1620, 1511 cm-1 HRESI-MS: m/z calculated for 
C11H8N3O [M - H]- 198.0673, found 198.0667. 
 
Synthesis of 1-(4-nitrophenyl)-3-methyl-1,4-dihydro-5H-pyrazolin-5-one 10g  
 The compound was produced by General Method A 
using (4-nitrophenyl)hydrazine hydrochloride 9g 
(1.0 g, 5.2 mmol). The reaction mixture was diluted 
with CHCl3 (100 mL) and the organic layer washed 



















































(100 mL), dried over anhydrous MgSO4 and concentrated. The crude residue was 
purified by recrystallization from ethanol (20 mL) to afford 10g (424 mg, 36%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.31; Mp 111-113 °C; 1H NMR 
(300 MHz, CDCl3) δ 8.13 (d, J = 9.0 Hz, 2H, H7, H11), 7.07 (d, J = 9.0 Hz, 2H, H8, 
H10), 3.40 (s, 2H, H4), 2.02 (s, 3H, H12); 13C NMR (75 MHz, CDCl3) δ 170.4 (C9), 
150.2 (C5), 143.7 (C3), 140.0 (C6), 126.0 (C8, C10), 112.2 (C7, C11), 44.5 (C4), 15.1 
(C12);  IR (neat) ν 3310, 3095, 2983, 2906, 1709, 1594, 1320, 1112, 843 cm-1; HRESI-
MS: m/z calculated for C10H8N3O3 [M - H]- 218.0571, found 218.0566. 
 
Synthesis of 1,3-diphenyl-1,4-dihydro-5H-pyrazolin-5-one 13a  
 The compound was produced by General 
Method B using phenylhydrazine hydrochloride 
(1.0 g, 6.9 mmol) and 1.1 eq of ethyl 3-oxo-3-
phenylpropanoate 12a. The crude residue was 
purified by silica gel column chromatography 
using a gradient (Pet. spirit:EtOAc, 80:20) to 
afford 13a (835 mg, 51%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 60:40) = 
0.66; Mp 129-131 °C; 1H NMR (500 MHz, CDCl3) δ 7.96 (apparent doublet, J = 8.1 
Hz, 2H, H7, H11), 7.74 (m, 2H, H7', H11'), 7.42 (m, 5H, H8, H10, H8', H10', H9'), 7.20 
(t, J = 7.3 Hz, 1H, H9), 3.78 (s, 2H, H4); 13C NMR (125 MHz, CDCl3) δ 170.3 (C5), 
154.7 (C3), 138.2 (C6), 130.9 (C6'), 130.7 (C9’), 129.0 (C8', C10'), 128.9 (C8, C10), 
126.0 (C7', C11'), 125.3 (C9), 119.1 (C7, C11), 39.7 (C4); IR (neat) ν 3067, 3027, 2960, 
2701, 1250, 828, 755 cm-1; HRESI-MS: m/z calculated for C15H11N2O [M - H]- 




































Synthesis of 1-phenyl-3-(p-tolyl)-1,4-dihydro-5H-pyrazolin-5-one 13b  
 The compound was produced by General 
Method B using phenylhydrazine (175 mg, 1.6 
mmol) and (1.1 eq) of ethyl 3-oxo-3-(p-tolyl) 
propanoate 12b. The crude residue was purified 
by silica gel column chromatography using a 
gradient (Pet. spirit:EtOAc, 85:15) to afford 
13b (330 mg, 81%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.53; Mp 
141-143 °C; 1H NMR (500 MHz, CDCl3) δ 7.96 (apparent doublet, J = 7.9 Hz, 2H, H7, 
H11), 7.63 (d, J = 7.5 Hz, 2H, H7', H11'), 7.41 (apparent triplet, J = 7.4 Hz, 2H, H8, 
H10), 7.21 (m, 3H, H9, H8¢, H10¢), 3.76 (s, 2H, H4), 2.39 (s, 3H, H13); 13C NMR (125 
MHz, CDCl3) δ 170.3 (C5), 154.8 (C3), 141.2 (C6), 138.2 (C6¢), 129.7 (C8', C10'), 
128.9 (C8, C10), 128.2 (C9'), 126.0 (C7', C11'), 125.3 (C9), 119.1 (C7, C11), 39.7 (C4), 
21.6 (C13); IR (neat) ν 3033, 2941, 2853, 1703, 816, 751cm-1; HRESI-MS: m/z 
calculated for C16H13N2O [M - H]- 249.1036, found 249.1028. 
 
Synthesis of 1-phenyl-3-(4-methoxyphenyl)-1,4-dihydro-5H-pyrazolin-5-one 13c  
 The compound was produced by General 
Method B using phenylhydrazine (169 mg, 1.5 
mmol) and 1.1 eq of ethyl 3-(4-
methoxyphenyl)-3-oxopropanoate 12c. The 
crude residue was purified by silica gel column 
(Pet. spirit:EtOAc, 75:25) to afford 13c (275 
mg, 66%) as a yellow powder. TLC Rf (Pet. 











































































(apparent doublet, J = 8.2 Hz, 2H, H7, H11), 7.67 (d, J = 8.5 Hz, 2H, H7', H11'), 7.40 
(apparent triplet, J = 7.8 Hz, 2H, H8, H10), 7.19 (t, J = 7.3 Hz, 1H, H9), 6.93 (d, J = 8.5 
Hz, 2H, H8¢, H10¢), 3.83 (s, 3H, H18), 3.74 (s, 2H, H4); 13C NMR (125 MHz, CDCl3) δ 
170.2 (C5), 161.6 (C9'), 154.5 (C3), 138.2 (C6), 128.9 (C8, C10), 127.6 (C7', C11'), 
125.1 (C9), 123.7 (C6'), 119.0 (C7, C11), 114.4 (C8', C10'), 55.4 (C18), 39.8 (C4); IR 
(neat) ν 3043, 2950, 2843, 1697, 1253, 835, 745, cm-1; HRESI-MS: m/z calculated for 
C16H15N2O2 [M + H]+  267.1142, found 267.1134. 
 
Synthesis of 1-phenyl-3-(4-fluorophenyl)-1,4-dihydro-5H-pyrazolin-5-one 13d  
The compound was produced by General 
Method B using phenylhydrazine (100 mg, 0.92 
mmol) and 1.1 eq of ethyl 3-(4-fluorophenyl)-
3-oxopropanoate 12d. The crude residue was 
purified by using silica gel column 
chromatography (Pet. spirit:EtOAc, 80:20) to 
afford 13d (154 mg, 65%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.4; 
Mp 190-192 °C; 1H NMR (500 MHz, CDCl3) δ 7.95 (apparent doublet, J = 7.9 Hz, 2H, 
H7, H11), 7.77 (dd, J = 8.5, 5.4 Hz, 2H, H8', H10'), 7.43 (apparent triplet, J = 7.9 Hz, 
2H, H8, H10), 7.22 (t, J = 7.4 Hz, 1H, H9), 7.15 (t, J = 8.5 Hz, 2H, H7', H11'), 3.82 (s, 
2H, H4); 13C NMR (125 MHz, CDCl3) δ 170.2 (C5), 165.4 (d, J = 245.7 Hz, C9'), 153.7 
(C3), 138.2 (C6), 129.0 (C8, C10), 128.2 (d, J = 8.8 Hz, C7'/11'), 127.4 (C6') 125.5 
(C9), 119.2 (C7, C11), 116.4 (d, J = 22.68 Hz, C8'/10'), 39.8 (C4); IR (neat) ν 2960, 
2921, 2852, 1700, 1593, 1329, 1217 cm-1; HRESI-MS: m/z calculated for C15H10N2OF 







































Synthesis of 1-phenyl-3-(4-chlorophenyl)-1,4-dihydro-5H-pyrazolin-5-one 13e 
The compound was produced by General 
Method B using phenylhydrazine hydrochloride 
and 1.1 eq of ethyl 3-(4-chlorophenyl)-3-
oxopropanoate 12e. The crude residue was 
purified by silica gel column chromatography 
(Pet. spirit:EtOAc, 90:10) to afford 13e (40 mg, 
21%) as a yellow powder. TLC Rf  (Pet. spirit:EtOAc, 80:20) = 0.53; Mp 134-136 °C; 
1H NMR (500 MHz, CDCl3) δ 7.94 (apparent doublet, J = 7.9 Hz, 2H, H7, H11), 7.68 
(d, J = 8.4 Hz, 2H, H7', H11'), 7.42 (m, 4H, H8, H8', H10, H10'), 7.21 (t, J = 7.4 Hz, 
1H, H9), 3.78 (s, 2H, H4); 13C NMR (125 MHz, CDCl3) δ 169.9 (C5), 153.4 (C3), 137.9 
(C6), 136.6 (C6'), 129.2 (C9'), 129.1 (C8, C10), 128.8 (C8', C10'), 127.1 (C7', C11'), 
125.3 (C9), 118.9 (C7, C11), 39.4 (C4); IR (neat) ν 3064, 2950, 2922, 2852, 1696, 
1493, 823, 750 cm-1; HRESI-MS: m/z calculated for C15H12N2OCl [M + H]+  271.0649, 
found 271.0638. 
 
Synthesis of 1-phenyl-3-(4-bromophenyl)-1,4-dihydro-5H-pyrazolin-5-ol 13f  
The compound was produced by General 
Method B using phenylhydrazine (167 mg, 1.5 
mmol) and 1.1 eq of ethyl 3-(4-bromophenyl)-
3-oxopropanoate 12f. The crude residue was 
purified by silica gel column chromatography 
(Pet. spirit:EtOAc, 90:10) to afford 13f (340 
mg, 69%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.37; Mp 158-










































































H11, H11'), 7.60 (d, J = 7.6 Hz, 2H, H8', H10'), 7.48 (apparent triplet, J = 7.6 Hz, 2H, 
H8, H10), 7.30 (t, J = 7.4 Hz, 1H, H9), 6.04 (s, 1H, H4); 13C NMR (100 MHz, d6-
DMSO) δ 154.3 (C5), 148.9 (C3), 139.2 (C6), 133.1 (C6'), 131.9 (C8', C10'), 129.3 
(C7', C11'), 127.5 (C8, C10), 126.3 (C9), 121.6 (C7, C11), 121.3 (C9'), 85.6 (C4); IR 
(neat) ν 3062, 2951, 2900, 1691, 820, 750, 500 cm-1; HRESI-MS: m/z calculated for 




 The compound was produced by General 
Method B using phenylhydrazine (200 mg, 
1.4 mmol) and 1.1 eq of ethyl 3-oxo-3-(4-
(trifluoromethyl)phenyl)propanoate 12g. 
The crude residue was purified by silica gel 
column chromatography (Pet. spirit:EtOAc, 
90:10) to afford 13g (221 mg, 49%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 
80:20) = 0.44; Mp 156-158 °C; 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 8.0 Hz, 2H, 
H8', H10'), 7.89 (apparent doublet, J = 8.0 Hz, 2H, H7, H11), 7.72 (d, J = 8.1 Hz, 2H, 
H7', H11'), 7.44 (apparent triplet, J = 7.8 Hz, 2H, H8, H10), 7.24 (m, 1H, H9), 3.87 (s, 
2H, H4); 13C NMR (125 MHz, CDCl3) δ 170.0 (C5), 153.2 (C3), 138.0 (C6), 134.2 
(C6'), 132.5 (C9'), 129.1 (C7', C11'), 126.3 1 (C8, C10), 126.1 (C8', C10'), 125.8 (C9), 
125.1 (C17), 119.3 (C7, C11), 39.5 (C4); IR (neat) ν 3028, 2895, 1607, 1111, 846, 758,  










































Synthesis of 1-phenyl-3-(4-cyanophenyl)-1,4-dihydro-5H-pyrazolin-5-ol 13h 
 The compound was produced by General 
Method B using phenylhydrazine hydrochloride 
(200 mg, 1.3 mmol) and 1.1 eq of ethyl 3-(4-
cyanophenyl)-3-oxopropanoate 12h. The crude 
residue was purified by silica gel column 
chromatography (DCM) to afford 13h (163 mg, 
45%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.42; Mp 211-213 °C; 1H 
NMR (400 MHz, d6-DMSO) δ 11.99 (s, 1H, OH), 8.30 (d, J = 8.0 Hz, 2H, H8¢, H10¢), 
7.87 (d, J = 7.8 Hz, 2H, H7¢, H11¢), 7.82 (apparent doublet, J = 7.8 Hz, 2H, H7, H11), 
7.50 (apparent triplet, J = 7.4 Hz,, 2H, H8, H10), 7.34 (t, J = 7.4 Hz, 1H, H9), 6.17 (s, 
1H, H4); 13C NMR (100 MHz, DMSO) δ 154.5 (C5), 148.3 (C3), 139.0 (C6), 138.3 
(C9'), 133.0 (C7', C11'), 129.4 (C8, C10), 126.6 (C9), 126.1 (C8', C10'), 121.9 (C7, 
C11), 119.4 (C17), 110.4 (C6'), 86.3 (C4); IR (neat) ν 2885, 2225, 1554, 1516, 847, 764 
cm-1; HRESI-MS: m/z calculated for C16H12N3O [M + H]+ 262.0983, found 262.0980. 
 
Synthesis of 1-phenyl-3-(4-nitrophenyl)-1,4-dihydro-5H-pyrazolin-5-ol 13i 
 The compound was produced by General 
Method B using phenylhydrazine 
hydrochloride (250 mg, 0.69 mmol) and 
1.1 eq of ethyl 3-(4-nitrophenyl)-3-
oxopropanoate 12i. The crude residue was 
purified by using silica gel column 
chromatography (Pet. spirit:EtOAc, 80:20) to afford 13i (122 mg, 27 %) as red-white 











































































d6-DMSO) δ 8.28 (d, J = 8.8 Hz, 2H, H8', H10'), 8.10 (d, J = 8.8 Hz, 2H, H7', H11'), 
7.83 (apparent doublet, J = 8.5 Hz, 2H, H7, H11), 7.51 (apparent triplet, J = 8.5 Hz, 2H, 
H8, H10), 7.34 (t, J = 8.4 Hz, 1H, H9), 6.23 (s, 1H, H4); 13C NMR (100 MHz, DMSO) 
δ 154.7 (C9'), 147.9 (C6'), 147.0 (C5), 140.2 (C3), 139.0 (C6), 129.4 (C7', C11'), 126.7 
(C9), 126.3 (C8, C10), 124.4 (C8', C10'), 121.9 (C7, C11), 86.6 (C4); IR (neat) ν 2835, 
1518, 1335, 750, 686 cm-1; HRESI-MS: m/z calculated for C15H12N3O3 [M + H]+ 
282.0879, found 282.0879. 
 
4.4 Methods for the synthesis of carbodithioates 1, 8a-f, 11a-g and 14a-i 
Method A (8a-f): n-butyllithium in hexane 2.3 M (0.5 mL, 1.1 mmol) was added 
dropwise to a solution of the pyrazol-3-one 7 (1.1 mmol) in anhydrous THF (12 mL) at 
0 °C. Stirring was continued for 1 h before adding dropwise a solution of carbon 
disulfide (87.4 µL, 1.1 mmol) in anhydrous THF (2mL). The mixture was stirred at 
room temperature for a further 1.5 h before adding a solution of the alkyl halide (1.2 
mmol) in anhydrous THF (5 mL) and stirring at room temperature for a further 16 h 
while monitoring by TLC (Pet. spirit:EtOAc). The solvent was evaporated and the 
residue taken up into CHCl3 and treated with saturated potassium chloride (10 mL). The 
organic layer was washed successively with H2O and brine, dried over anhydrous 
MgSO4 and concentrated. The crude residue was purified by silica gel column 
chromatography. 
 
Method B (11a-g): n-butyllithium in hexanes 2.1 M (1.0 eq) was added dropwise to a 
solution of the substituted pyrazol-3-one (10a-g) in anhydrous THF (12 mL) at 0 °C. 
After stirring for 1 h, carbon disulfide (1.0 eq) in anhydrous THF (2 mL) was added 
dropwise and the mixture was stirred at room temperature for 1.5 h before adding n-
 97 
bromopropane (1.0 eq) in anhydrous THF (5 mL) dropwise. The reaction was stirred at 
room temperature for 16 h while monitoring by TLC (Pet. spirit:EtOAc, 80:20). The 
mixture was diluted with EtOAc (10 mL) and saturated potassium chloride (10 ml) was 
added. The organic layer was washed successively with H2O and brine, dried over 
anhydrous MgSO4 and concentrated. The crude residue was purified by silica gel 
column chromatography. 
 
Method C (14a-i): n-butyllithium in hexane 1.2 M (1.0 eq) was added dropwise to a 
solution of the substituted pyrazol-3-one (13a-i) in anhydrous THF (15 mL) at 0 °C. 
Stirring was continued for 1 h before adding dropwise carbon disulfide (1.0 eq) in 
anhydrous THF (3 mL). The mixture was stirred at room temperature for 1.5 h before 
adding n-bromopropane (1.0 eq) in anhydrous THF (6 mL) and stirring at room 
temperature for a further 16 h while monitoring by TLC (Pet. spirit:EtOAc, 80:20). The 
mixture was diluted with EtOAc (10 mL) and saturated potassium chloride (15 mL) was 
added. The organic layer was washed successively with H2O and brine, dried over 




carbodithioate (HMPC) 1  
n-butyllithium in hexane 2.1 M (1.9 mL, 3.9 mmol) was added 
dropwise to a solution of pyrazolone-5-one 7 (690 mg, 3.9 mmol) 
in anhydrous THF (25 mL) at 0 °C. The mixture was stirred at 
0 °C for 1 h before adding dropwise carbon disulfide (0.2mL, 3.9 




















room temperature for another 1.5 h before adding 1-propylbromide (360 µL, 3.9 mmol) 
in anhydrous (12 mL) THF. The reaction was stirred at room temperature for 16 h while 
monitoring by TLC (Pet. spirit:EtOAc, 80:20). The residue was diluted with hexane (20 
mL) and saturated potassium chloride (15 ml) was added. The organic layer was washed 
successively with H2O and brine, dried over anhydrous Na2SO4 and concentrated. The 
crude residue was purified by silica gel column chromatography to afford HMPC 1 (593 
mg, 52%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.78; Mp 66-68 °C; 
1H NMR (500 MHz, CDCl3) δ 7.81 (apparent doublet, J = 7.7 Hz, 2H, H7, H11), 7.46 
(apparent triplet, J = 8.0 Hz, 2H, H8, H10), 7.31 (t, J = 7.4 Hz, 1H, H9), 3.37 (t, J = 7.4 
Hz, 2H, H14), 2.67 (s, 3H, H12), 1.82 (sextet, 7.4 Hz, 2H, H15), 1.09 (t, J = 7.4 Hz, 3H, 
H16); 13C NMR (125 MHz, CDCl3) δ 213.8 (C13), 157.6 (C5), 146.8 (C3), 137.2 (C6), 
129.1 (C8, C10), 127.0 (C9), 121.7 (C7, C11), 111.3 (C4), 35.6 (C14) , 21.2 (C15), 18.1 
(C12), 13.7 (C16); IR (neat) ν 2964, 2929, 2870, 1554, 1457, 969, 758 cm-1; HRESI-
MS: m/z calculated for C14H15N2OS2 [M - H]-  291.0631, found 291.0626. 
 
Synthesis of Methyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate 
8a 
General Method A using iodomethane (163 mg, 1.1 mmol) afforded 
8a (248 mg, 85%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 
80:20) = 0.75; Mp 86-88 °C; 1H NMR (500 MHz, CDCl3) δ 13.70 (s, 
1H, OH), 7.81 (apparent doublet, J = 7.7 Hz, 2H, H7, H11), 7.45 
(apparent triplet, J = 7.9 Hz, 2H, H8, H10), 7.31 (t, J = 7.4 Hz, 1H, 
H9), 2.75 (s, 3H, H14), 2.67 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 214.4 (C13), 


















111.6 (C4), 18.1 (C14), 17.4 (C12); IR (neat) ν 3056, 2924, 1490, 952, 749 cm-1; 
HRESI-MS: m/z calculated for C12H11N2OS2 [M - H]- 263.0318, found 263.0313. 
 
Synthesis of Ethyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate 8b 
General Method A using iodoethane (179 mg, 1.1 mmol) afforded 
8b (265 mg, 86%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 
80:20) = 0.78; Mp 76-78 °C; 1H NMR (300 MHz, CDCl3) δ 13.77 
(s, 1H, OH), 7.81 (apparent doublet, J = 7.9 Hz, 2H, H7, H11), 
7.45 (apparent triplet, J = 7.9 Hz, 2H, H8, H10), 7.30 (t, J = 7.4 
Hz, 1H, H9), 3.38 (t, J = 7.4 Hz, 2H, H14), 2.66 (s, 3H, H12), 1.43 (t, J = 7.4 Hz, 3H, 
H15); 13C NMR (75 MHz, CDCl3) δ 213.7 (C13), 157.8 (C5), 146.9 (C3), 137.3 (C6), 
129.2 (C8, C10), 127.1 (C9), 121.7 (C7, C11), 111.3 (C4), 28.3 (C14), 18.2 (C12), 12.8 
(C15); IR (neat) ν 2967, 2929, 1455, 966, 911, 688 cm-1; HRESI-MS: m/z calculated for 




General Method A using allyl bromide (139 mg, 1.1 mmol) 
afforded 8c (176 mg, 55%) as a yellow powder. TLC Rf (Pet. 
spirit:EtOAc, 80:20) = 0.75; Mp 58-60 °C; 1H NMR (500 MHz, 
CDCl3) δ 13.66 (s, 1H, OH), 7.81 (apparent doublet J = 7.9 Hz, 
2H, H7, H11), 7.46 (apparent triplet, J = 7.9 Hz, 2H, H8, H10), 
7.31 (t, J = 7.4 Hz, 1H, H9), 5.96 (td, J = 17.0, 7.0 Hz, 1H, H15), 
5.34 (dd, J = 71.3, 13.5 Hz, 2H, H16), 4.07 (d, J = 7.0 Hz, 2H, H14), 2.67 (s, 3H, H12); 





































(C15), 129.1 (C8, C10), 127.1 (C9), 121.7 (C7, C11), 120.1 (C16), 111.3 (C4), 36.6 
(C14), 18.1 (C12); IR (neat) ν 3090, 2919, 2850, 1558, 1457, 902, 750 cm-1; HRESI-
MS: m/z calculated for C14H13N2OS2 [M - H]- 289.0475, found 289.0469. 
 
Synthesis of butyl-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-
carbodithioate 8d  
General Method A using n-bromobutane (157 mg, 1.1 mmol) 
afforded 8d (250 mg, 74%) as a yellow powder. TLC Rf (Pet. 
spirit:EtOAc, 80:20) = 0.71; Mp 90-92 °C; 1H NMR (300 
MHz, CDCl3) δ 13.78 (s, 1H, OH), 7.81 (apparent doublet, J 
= 7.8 Hz, 1H, H7, H11), 7.44 (apparent triplet, J = 7.9 Hz, 
2H, H8, H10), 7.30 (t, J = 7.4 Hz, 1H, H9), 3.38 (t, 2H, J = 
7.4 Hz, H14), 2.66 (s, 3H, H12), 1.75 (Quintet, 2H, H15), 1.50 (sextet, J = 14.5, 7.3 Hz, 
2H, H16), 0.98 (t, J = 7.3 Hz, 3H, H17); 13C NMR (75 MHz, CDCl3) δ  213.8 (C13), 
157.7 (C5), 146.8 (C3), 137.3 (C6), 129.1 (C8, C10), 127.1 (C9), 121.7 (C7, C11), 
111.3 (C4), 33.6 (C14), 29.8 (C15), 22.3 (C16), 18.2 (C12), 13.7 (C17); IR (neat) ν 
2964, 2927, 2865, 1521, 1457, 911, 750 cm-1; HRESI-MS: m/z calculated for 
C15H17N2OS2 [M - H]- 305.0788, found 305.0782. 
 
Synthesis of Benzyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate 8e 
General Method A using benzyl bromide (196 mg, 1.1 mmol) 
afforded 8e (290 mg, 77%) as a yellow powder. TLC (Pet. 
spirit:EtOAc, 80:20) Rf = 0.75; Mp 78-80 °C; 1H NMR (500 









































H11), 7.43 (m, 4H, H8, H10, H7¢, H11¢), 7.34 (m, 4H, H9, H9¢, H8¢ ,H11¢), 4.64 (s, 2H, 
H14), 2.64 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 212.6 (C13), 157.7 (C5), 146.8 
(C3), 137.1 (C6), 134.6 (C6¢), 129.5 (C7¢, C11¢), 129.1 (C8, C10), 128.8 (C8¢, C10¢), 
127.9 (C9¢), 127.1 (C9), 121.6 (C7, C11), 111.1 (C4), 38.7 (C14), 18.1 (C12); IR (neat) 
ν 2922, 2849, 1558, 1492, 903, 812, 702 cm-1; HRESI-MS: m/z calculated for 
C18H17N2OS2 [M + H]+ 341.0782, found 341.0786. 
 
Synthesis of pyridin-3-ylmethyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-
carbodithioate 8f   
General Method A using 3-(Bromomethyl)pyridine 
hydrobromide (278 mg, 0.57 mmol) to afford 8f (117 mg, 
60%) as a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) 
= 0.72; Mp 153-155 °C; 1H NMR (500 MHz, CDCl3) δ 8.69 
(s, 1H, H7'), 8.55 (d, J = 3.9 Hz, 1H, H9'), 7.80 (apparent 
doublet, J = 7.8 Hz, 2H, H7, H11), 7.75 (d, J = 7.8 Hz, 1H, H11'), 7.46 (apparent triplet, 
J = 7.8 Hz, 2H, H8, H10), 7.33 (t, J  = 7.4 Hz, 1H, H9), 7.28(m, 1H, H10'), 4.64 (s, 2H, 
H14), 2.65 (s, 3H, H12); 13C NMR (125 MHz, CDCl3) δ 211.4 (C13), 157.8 (C5), 150.5 
(C9'), 149.0 (C7'), 146.7 (C3), 137.0 (C6), 136.8 (C11'), 131.2 (C6'), 129.1 (C8, C10), 
127.2 (C9), 123.5 (C10'), 121.7 (C7, C11), 111.3 (C4), 35.2 (C14), 18.0 (C12); IR 
(neat) ν 2966, , 2925, 1416, 1388, 974, 627 cm-1; HRESI-MS: m/z calculated for 


























Synthesis of propyl 3-methyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-pyrazole-4-
carbodithioate 11a  
The compound was produced by General Method B using 10a 
(200 mg, 1.06 mmol) to afford 11a (245 mg, 75%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.82; Mp 103-
104 °C; 1H NMR (500 MHz, CDCl3) δ 13.70 (s, 1H, OH), 7.67 
(d, J = 8.2 Hz, 2H, H7, H11), 7.25 (d, J = 7.8 Hz, 2H, H8, H10), 
3.38 (t, J = 7.3 Hz, 2H, H14), 2.67 (s, 3H, H12), 2.38 (s, 3H, 
H17), 1.82 (dd, J = 14.7, 7.3 Hz, 2H, H15), 1.10 (t, J = 7.3 Hz, 3H, H16); 13C NMR 
(125 MHz, CDCl3) δ 213.8 (C13), 157.7 (C5), 146.8 (C3), 137.2 (C6), 134.9 (C9), 
129.8 (C8, C10), 121.9 (C7, C11), 111.5 (C4), 35.8 (C14), 21.5 (C15), 21.3 (C17), 18.3 
(C12), 13.8 (C16); IR (neat) ν 2969, 2925, 2870, 1558, 1507, 1058, 965, 816 cm-1; 
HRESI-MS: m/z calculated for C15H17N2OS2 [M - H]- 306.0788, found 306.0782. 
 
Synthesis of propyl 3-methyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-pyrazole-4-
carbodithioate 11b 
The compound was produced by General Method B using 10b 
(226 mg, 1.1 mmol) to afford 11b (226 mg, 63%) as a yellow 
powder. TLC Rf  (Pet. spirit:EtOAc, 80:20) = 0.71; Mp 102-
104 °C; 1H NMR (500 MHz, CDCl3) δ 13.63 (s, 1H, OH), 7.67 
(d, J = 7.8 Hz, 2H, H7, H11), 6.96 (d, J = 7.8 Hz, 2H, H8, H10), 
3.83 (s, 3H, H18), 3.37 (t, J = 7.5 Hz, 2H, H14), 2.66 (s, 3H, 
H12), 1.81 (t, J = 7.4Hz, 2H, H15), 1.09 (t, J = 7.4 Hz, 3H, H16); 13C NMR (125 MHz, 
CDCl3) δ 213.7 (C13), 158.6 (C5), 157.3 (C9), 146.6 (C3), 130.4 (C6), 123.5 (C8, C10), 









































(C16); IR (neat) ν 2963, 2923, 1558, 1507, 964, 738 cm-1; HRESI-MS: m/z calculated 
for C15H17N2O2S2 [M - H]- 321.0737, found 321.0731. 
 
Synthesis of propyl 1-(4-fluorophenyl)-5-hydroxy-3-methyl-1H-pyrazole-4-
carbodithioate 11c  
The compound was produced by General Method B using 10c 
(150 mg, 0.78 mmol) to afford 11c (164 mg, 67%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.77; Mp 97-99 °C; 
1H NMR (500 MHz, CDCl3) δ 13.78 (s, 1H, OH), 7.78 (m, 2H, 
H8, H10), 7.14 (t, J = 8.0 Hz, 2H, H7, H11), 3.37 (t, J = 7.4 Hz, 
2H, H14), 2.65 (s, 3H, H12), 1.82 (sextet, J = 7.3 Hz, 2H, H15), 
1.09 (t, J = 7.3 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 214.1 (C13), 162.4 (d, J = 
248 Hz, C9), 160.4 (C5), 157.6 (C3), 147.0 (C6), 123.7 (J = 8.8 Hz, C7, C11), 116.2 (d, 
J = 22 Hz, C8, C10), 111.3 (C4), 35.9 (C14), 21.4 (C15), 18.2 (C12), 13.8 (C16); IR 
(neat) ν 3069, 2970, 1934, 1507, 1223, 967, 765 cm-1; HRESI-MS: m/z calculated for 
C14H14FN2OS2 [M - H]- 309.0537, found 309.0532. 
 
Synthesis of propyl 1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazole-4-
carbodithioate 11d 
The compound was produced by General Method B using 10d 
(150 mg, 0.72 mmol) to afford 11d (140 mg, 59%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.77; Mp 132-
134 °C; 1H NMR (500 MHz, CDCl3) δ 13.87 (s, 1H, OH), 7.79 
(d, J = 8.6 Hz, 2H, H7, H11), 7.41 (d, J = 8.7 Hz, 2H, H8, H10), 








































7.3 Hz, 2H, H15), 1.09 (t, J = 7.3 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 214.2 
(C13), 157.8 (C5), 147.2 (C3), 136.0 (C6), 132.6 (C9), 129.3 (C8, C10), 122.7 (C7, 
C11), 111.4 (C4), 35.9 (C14), 21.4 (C15), 18.2 (C12), 13.8 (C16); IR (neat) ν 3051, 
2968, 2926, 1416, 827, 760 cm-1; HRESI-MS: m/z calculated for C14H14ClN2OS2 [M - 
H]- 325.0242, found 325.0236. 
 
Synthesis of propyl 1-(4-bromophenyl)-5-hydroxy-3-methyl-1H-pyrazole-4-
carbodithioate 11e  
The compound was produced by General Method B using 10e 
(140 mg, 0.55 mmol) to afford 11e (73 mg, 35%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.81; Mp 118-
120 °C; 1H NMR (500 MHz, CDCl3) δ 13.89 (s, 1H, OH), 7.74 
(d, J = 8.1 Hz, 2H, H7, H11), 7.56 (d, J = 8.1 Hz, 2H, H8, H10), 
3.37 (t, J = 6.9 Hz, 2H, H14), 2.65 (s, 3H, H12), 1.82 (dd, J = 
14.2, 7.0 Hz, 2H, H15), 1.09 (t, J = 7.0 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 
214.1 (C13), 157.9 (C5), 147.3 (C3), 136.5 (C6), 132.3 (C8, C10), 123.0 (C7, C11), 
120.5 (C9), 111.4 (C4), 35.9 (C14), 21.4 (C15), 18.3 (C12), 13.8 (C16); IR (neat) ν 
2964, 2925, 1550, 1522, 968, 825, 756 cm-1; HRESI-MS: m/z calculated for 


























Synthesis of propyl 1-(4-cyanophenyl)-5-hydroxy-3-methyl-1H-pyrazole-4-
carbodithioate 11f 
The compound was produced by General Method B using 10f 
(150 mg, 0.75 mmol) to afford 11f (77 mg, 32%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.66; Mp 136-
138 °C; 1H NMR (300 MHz, CDCl3) δ 8.07 (d, J = 8.7 Hz, 2H, 
H7, H11), 7.74 (d, J = 8.7 Hz, 2H, H8, H10), 3.38 (t, J = 7.4 Hz, 
2H, H14), 2.67 (s, 3H, H12), 1.83 (sextet, J = 7.4 Hz, 2H, H15), 
1.10 (t, J = 7.4 Hz, 3H, H16); 13C NMR (75 MHz, CDCl3) δ 158.6 (C5), 148.1 (C3), 
141.0 (C6), 133.4 (C8, C10), 121.2 (C7, C11), 118.6 (C9), 111.3 (C4), 110.0 (C17), 
36.0 (C14), 21.3 (C15), 18.3 (C12), 13.9 (C16); IR (neat) ν 3122, 3064, 2968, 2227, 
1549, 1418, 958, 742 cm-1; HRESI-MS: m/z calculated for C15H14N3OS2 [M - H]- 
316.0584, found 316.0578. 
 
Synthesis of propyl 5-hydroxy-3-methyl-1-(4-nitrophenyl)-1H-pyrazole-4-
carbodithioate 11g 
The compound was produced by General Method B using 10g 
(124 mg, 0.56 mmol) to afford 11g (124 mg, 65%) as a yellow 
powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.75; Mp 117-
119 °C; 1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.9 Hz, 2H, 
H7, H11), 8.15 (d, J = 8.9 Hz, 2H, H8, H10), 3.40 (t, J = 7.3 Hz, 
2H, H14), 2.70 (s, 3H, H12), 1.86 (sextet, J = 7.3 Hz, 2H, H15), 
1.13 (t, J = 7.3 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 214.6 (C13), 158.8 (C5), 
148.3 (C3), 145.6 (C9), 142.5 (C6), 124.9 (C8, C10), 120.9 (C7, C11), 111.3 (C4), 36.1 









































1418, 958, 742 cm-1; HRESI-MS: m/z calculated for C14H14N3O3S2 [M - H]-  336.0482, 
found 336.0477. 
 
Synthesis of propyl 5-hydroxy-1,3-diphenyl-1H-pyrazole-4-carbodithioate 14a  
 The compound was produced by General Method C using 
13a (100 mg, 0.42 mmol) to afford 14a (90 mg, 60%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.73; 
Mp 89-91 °C; 1H NMR (500 MHz, CDCl3) δ 13.74 (s, 1H, 
OH), 7.88 (apparent doublet, J = 8.2 Hz, 2H, H7, H11), 
7.58 (d, J = 7.3 Hz, 2H, H7', H11'), 7.46 (m, 5H, H8, H10, 
H8', H10', H9'), 7.33 (t, J = 7.5 Hz, 1H, H9), 3.18 (t, J = 7.3 Hz, 2H, H14), 1.63 (dd, J = 
14.8, 7.4 Hz, 2H, H15), 0.94 (t, J = 7.3 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 
215.0 (C13), 157.1 (C5), 149.5 (C3), 137.2 (C6), 133.5 (C6'), 130.0 (C8', C10'), 129.1 
(C9'), 129.0 (C8, C10), 128.1 (C7', C11'), 127.2 (C9), 121.9 (C7, C11), 110.3 (C4), 36.0 
(C14), 21.07 (C15), 13.49 (C16); IR (neat) ν 2959, 2925, 1545, 1507, 958, 757 cm-1; 
HRESI-MS: m/z calculated for C19H18N2ONaS2 [M - H]- 377.0764, found 377.0758. 
 
Synthesis of propyl 5-hydroxy-1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carbodithioate 
14b  
The compound was produced by General Method C using 
13b (200 mg, 0.79 mmol) to afford 14b (31 mg, 10%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.85; 
Mp 81-83 °C; 1H NMR (500 MHz, CDCl3) δ 13.7 (s, 1H, 
OH), 7.88 (apparent doublet, J = 7.7 Hz, 2H, H7, H11), 




















































H9), 7.25 (m,  2H, H8', H10'), 3.18 (t, J = 7.4 Hz, 2H, H14), 2.43 (s, 3H, H17), 1.65 
(sextet, J = 7.4 Hz, 2H, H15), 0.95 (t, J = 7.4 Hz, 3H, H16); 13C NMR (125 MHz, 
CDCl3): δ 215.4 (C13), 157.2 (C5), 149.6 (C3), 138.9 (C6), 137.1 (C6'), 130.6 (C9'), 
130.0 (C8, C10), 129.1 (C8', C10'), 129.0 (C7', C11'), 127.4 (C9), 122.0 (C7, C11), 
110.5 (C4), 36.1 (C14), 21.6 (C17), 21.0 (C15), 13.4 (C16); IR (neat) ν 2959, 2925, 
2868, 1542, 1512, 1450, 958, 757 cm-1; HRESI-MS: m/z calculated for C20H19N2OS2 
[M - H]- 367.0944, found 367.0939. 
 
Synthesis of propyl 5-hydroxy-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-4-
carbodithioate 14c  
The compound was produced by General Method C using 
13c (205 mg, 0.77 mmol) to afford 14c (108 mg, 36%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.85; 
Mp 118-120 °C; 1H NMR (500 MHz, CDCl3) δ 13.7 (s, 
1H, OH), 7.88 (apparent doublet, J = 8.0 Hz, 2H, H7, 
H11), 7.48 (m, 4H, H8, H7', H10, H11'), 7.32 (t, J = 7.4 
Hz, 1H, H9), 6.98 (d, J = 8.6 Hz, 2H, H8', H10'), 3.87 (s, 3H, H18), 3.19 (t, J = 7.4 Hz, 
2H, H14)  1.65 (sextet, J = 7.4 Hz, 2H, H15), 0.96 (t, J = 7.4 Hz, 3H, H16); 13C NMR 
(125 MHz, CDCl3) δ 215.2 (C13), 160.6 (C9'), 157.1 (C5), 149.6 (C6'), 137.3 (C6), 
131.5 (C7', C11'), 129.2 (C8, C10), 127.3 (C9), 125.9 (C3), 122.1 (C7, C11), 113.8 
(C8', C10'), 110.9 (C4), 55.5 (C18), 36.2 (C14), 21.3 (C15), 13.7 (C16); IR (neat) ν 
2968, 1553, 1507, 1248, 960, 878 cm-1; HRESI-MS: m/z calculated for C20H21N2O2S2 






























Synthesis of propyl 3-(4-fluorophenyl)-5-hydroxy-1-phenyl-1H-pyrazole-4-
carbodithioate 14d  
The compound was produced by General Method C using 
13d (180 mg, 0.70 mmol) to afford 14d (135 mg, 51%) as 
a yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.83; 
Mp 117-118 °C; 1H NMR (500 MHz, CDCl3) δ 13.7 (s, 
1H, OH), 7.86 (apparent doublet, J = 7.9 Hz, 2H, H7, 
H11), 7.56 (dd, J = 8.4, 5.5 Hz, 2H, H8', H10'), 7.47 
(apparent triplet, J = 7.9 Hz, 2H, H8, H10), 7.34 (t, J = 7.4 Hz, 1H, H9), 7.14 (t, J = 8.6 
Hz, 2H, H7', H11'), 3.19 (t, J = 7.4 Hz, 2H, H14), 1.64 (sextet, J = 7.4 Hz, 2H, H15), 
0.95 (t, J = 7.4 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 215.0 (C13), 165.0 (d, J = 
245.1 Hz, C9'), 162.8 (C5), 157.3 (C6'), 148.7 (C6), 137.3 (C3), 132.2 (d, J = 8.5 Hz, 
C7', C11'), 129.2 (C8, C10), 127.5 (C9), 122.1 (C7, C11), 115.4 (d, J = 21.4 Hz, C8', 
C10'), 110.4 (C4), 36.2 (C14), 21.2 (C15), 13.7 (C16); IR (neat) ν 2968, 2875, 1550, 
1507, 1227, 965, 880 cm-1; HRESI-MS: m/z calculated for C19H16FN2OS2 [M - H]-
371.0694, found 371.0688. 
 
Synthesis of propyl 3-(4-chlorophenyl)-5-hydroxy-1-phenyl-1H-pyrazole-4-
carbodithioate 14e  
The compound was produced by General Method C using 
13e (191 mg, 0.70 mmol) to afford 14e (30 mg, 11%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.67; 
Mp 118-120 °C; 1H NMR (500 MHz, CDCl3) δ 13.6 (s, 
1H, OH), 7.86 (apparent doublet, J = 8.1 Hz, 2H, H7, 






















































triplet, J = 7.9 Hz, 2H, H8, H10), 7.43 (d, J = 8.3 Hz, 2H, H7', H11'), 7.34 (t, J = 7.4 
Hz, 1H, H9), 3.21 (t, J = 7.4 Hz, 2H, H14), 1.66 (sextet, J = 7.4 Hz, 2H, H15), 0.96 (t, J 
= 7.4 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 215.0 (C13), 157.4 (C5), 148.3 
(C3), 137.3 (C6), 135.4 (C6'), 132.3 (C9'), 131.6 (C7', C11') , 129.30 (C8, C10), 128.63 
(C8', C10'), 127.6 (C9), 122.1 (C7, C11), 110.4 (C4), 36.3 (C14), 21.0 (C15), 13.9 
(C16); IR (neat) ν 3064, 2962, 2928, 1549, 1448, 960, 875, 759 cm-1; HRESI-MS: m/z 
calculated for C19H16ClN2OS2 [M - H]- 387.0398 found 387.0393.  
 
Synthesis of propyl 3-(4-bromophenyl)-5-hydroxy-1-phenyl-1H-pyrazole-4-
carbodithioate 14f  
The compound was produced by General Method C using 
13f (213 mg, 0.67 mmol) to afford 14f (118 mg, 40%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.81; 
Mp 116-118 °C; 1H NMR (500 MHz, CDCl3) δ 13.6 (s, 1H, 
OH), 7.86 (apparent doublet, J = 7.9 Hz, 2H, H7, H11), 7.59 
(d, J = 8.3 Hz, 2H, H8', H10'), 7.48 (m, 4H, H8, H7', H10, 
H11'), 7.35 (t, J = 7.4 Hz, 1H, H9), 3.21 (t, J = 7.4 Hz, 2H, H14), 1.66 (sextet, J = 7.4 
Hz, 2H, H15), 0.97 (t, J = 7.4 Hz, 3H, H16); 13C NMR (125 MHz, CDCl3): δ 215.0 
(C13), 157.1 (C5), 143.6 (C3), 137.3 (C6), 132.6 (C6'), 131.9 (C7', C11'), 131.5 (C8, 
C10), 129.3 (C8', C10'), 127.6 (C9), 123.9 (C9'), 122.1 (C7, C11), 110.2 (C4), 36.3 
(C14), 21.4 (C15), 13.5 (C16); IR (neat) ν 2958, 2922, 1520, 968, 875, 755 cm-1; 





Synthesis of propyl 5-hydroxy-1-phenyl-3-(4-(trifluoromethyl)phenyl)-1H-
pyrazole-4-carbodithioate 14g  
The compound was produced by General Method C using 
13g (173 mg, 0.50 mmol) to afford 14g (53 mg, 22%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.48; 
Mp 149-151 °C; 1H NMR (500 MHz, C6D6) δ 13.9 (s, 1H, 
OH), 7.95 (d, J = 7.9 Hz, 2H, H8',H10'), 7.46 (apparent 
doublet, J = 8.3 Hz, 2H, H7, H11), 7.44 (d, J = 8.3 Hz, 
H7', H11'), 7.13 (apparent triplet, J = 8.1 Hz, 2H, H8, H10), 6.98 (t, J = 7.4 Hz, 1H, 
H9), 2.83 (t, J = 7.4 Hz, 2H, H14), 1.27 (sextet, J = 7.4 Hz, 2H, H15), 0.6 (t, J = 7.4 Hz, 
3H, H16); 13C NMR (125 MHz, C6D6): δ 214.3 (C13), 157.4 (C5), 147.9 (C3), 138.1 
(C6), 137.6 (C6'), 130.9 (C7', C11'), 129.0 (C8, C10), 128.0 (J = 32 Hz C9’), 127.8 ( J = 
270.2 Hz C17), 127.2 (C8', C10'), 125.0 (C9), 121.5 (C7, C11), 110.6 (C4), 35.9 (C14), 
21.1 (C15), 12.9 (C16) ; IR (neat) ν 2963, 2930, 1509, 1112, 959, 878, 755 cm-1; 
HRESI-MS: m/z calculated for C20H16FN2OS2 [M - H]- 421.0662, found 421.0656. 
 
Synthesis of propyl 3-(4-cyanophenyl)-5-hydroxy-1-phenyl-1H-pyrazole-4-
carbodithioate 14h  
The compound was produced by General Method C using 
13h (134 mg, 0.51 mmol) to afford 14h (32 mg, 16%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.22; 
Mp 158-160 °C; 1H NMR (500 MHz, CDCl3) δ 13.58 (s, 
1H, OH), 7.83 (d, J = 8.3 Hz, 2H, H8',H10'), 7.73 (apparent 
doublet , J = 8.3 Hz, 2H, H7, H11), 7.71 (d, J = 8.3 Hz, 
























































H9), 3.20 (t, J = 7.4 Hz, 2H, H14), 1.64 (sextet, J = 7.5 Hz, 2H, H15), 0.95 (t, J = 7.3 
Hz, 3H, H16); 13C NMR (125 MHz, CDCl3) δ 157.4 (C5), 147.7 (C3), 140.6 (C6), 
138.7 (C9'), 137.1 (C6'), 132.1 (C7', C11'), 131.1 (C8, C10), 129.4 (C8', C10'), 127.8 
(C9), 122.1 (C7, C11), 113.2 (C17), 110.1 (C4), 36.4 (C14), 21.2 (C15), 13.7 (C16); IR 
(neat) ν 3055, 2918, 2852, 2225, 1118, 845, 755 cm-1; HRESI-MS: m/z calculated for 
C20H16N3OS2 [M - H]- 378.0744, found 378.0735. 
 
Synthesis of propyl 5-hydroxy-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole-4-
carbodithioate 14i  
The compound was produced by General Method C using 
13i (86 mg, 0.30 mmol) to afford 14i (20 mg, 16%) as a 
yellow powder. TLC Rf (Pet. spirit:EtOAc, 80:20) = 0.38; 
Mp 128-130 °C; 1H NMR (400 MHz, CDCl3) δ 13.59 (s, 
1H, OH), 8.32 (d, J = 8.5 Hz, 2H, H8', H10'), 7.86 
(apparent doublet, J = 7.9 Hz, 2H, H7, H11), 7.80 (d, J = 
8.5 Hz, 2H, H7', H11'), 7.50 (apparent triplet, J = 7.8 Hz, 2H, H8, H10), 7.37 (t, J = 7.3 
Hz, 1H, H9), 3.22 (t, J = 7.3 Hz, 2H, H14), 1.66 (sextet, J = 7.3 Hz, 2H, H15), 0.96 (t, J 
= 7.3 Hz, 3H, H16); 13C NMR (100 MHz, CDCl3) δ 215.0 (C13), 157.4 (C9'), 148.6 
(C6'), 147.4 (C5), 140.6 (C3), 137.1 (C6), 131.2 (C7', C11'), 129.4 (C8, C10), 127.8 
(C9), 123.4 (C8', C10'), 122.1 (C7, C11), 110.1 (C4), 36.4 (C14), 21.2 (C15), 13.7 
(C16); IR (neat) ν 3067, 2996, 2887, 1545, 1336, 844, 756 cm-1; HRESI-MS: m/z 






























4.5 Synthesis and characterization data for Chapter 3 compounds PSPC 15, PSPC-
1S 16 and PSPC-6S 17 
Synthesis of 3-(Phenylthio)pyrazine-2-carbonitrile (PSPC-1S 16) 
	3-Chloropyrazine-2-carbonitrile 18 (250 mg, 1.79 mmol) and 
NaSPh (260 mg, 1.97 mmol, 1.1 eq), were dissolved in anhydrous 
THF (18 mL) under Ar and the mixture heated at reflux for 1 h. 
The solvent was removed in vacuo and the residue diluted with 
5% KOH (20 mL) and extracted with EtOAc (3 x 15 mL). The organic layer was dried 
over anhydrous MgSO4, filtrated and concentrated in vacuo. The crude residue was 
purified by silica gel column chromatography using a gradient from 100:0 to 90:10 pet. 
spirit:EtOAc to yield PSPC-1S 16 (313 mg, 82%) as an off-white crystalline solid. Mp  
120 – 122 °C; 1H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 1.6 Hz, 1H, H6), 8.34 (d, J = 
1.6 Hz, 1H, H5), 7.58 (d, J = 6.6 Hz, 2H, H11, H15), 7.48 (t, J = 7.5 Hz, 3H, H12, H13, 
H14); 13C NMR (125 MHz, CDCl3) δ 161.5 (C2), 146.4 (C6), 140.6 (C5), 135.7 (C12, 
C14), 130.3 (C13), 129.8 (C11, C15), 127.6 (C10), 126.6 (C3), 114.4 (C7); HRESI-MS: 
m/z calculated for C11H7N3NaS [M + Na]+ 236.0253, found 236.0247. 
 
3-(Phenylsulfinyl)pyrazine-2-carbonitrile (PSPC-6S 17)  
3-(Phenylthio)pyrazine-2-carbonitrile (PSPC-1S 16, 100 mg, 0.47 
mmol) was dissolved in anhydrous CH2Cl2 (5.0 mL) under Ar 
and  m-CPBA (97 mg, 0.56 mmol , 1.2 eq) was added.  After 
stirring at rt for 24 h, the mixture was diluted with CH2Cl2 (5.0 
mL) and washed with saturated Na2S2O4 (5.0 mL), 1 M NaOH (5.0 mL), water (5.0 mL) 
and brine (5.0 mL). The organic layer was separated and dried over anhydrous MgSO4, 
















chromatography using a gradient from 100:0 to 70:30 pet. spirit:EtOAc to yield PSPC-
6S 17 (71 mg, 66%) as a hygroscopic off-white solid. Mp 103-105 °C; 1H NMR (500 
MHz, CDCl3) δ 8.86 (d, J = 2.2 Hz, 1H, H6), 8.77 (d, J = 2.2 Hz, 1H, H5), 7.93 (m, 2H, 
H11, H15), 7.55 (t, J = 6.6 Hz, 3H, H12, H13, H14); 13C NMR (125 MHz, CDCl3) δ 
164.1 (C2), 147.2 (C6), 146.0 (C5), 141.6 (C10), 132.6 (C13), 129.9 (C12, C14), 127.6 
(C3), 125.1 (C11, C15), 113.0 (C7); HRESI-MS: m/z calculated for C11H7N3NaOS [M + 
Na]+ 252.0202, found 252.0202. 
 
3-(Phenylsulfonyl)pyrazine-2-carbonitrile (PSPC 15)   
3-(Phenylthio)pyrazine-2-carbonitrile (PSPC-1S 16,  100 mg, 
0.47 mmol) was dissolved in anhydrous CH2Cl2 (5.0 mL) under 
Ar and m-CPBA (178 mg, 1.03 mmol , 2.2 eq) was added. After 
stirring at rt for 24 h, the mixture was diluted with CH2Cl2 (5.0 
mL) and washed with saturated Na2S2O4 (5.0 mL), 1 M NaOH 
(5.0 mL), water (5.0 mL) and brine (5.0 mL). The organic layer was separated and dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was 
purified by silica gel chromatography using a gradient from 100:0 to 75:25 pet. 
spirit:EtOAc to yield PSPC 15 (42 mg, 36 %) as an off-white amorphous solid. Mp 110-
112 °C; 1H NMR (500 MHz, CDCl3) δ 8.88 (d, J = 2.2 Hz, 1H, H6), 8.84 (d, J = 2.2 Hz, 
1H, H5), 8.16 (d, J = 7.4 Hz, 2H, H11, H15), 7.74 (t, J = 7.5 Hz, 1H, H13), 7.63 (t, J = 
7.8 Hz, 2H, H12, H14); 13C NMR (125 MHz, CDCl3) δ 157.2 (C2), 147.3 (C6), 146.1 
(C5), 137.1 (C10), 135.4 (C13), 129.84 (C12, C14), 129.81 (C11, C15), 128.4 (C3), 
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5.1 History of Mycobacterium tuberculosis infections 
5.1.1 Epidemiology of Tuberculosis  
Tuberculosis (TB) is one of the leading infectious diseases worldwide and is 
especially prevalent in developing countries. It has been given several names, including 
consumption, phthisis, scrofula, Pott’s disease and the white plague. In 2016, the World 
Health Organisation (WHO) estimated that between 2000–2016 there were 10.4 million 
new cases of tuberculosis and 1.4 million deaths among HIV-negative people, and it was 
emphasised that 49 million people survived the illness through effective diagnosis and 
treatment.1 People infected by the Human Immune Virus (HIV) are at greatly increased risk 
of TB due to their compromised immune systems. In many countries, the rate of 
tuberculosis is increased due to poor public health and high rates of HIV-infection.2  
 
5.1.2 Origins of Tuberculosis  
Tuberculosis has plagued humanity since antiquity, with the earliest unambiguous 
detection dating back 17,000 years.3 The question of whether tuberculosis originated in 
cows and then species-transferred by zoonosis to humans, or whether it diverged from a 
common ancestor, remains controversial.4  
The Mycobacterium tuberculosis complex (MTBC) is composed of the following 
species from the Mycobacterium genus; tuberculosis, africanum, bovis, microti, canetti, 




agent of human tuberculosis is Mycobacterium tuberculosis (MTB).5,6 It was shown in 
2008 that the MTBC is made up of two independent clades, one exclusively composed of 
human lineage and the other a mix of human and animal. It was inferred that the latter was 
derived from a human pathogenic lineage, which supports the hypothesis that the MTBC 
originated in a human host in East Africa approximately 40,000 years ago.7 This period of 
time aligns with the mass human migration out of the Horn of Africa. Genetic analyses 
tracking the two clades indicated that one clade spread from humans to animals over a 
period of 10,000-20,000 years. In the last 200 years, the human-associated pathogenic 
lineages have diversified along with population density increases, industrialisation and 
human mobility.7 
 
5.2 Tuberculosis incidence  
TB is the second leading cause of death worldwide from a single bacterial 
pathogen.8,9 Of an estimated 1.7 billion people infected with M. tuberculosis, 5-15% will 
develop active TB during their lifetime. The most cases of TB occur in South-East Asia 
(45%), the African (25%) and Western Pacific regions (17%) (Figure 5.1(a)).8 Ambitious 
targets set by the WHO in 2017 aim to “end the global TB epidemic” by 2035, which 
requires TB incidence and death rates to be reduced by 90% and 95%, respectively, 
compared to levels in 2015 (Figure 5.1(b)). Co-infection with HIV accounted for 57% of 
new TB cases and there were an estimated 374 000 deaths from TB among HIV-positive 










Figure 5.1 (a) Estimated worldwide TB incidence in 2016.8 (b) Prospective incidence and 
death rate targets set by the WHO aiming to “end the global TB epidemic” by 2035. 
 
TB has become increasingly dangerous, especially in Eastern Europe, Asia and 




resistant (XDR-TB) M. tuberculosis strains. MDR/XDR-TB accounts for 4.1% of new 
cases each year, with an estimated 19% of these having received prior treatment. The global 
distribution of MDR/XDR-TB incidence is shown in Figure 5.2. The countries with the 
largest number of cases are India, China and the Russian Federation. Only about 15% of 
MDR-TB cases are correctly detected and of these about 50% are successfully treated. 
 
Figure 5.2 Estimated incidence of MDR/XDR-TB in 2016.8  
 
5.3 Types of Tuberculosis Infection 
Approximately 90% of individuals infected with M. tuberculosis have 
asymptomatic latent tuberculosis infections (LTBI).11 This is where individuals are carriers 
of the disease but do not present symptoms. It has been estimated that as much as one third 
of the global population has LTBI.12 Individuals with LTBI have been in previous contact 
with individuals infected with M. tuberculosis, but have an innate immune capability to 
suppress activation. In immunosuppressed patients, the rate of ‘latent-reactivation’ is much 




that the latent condition will progress to active disease.13-15 For patients with 
HIV/tuberculosis co-infection the lifetime risk is 50%.14,16   
HIV is just one of several risk factors that accelerate the transition of LTBI to active 
pulmonary tuberculosis.17 Others include type 2 diabetes mellitus18, excessive alcohol 
consumption19 and smoking.20 Some people with culture-positive, active tuberculosis may 
not display a prolonged cough, and some may even be completely asymptomatic 
(subclinical).21 People with subclinical tuberculosis, like those suffering from active 
tuberculosis, are capable of transmitting the disease.22  
Tuberculosis can be viewed as a dynamic continuum varying between LTBI and 
active disease,22 where individuals can advance or revert depending on immunity and 
comorbidities (e.g. HIV). Those who have eliminated the disease through innate immune 
responses without T-cell priming (adaptive/acquired immunity) can show a negative 
tuberculin skin test (TST) or interferon-γ release assay (IGRA). Some individuals who 
eliminate the disease still retain a strong memory T-cell response and test positive on TST 
and IGRA.22  
 
5.4 General aspects of tuberculosis disease 
TB primarily affects the lungs in more than 75% of active cases, although it can 
infect and damage other organs, such as the kidneys and heart in what is termed 
extrapulmonary tuberculosis.2 People showing signs and symptoms of TB, such fever, 
weight loss and cough with blood, can pass the bacteria to others through the air.23 About 5% 




is estimated that 95% of people recover from TB upon drug treatment, while 5% may suffer 
relapse (Figure 5.3). Untreated active disease usually results in death.2,23  
 
 
Figure 5.3 Schematic of M. tuberculosis infection, transmission, progression to active 
disease and outcomes. Adapted from Koul et al.2  
 
5.5 Current treatments for TB and the problem of drug resistance 
The WHO classifies anti-TB drugs into five groups based on evidence of their 
effectiveness, safety and when they are indicated for use. The first-line drugs (Group 1, 
Table 5.1) are typically used in a four-drug combination. The second-line drugs (Groups 2-
4) are reserved for the treatment of MDR-TB. Group 5 (third-line drugs, Table 5.1) have 
potentially limited efficacy and there are long-term clinical concerns associated with their 
use. The second-line drugs are introduced into treatment regimens after drug-resistant 
strains of M. tuberculosis are encountered, often due to a primary antibiotic emergency, 







Table 5.1 The WHO classification of anti-TB drug treatments.24,25  
Group Drugs 
Group 1. First-line oral agents 
Isoniazid, Pyrazinamide, Rifampicin, Rifabutin, 
Ethambutol, Rifapentine 
Group 2. Injectable drugs  
Streptomycin, Kanamycin, Amikacin, 
Capreomycin 
Group 3. Fluoroquinolones Levofloxacin, Moxifloxacin, Gatifloxacin 
Group 4. Oral bacteriostatic 
second-line drugs 
Ethionamide, Prothionamide, Cycloserine, 
Terizidone, para-aminosalicylic acid 
Group 5. Drugs with limited data on efficacy 
and long-term safety in the treatment of drug-
resistant TB 





The cell wall of M. tuberculosis, a complex structure that is required for cell 
viability and resistance to antibiotics, has been the target of many TB drugs. The multi-
layered, strongly hydrophobic cell wall in MTB shows low permeability and presents a 
formidable barrier to the penetration of antibacterial compounds. The mycobacterial cell 
wall (Figure 5.4) is made of polysaccharide and glycolipids cross-linked by peptides 





Figure 5.4 Schematic of the mycobacterial cell wall showing the distinct layering of the 
lipid bilayer, mycolic acid-arabinogalactan-peptidoglycan complex (MAPc) and surface 
glycolipids. 26 
 
5.5.1 Drug-resistance in Tuberculosis  
MDR-TB is defined as TB that is resistant to the first-line anti-TB drugs INH and 
RIF. Treatment of MDR infections is complicated, long and expensive and can cause 
considerable adverse side effects. XDR-TB involves resistance to INH and RIF and at least 
one of the second-line fluoroquinolones or injectable drugs amikacin, capreomycin and 
kanamycin.27,28 The more recently discovered TDR-TB is resistant to all current anti-TB 
drugs. The largest numbers of cases of TDR-TB are in China, India, Africa and Eastern 
Europe. The target and mode of action of some of the first-line TB drugs are summarised in 






Table 5.2 Structures, year of introduction, molecular targets and mode of action of four 
first-line drugs for treating tuberculosis.29  





























5.6 Recently approved and emerging tuberculosis treatments 
The increasing number of MDR and XDR-TB cases and the long treatment times 
required with current agents drives a pressing need to develop new anti-TB drugs, 
especially those acting via novel mechanisms as these are less likely to be susceptible to 
established resistance mechanisms.30 The past 5 years has seen several new candidates 
emerge with promising anti-TB activity, including 17 new drugs in clinical trials (August 





Figure 5.5 Global pipeline of clinical-stage anti-TB drugs. Adapted from reference8.  
 
5.6.1 Delamanid 
Delamanid is currently in phase III clinical trials for the treatment of MDR-TB. The 
drug is a dihydronitroimidazoxazole derivative that interferes with mycobacterial cell wall 
synthesis by disrupting methoxymycolic acid and keto-mycolic acid (Figure 5.6). 
Delamanid is actually a prodrug that is activated intracellularly by the nitroreductase 
Rv3547 in M. tuberculosis.31 Activation leads to production of active nitrogen species, such 
as nitric oxide, that are lethal to the bacteria under anaerobic conditions.32 In a recent study, 
delamanid showed improved treatment outcomes and reduced the risk of mortality in adults 
with MDR-TB.33 However, it was noted in another clinical study that patients receiving 
delamanid are at increased risk of QT prolongation and cardiotoxicity, especially when the 





Figure 5.6 Chemical structure of delamanid and its cell wall site of action. Adapted from 
reference.30 
 
5.6.2 Bedaquiline (SirturoTM)  
Bedaquiline (BDQ) was approved for use against MDR-TB by the US FDA in 
2012.35 The drug belongs to the diarylquinoline chemical class and acts as a selective 
inhibitor of mycobacterial ATP synthase, an enzyme that is essential for the generation of 
energy in M. tuberculosis.36 The drug binds to the c subunit of MTB ATP synthase, 
preventing oligomerization of c proteins to form the c-ring, which leads to inhibition of 
proton translocation and shuts down the enzyme’s function (Figure 5.7).37  BQD was the 
first approved anti-TB drug acting via a novel mechanism since Rifampicin in 1970.38  
Common side-effects of bedaquiline include nausea (30%), arthralgia (26%), 
headache (22%), haemoptysis (14%), chest pain (9%), anorexia (7%) and rash (6%).38 
During Phases II trials with bedaquiline (440 patients), a significantly increased mortality 
risk was noted in the bedaquiline-treated cohort, leading to the drug attracting a “Black-Box” 
warning label.39 A key problem with bedaquiline is its extremely long terminal elimination 




has also been noted that bedaquiline shows cardiotoxicity through both QT-prolongation 
and hERG inhibition.41 
 
 
Figure 5.7 Bedaquiline (BDQ) acts as an ATP synthase inhibitor that shuts down proton 
translocation and ATP generation.30  
 
5.7 Amiloride as a new scaffold for TB drug development 
Amiloride hydrochloride has been used clinically as a potassium-sparing diuretic for 
half a century after it was developed by the Cragoe group at Merck in 1967.42 Amiloride is 
only weakly diuretic, however, and its most common clinical usage is as an anti-kaliuretic 
in combination with other diuretics (e.g. furosemide) to limit potassium loss.43 In 2015, the 
research group of Prof Gregory Cook at the University of Otago (Dunedin, NZ) tested 
amiloride in vitro against M. tuberculosis and found that it showed weak activity (minimum 
inhibitory concentration; MIC = 256 µM, Table 5.3). Based on this preliminary finding, 




amiloride (EIPA) and hexamethylene amiloride (HMA), were tested and found to show 
higher activity (MIC = 64 and 32 µM, respectively).  
 
Table 5.3 Antibacterial activity (MIC, µM) of amiloride and its 5-substituted derivatives 
EIPA and HMA against M. tuberculosis. Data provided by Prof Gregory Cook (University 
of Otago, NZ). 
 
 
Prof Cook’s idea for testing amiloride, EIPA and HMA for anti-TB activity came 
about because these molecules contain an arginine-mimicking acylguanidine side chain. He 
rationalized that because of this, the compounds might serve to mimic the side chain of the 
conserved arginine residue in subunit c of the mycobacterial ATP synthase in the same way 
that the arginine-mimicking N,N-dimethylaminoethanol side chain of bedaquiline does (see 
chemical structure, Figure 5.7), leading to inhibition. While this was the original rationale 
for testing the compounds, it is not yet known whether the anti-TB activity of amiloride and 





5.8 Anti-TB Activity of Amiloride Derivatives from the Kelso Laboratory at UOW 
Based on the above preliminary findings, a series of novel amiloride derivatives that 
had been synthesised in the Kelso Laboratory at UOW (for a separate anticancer project)44 
were screened for anti-TB activity. This testing focused on compounds containing 
modifications at the 6-position of amiloride’s pyrazine core because there had been no 
previous reports on the synthesis or bioactivity of 6-substituted amilorides in the literature. 
This gap in structure-activity knowledge around amiloride derivatives potentially allowed 
for the development of novel chemistry and patentable new classes of anti-TB compounds. 
One of the key goals in the early part of the program was to enhance amiloride’s anti-
tubercular activity, while at the same time abrogating its diuretic and potassium-sparing 
effects, which arise through inhibition of renal epithelial sodium channels (ENaCs). In 
medicinal chemistry, this is known as the Selective Optimisation of Side-Activity (SOSA)45 
approach. 
Early screening efforts revealed that benzofuran-2-yl substitution at the 6-position 
was highly favourable, with HM2-16F 20 showing MIC = 4 µM (Figure 5.8). The 
corresponding HMA derivative (BB2-50F 19) also showed good activity (MIC = 4-8 µM).  






Figure 5.8 Increases in anti-TB activity achieved with 6-benzofuran-2-yl amiloride 
derivatives. 
 
5.9 Preliminary evaluation of BB2-50F 19 and HM2-16F 20 as anti-TB leads 
Several pieces of evidence from Prof Gregory Cook’s laboratory supported that 6-
substituted amiloride and HMA derivatives warranted further exploration as anti-TB 
compounds. Firstly, time-kill assays under hypoxic conditions revealed that BB2-50F 19 
kills the highly resistant, non-replicating TB cells, producing a readout of 0 colony 
formation units (CFU)/mL after a 17 day treatment. This very encouraging finding was not 
observed with either bedaquiline (BDQ) or HM2-16F 20, which both showed 
approximately 1 x 107 CFU/mL remaining after the same time period (Figure 5.9 (A)). 
These effects were verified by Most Probable Number (MPN) experiments and 
measurements of the culture Optical Density at 600 nm (OD600) (Figure 5.9 B and C). 
Under hypoxic conditions, only non-replicating M. tuberculosis can continue to respire, 




that the tough, non-replicating mycobacteria, termed persisters, might potentially be 
















Figure 5.9 Time-kill assays performed under hypoxic conditions showing that BB2-50F 19 
kills non-replicating M. tuberculosis, as indicated by reductions in: CFU (A), LogMPN (B) 
and OD600 (C) after drug treatment. 
 
5.10 Synergistic effects of 6-substituted amiloride derivatives with anti-TB drugs   
Standard treatment regimens for both susceptible and MDR-TB involve the use of 
combinations of several antibiotics (see Section 5.5.1). Given this, it is important to 







to identify possible synergies. The concept behind using combinations of two, three, or 
even more drugs to treat TB is that this can greatly increase the activities of the individual 
drugs, thereby not only increasing their efficacy but also reducing toxicity by allowing 
lower doses of the individual drugs to be administered to achieve the required therapeutic 
effects. Use of multiple agents acting via different mechanisms also suppresses the 
emergence of drug resistance. 
To establish whether BB2-50F 19 and HM2-16F 20 show synergies with standard 
TB antibiotics, a checkerboard assay was performed by Prof Cook’s laboratory using 
Bacille Calmette-Guerin (BCG), which serves as a TB surrogate for in vitro studies.46 The 
bacteria were treated with checkerboard combinations of BB2-50F 19 and the anti-TB 
drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and bedaquiline (BDQ). 
HM2-16F 20 was explored in checkerboard combinations with bedaquiline and 
streptomycin (Strep), only. In these assays, fractional inhibitory concentrations (FIC) were 
calculated and then summed according to the following formula:47  
ΣFIC = FIC A + FIC B 
Where FIC A is the MIC of drug A in the combination/MIC of drug A alone, and 
FIC B is the MIC of drug B in the combination/MIC of drug B alone. ΣFIC £ 0.5 indicates 
a synergistic effect between the two drugs; ΣFIC > 0.5-2 indicates indifference and ΣFIC > 
2 indicates an antagonistic effect. 
The results showed that the combination of BB2-50F 19 with BDQ and RIF showed 
clear synergy, while INH-50F and PZA-50F combinations showed no effect. The 
combination of HM2-16F 20 with BDQ or streptokinase showed no effect, nor did the 




Table 5.4 Checkerboard synergy assays exploring combinations of BB2-50F 19 and HM2-
16F 20 with anti-TB drugs.  
  INH-50F RIF-50F PZA-50F BDQ-50F 
ΣFIC 2 0.42 2 0.31 
 BDQ-16F 50F-16F 16F-Strep  
ΣFIC 0.75 2 2  
 
5.11 Summary of Thesis Aims for Part B 
5.11.1 Synthesis of 6-substituted amiloride derivatives using Suzuki-Miyaura Cross-
Coupling Chemistry 
The primary goal of Part B of the thesis was to develop structure-activity 
relationships around 6-substituted amiloride derivatives as new anti-TB agents. 
Development of SAR around the class would enable greater understanding of the structural 
requirements for activity and could lead to identification of compounds with clinically 
relevant potency and drug-like properties. This type of study is a critical requirement in all 
early-stage medicinal chemistry/drug discovery/development programs. In a broader 
program in the Kelso Lab, matched pairs of 6-substituted amiloride (e.g. HM2-16F 20) and 
6-substituted HMA (e.g. BB2-50F 19) analogues were targeted for study to better 
understand the differences between the two classes and, specifically, to identify which is 
superior in terms of potency, efficacy, toxicity and drug properties. 6-Substituted HMA 
analogues were explored concurrently by other Kelso Lab members whereas my PhD 
studies were focussing exclusively on the 6-amiloride series.  
A great deal of work has been carried out over the past 5-decades exploring the 




targets.48-53 Surprisingly, at the outset of this work there had been no reports exploring 
structural variations at amiloride’s 6-position against any targets in either the patent or 
scientific literature. Further, 2-halopyrazines as a class are well suited to metal-catalysed 
cross-coupling reactions,54 which are heavily deployed in almost all modern medicinal 
chemistry analogue elaboration programs. The first aim of this work was to develop a Pd-
catalysed Suzuki-Miyaura reaction for installation of aryl and heteroaryl substituents at the 
amiloride 6-position. The strategy revolved around first performing the Suzuki-Miyaura 
reactions with commercial (het)aryl-boronic acids and the commercially available 6-
chloropyrazine methyl ester 21, followed by conversion of the esters to acylguanidines 
(Scheme 5.1). 
           
 
Scheme 5.1 General strategy for the synthesis of 6-substituted amiloride analogues starting 
from the commercially available 6-chloropyrazine methyl ester 21. 
 
5.11.2 Synthesis of substituted 6-benzofuran-2-yl amiloride analogues 
The lead 6-substituted amiloride analogue in the program at the outset of the study 
(i.e. HM2-16F 20) contained a benzofuran-2-yl substituent at the pyrazine 6-position. A 
key focus of this study therefore was to explore the structure-activity relationships of HM2-
16F 20 analogues carrying a variety of substituents around the benzofuran moiety. While a 
small selection of substituted benzofuran-2-yl boronic acids were available commercially 




a more diverse set of benzofuran analogues was desired to deepen the structure-activity 
understanding around this key motif, and this required the development of more novel 
chemistry.  
The aim of the second part of this project was to develop a one-pot Sonogashira-
tandem benzofuran cyclisation approach that could be used to access additional substituted 
benzofuran-2-yl analogues (Scheme 5.2). This strategy involved first subjecting the 6-
chloropyrazine methyl ester 21 to a Sonogashira reaction using TMS-acetylene. 
Desilylation to reveal the terminal alkyne would then be followed by a second Sonogashira 
reaction with a substituted 2-iodophenol. Arcadi et al showed that the 2-hydroxyphenyl 
acetylide products of these Sonogashira reactions can cyclise in situ to generate 
benzofurans.55-57 Whilst this is a known reaction, it had never previously been reported on a 
pyrazine scaffold, let alone a poly-functionalised pyrazine as proposed here. The large 
number of commercially available iodophenols made this an attractive strategy for enabling 
general access to a broad range of substituted 6-benzofuran-2-yl amiloride methyl esters, 
which could then be transformed to acylguanidines. 
 
Scheme 5.2 Strategy for use of a one-pot Sonogashira-tandem benzofuran cyclisation 





Synthesis and structure-activity relationships of 6-
substituted amiloride analogues as anti-TB agents  
 
6.1 Suzuki-Miyaura reactions on pyrazines 
   The Suzuki-Miyaura reaction is one of the most reliable C-C bond forming 
reactions and is used extensively in synthetic and medicinal chemistry.58 The palladium-
catalysed reaction typically employs aryl halides as substrates and is especially suited to 
electron deficient heteroaryl halides. In this respect, halo-pyrazines appear as suitable 
reaction substrates. The following paragraphs describe some literature precedents that 
demonstrate the utility of the Suzuki-Miyaura reaction for producing substituted pyrazines. 
In 1992, McKillop et al59 reported the Suzuki-Miyaura coupling of an unsubstituted 
chloropyrazine with aryl boronic acids in the presence of a palladium catalyst bearing a 
phosphine ligand (dppb) (Scheme 6.1).  
 
 
Scheme 6.1 Early Suzuki-Miyaura coupling reactions of chloropyrazine with aryl boronic 
acids reported by McKillop et al.59 
 
The reaction was extended to functionalised bromopyrazines, which were shown to 




excellent yields (Scheme 6.2). The functional groups present in the boronic acid partners 
were found to have little effect on the coupling yield or reaction rate.60  
 
 
Scheme 6.2 Suzuki-Miyaura coupling of substituted bromopyrazines with aryl boronic 
acids reported by Jones et al.60 
 
Thompson et al61 reported Suzuki-Miyaura reactions with amino-substituted 
pyrazines in the presence of Pd(PPh3)2Cl2. Cross-coupling of 2-amino-5-bromopyrazine 
with heteroaryl boronic acids at reflux gave the coupled products in moderate 60-70% 
yields. Double couplings of 2-amino-5-bromopyrazine with arylene diboronic acids yielded 
bis-pyrazine products in 51-56% yields (Scheme 6.3).     
 
 





Tapolcsanyi et al62 examined the reactivity of 2-chloropyrazine with substituted 
phenylboronic acids at room temperature in the presence of Pd(PPh3)4 and found that the 
coupled products could be obtained in reasonable yields (53%, Scheme 6.4).  
 
 
Scheme 6.4 Suzuki coupling of chloropyrazine with a substituted phenyl boronic acid. 
 
6.2 Synthesis of 6-substituted HMA analogues 
Synthetic efforts in the Kelso Laboratory at UOW have been exploring methods for 
accessing HMA analogues bearing substituents at the 6-position of the pyrazine core for the 
purposes of evaluating the activity of 6-substituted HMA analogues against an anticancer 
target; urokinase plasminogen activator (uPA).44 The synthetic chemistry work performed 
(by others) identified that 6-(het)aryl substituents could be successfully installed onto the 
pyrazine methyl ester precursor 22 containing an hexamethyleneamine ring at the 5-
position using standard Suzuki-Miyaura conditions (R-B(OH)2, K2CO3, Pd(PPh3)4. The 6-
substituted methyl esters were then able to be advanced to the desired acylguanidines in a 
single step using the free base form of guanidine, generated in situ from the hydrochloride 



















Scheme 6.5 Synthesis of 6-substituted HMA analogues developed by other group members 
from the Kelso Lab at UOW.44 
 
6.3 Synthetic strategy overview  
The major goal of this chapter was to synthesise and evaluate the anti-TB activity of 
amiloride (as opposed to HMA) analogues carrying substituents at the 6-position of the 
pyrazine core. The proposed synthetic strategy drew from the related work on 6-substituted 
HMA analogues above, where 6-substituted pyrazine methyl esters would be prepared from 
the commercially available 6-chloromethyl ester precursor 21 using Suzuki-Miyaura 
reactions with various commercial (het)aryl boronic acids. This chemistry had not 
previously been explored in the Kelso Lab. The 6-substituted pyrazine methyl esters could 
then be transformed into acylguanidines using the free base guanidine method described 







Scheme 6.6 General strategy for the synthesis of 6-substituted amiloride analogues. 
 
Due to the high polarity of the target compounds it was expected that the crude 
acylguanidines would require purification by preparative rp-HPLC, which is typically 
carried out in the presence of 0.1% trifluoroacetic acid as this affords better peak shapes 
and compound separations, especially with basic compounds. Acylguanidines obtained 
after rp-HPLC would therefore be produced as TFA salts after lyophilization. These would 
need to be exchanged to hydrochloride (HCl) salts in a subsequent step by stirring with 
excess 0.1 N HCl in methanol63 due to the known toxicity of TFA and the confounding 
effects it can have in cellular assays.64-66   
  
6.4 Synthesis of 6-substituted pyrazine methyl esters 23a-23l by Suzuki-Miyaura 
cross-coupling reactions 
 The 6-chloromethyl ester precursor 21 was reacted with a variety of commercially 
available aryl and heteroaryl boronic acids in the presence of Pd(PPh3)4 and K2CO3. The 
reactions were all carried out in a 4:1 mixture of toluene and methanol with heating at 
reflux for between 1-4 h. The structures of the desired coupled products were all confirmed 




In most cases, the reactions were performed using a 10-fold excess of K2CO3 and 5 
mol % of Pd(PPh3)4 relative to chloropyrazine methyl ester 21. Progress of the reactions 
was monitored by disappearance of the starting ester 21 on thin layer chromatography 
(TLC), as well as by electrospray ionization mass spectrometry (EIS-MS) analysis of 
aliquots removed from the reaction mixtures. Upon completion, the reactions were cooled 
on ice and the catalyst removed by vacuum filtration over Celite®. Concentration in vacuo 
then yielded the crude products, which were purified by silica gel column chromatography. 
The quantities of pyrazine methyl esters produced (mg) and the reaction yields are 


















Table 6.1 Suzuki-Miyaura cross-coupling reactions of 5-chloropyrazine methyl ester 21 
with (het)aryl boronic acids to give 6-substituted pyrazine methyl esters 23a-23l. 
 
 
A common mechanism for the above Suzuki-Miyaura reactions, exemplified with 




oxidative insertion of palladium from the catalyst into the C-Cl bond of 5-chloropyrazine 
methyl ester 21 to form an organopalladium(II) intermediate. Reaction with the base (CO32-) 
then triggers transmetalation between the activated organopalladium (II) intermediate and 
the boronate to give the bis-arylated Pd (II) complex. The final step that delivers cross-
coupled product 23k involves a C-C bond-forming reductive elimination that concurrently 
regenerates the palladium (0) catalyst for the next reaction cycle.  
 
 
Scheme 6.7 Mechanism of the Suzuki-Miyaura reaction exemplified with the 6-N-
methylpyrrazole analogue 23k. 
 
The methyl esters were not very soluble in the solvents typically used for column 
chromatography (i.e. CH2Cl2 and hexane/ethyl acetate mixtures) and they required 




columns. The high polarity of the compounds also created difficulties whereby they were 
not eluting properly from the column with ethyl acetate mixtures. Addition of triethylamine 
(TEA, 0.01%) to hexane/ethyl acetate mixtures solved this problem. 1H and 13C NMR data 
for representative 6-substituted pyrazine methyl ester 23k are provided in Figure 6.1. 
The 1H spectrum of 23k (referenced to tetramethylsilane (TMS) internal standard at 
δ 0.00 ppm) showed two sharp singlets at δ 8.00 and 7.70 ppm, corresponding to the two 
pyrazole ring protons. A singlet at δ 3.74 with an integration of 3H was assigned to the 
methyl group attached to the pyrazole nitrogen. A second 3H singlet appearing at δ 3.87 
was assigned to the methyl ester. Assignment of the CH3 protons of the methyl esters in all 
other analogues was unambiguous as they all appeared within the range δ 3.80- 3.90. The 
compounds similarly all showed two broad singlets at around δ 6.9 and 6.6 ppm with 
integrations of 2H each, corresponding to the 3- and 5-NH2 groups on the pyrazine ring.  
The 13C APT spectrum (referenced to DMSO-d6 at 39.5 ppm, Figure 6.1) showed 
the carbonyl signal of the methyl ester at δ 167.2 ppm. Two negative signals for the C5 and 
C3 pyrazine carbons were observed at δ 155.3 ppm and 154.2 ppm. The two positive 
signals appearing at δ 137.8 and 129.7ppm were assigned to the pyrazole CH groups at C15 
and C13, respectively. The negative signal at δ 111.0 ppm was assigned to the pyrazine C2 
attached to the methyl ester. The two other negative signals at δ 124.0 and 118.6 ppm were 
assigned to the pyrazine C6 and pyrazole C14 carbons, respectively. The positive signals at 
δ 51.4 and 38.9 ppm were assigned to the methyl ester and pyrazole N-methyl groups, 
respectively. 2-Dimensional gCOSY, HSQC and HMBC spectra were used to confirm all 






Figure 6.1 1H (500 MHz, DMSO-d6) and 13C APT spectra (125 MHz, DMSO-d6) for 23k. 
 
6.5 Synthesis of 6-substituted acylguanidines 24a-24k 
Methyl esters 23a-23l were subjected to guanidinylation reactions using free base 
guanidine solutions of known concentration. The guanidine was generated in situ by 
dissolving a known amount of Na metal in anhydrous iPrOH (or MeOH in the case of 
compound 24d) and stirring for 40 min at 40 °C, followed by addition of anhydrous 
guanidine.HCl. Stirring the reaction mixtures for an additional 1 h at room temperature led 




base guanidine. Appropriate volumes of the solution were then added to the pyrazine 
methyl esters and the reactions heated at reflux. 
The reactions typically proceeded to completion to form a single major product after 
1-4.5 h with only minor side products observed by TLC. The reaction mixtures were 
concentrated to crude residues and purified by preparative rp-HPLC to yield TFA salts after 
lyophilisation. The TFA salts were stirred with 0.1 N HCl in methanol to yield the targets 
24a-24k as hydrochloride (HCl) salts in 18-83% yields after evaporation of the solvent. The 
acylguanidine products were all comprehensively characterised by spectroscopic analysis. 


















Table 6.2 Acylguanidinylation of methyl esters 23a-23l to give target analogues 24a-24k. 
 
 
A mechanism for the acylguanidinylation reactions is outlined in Scheme 6.8. 




sodium isopropoxide (or sodium methoxide) and releases H2 gas in the process. When 
guanidine.HCl is added, the nucleophilic free base guanidine form is obtained after 
neutralization by the basic alkoxide. Stock solutions of 2 M guanidine in iPrOH or MeOH 
could be stored under N2 in a refrigerator for several weeks without changes in reactivity. 
The free guanidine reacts with the carbonyl of the methyl esters via nucleophilic 
substitution causing loss of methanol (Scheme 6.8).  
 
 
Scheme 6.8 Mechanism for the guanidinylation of pyrazine methyl esters using free base 
guanidine to yield acylguanidines. The mechanism is exemplified with N-methyl pyrazole 
analogue 24j. 
 
The 1H spectrum of representative analogue 24j (Figure 6.2) confirmed loss of the 
methyl ester signal at δ 3.74 ppm. Introduction of the guanidine group was evident from the 
multiple NH signals in the region δ 8.46 - 10.45 ppm. The sharp signal at δ 10.45 ppm with 
an integration of 1H was assigned to the amide-like NH proton, with this signal being de-
shielded by the neighbouring electron withdrawing carbonyl and imino (N=C) groups. The 
two singlets at δ 8.46 and δ 8.74 ppm showing integration 2H were assigned to the 
guanidine NH2 groups. The singlets at δ 8.01 and δ 8.18 ppm showing a combined 
integration of 2H were assigned to the pyrazole H13 and H15 ring protons, respectively. 




groups in position 3 and 5 of the pyrazine ring. The 3H singlet at δ 3.9 ppm was assigned to 
the pyrazole N-methyl group. Disappearance of the methyl ester signal and appearance of 
new guanidine peaks was similarly observed for all analogues produced by the 
guanidinylation procedure. 
The 13C APT spectrum of 24j (referenced to DMSO-d6 at δ 39.5 ppm and phased 
such that CH3 and CH carbon signals are positive (up) and CH2’s and carbons with no 
protons attached are negative (down), Figure 6.2) showed the presence of a new signal 
(relative to the methyl ester precursor 23k) at δ 155.7 ppm, as expected for introduction of 
the sp2-guanidine carbon, along with loss of the methyl ester signal at δ 51.4 ppm. All other 
signals differed in chemical shift from the methyl ester precursor 23k by only ~2 ppm. 
Small impurity signals at δ 47.2 and 9.9 ppm were visible in the spectrum of 24j. A peak at 
m/z 276.1322 in the HRESI-MS, corresponding to the molecular formulas [C10H14N9O]+, 








Figure 6.2 1H (400 MHz, DMSO-d6) and 13C APT spectra (100 MHz, DMSO-d6) for 
representative acylguanidine 24j. 
 
6.6 Synthesis of substituted 6-benzofuran-2-yl amiloride analogues 26a-26i 
As the original lead compound HM2-16F 20 contained a benzofuran at the pyrazine 
6-position, it was of interest to systematically explore related analogues carrying 
substituents on the benzofuran ring system in order to establish structure-activity 
relationships around this key group. This SAR information could provide future guidance 
on the requirements for potent TB activity in this series and possibly deliver alternative lead 
structures with higher potency and superior physicochemical, toxicological and other drug 
properties. A similar strategy to the above was envisaged for the synthesis of substituted-6-
benzofuran-2-yl analogues that carried halogens, electron donating and electron 
withdrawing substituents attached to the benzofuran. It was anticipated that pyrazine 
methyl esters 25a-25i could be accessed using Suzuki-Miyaura coupling reactions between 
the 6-chloropyrazine methyl ester 21 and commercially available substituted benzofuran-2-




substituted pyrazine methyl esters could then be transformed into acylguanidines 26a-26i 
using the method described above. Choice of specific analogues for synthesis was based on 
commercial availability of the boronic acids alone, since no guiding SAR or other data 
existed. Due to the commercial availability of their boronic acids, two related analogues 
were pursued where the benzofuran-pyrazine attachment point was changed from the 2- to 
the 5-position on the benzofuran (26i). The other analogue (26h) was reduced at the 




Scheme 6.9 Strategy for the synthesis of substituted 6-benzofuran-2-yl amiloride analogues 
26a-26i. 
 
6.6.1 Synthesis of substituted benzofuran-2-yl methyl esters 25a-25i by Suzuki-
Miyaura cross-coupling reactions 
The commercial substituted benzofuran-2-yl boronic acids were reacted with 6-
chloropyrazine methyl ester 21 in the presence of Pd(PPh3)4 and K2CO3. The reactions were 
typically performed using a 10-fold molar excess of K2CO3 relative to the starting ester and 
5 mol% Pd(PPh3)4. The same solvent mixture used for the earlier Suzuki-Miyaura reactions 
(1:4 toluene/MeOH; see 6.4) was also used here. The reactions proceeded to completion in 




ester by TLC analysis and/or electrospray ionization mass spectrometry (EIS-MS). The 
reaction mixtures were cooled on ice and the catalyst removed by vacuum filtration through 
Celite®. Concentration of the filtrate and purification by silica gel column chromatography 
gave the desired 6-aryl esters as yellow solids in acceptable yields (34-60%). A summary of 
the reactions is provided in Table 6.3. 
 
Table 6.3 Suzuki-Miyaura cross-coupling reactions of 6-chloropyrazine methyl ester 21 





The 1H NMR spectrum of representative 5-methoxy-substituted benzofuran 
example 25b (Figure 6.3) clearly showed introduction of the benzofuran group onto the 
pyrazine at the 6-position. Three doublets at d 7.55, 7.15 and 7.11 ppm were assigned to the 
H18, H15 and H12 protons of the benzofuran, respectively. A doublet of doublet at d 6.90 
(J = 9.7, 4.9 Hz) corresponded to the benzofuran H17 proton. Two closely located singlets 
at d 3.80 and 3.79 ppm integrating for 3H each corresponded to the benzofuran 5-methoxy 
substituent and the pyrazine methyl ester CH3 groups.   
The 13C APT spectrum of 25b (Figure 6.3) showed a downfield carbonyl signal at δ 
166.8 ppm. The C16 of the phenyl ring, which was de-shielded due to the attached methoxy 
group, appeared as the most downfield aryl carbon at δ 156.3 ppm. The C5 and C3 signals 
of the pyrazine ring also appeared quite far downfield at δ 154.7 and 153.7 due to their 
attached NH2 groups. Two negative peaks at δ 154.7 and 149.0 ppm corresponded to the 
furan ring carbons C14 and C11, respectively. The negative signal at δ 129.3 ppm was 
assigned to ring junction carbon C13. Two negative signals at δ 119.4 and δ 112.6 ppm 
were assigned to C6 and C2 of the pyrazine ring. Four positive signals at δ 113.1, 112.4, 
103.7 and 103.6 ppm corresponded to the benzofuran CH protons, with the highest upfield 
signal arising from the carbon at the benzofuran 3-position (i.e. C12). Two positive signals 








Figure 6.3 1H (500 MHz, DMSO-d6) and 13C APT spectra (125 MHz, DMSO-d6) for 25b. 
 
6.6.2 Synthesis of substituted 6-benzofuran-2yl acylguanidines 26a-26i 
Substituted benzofuran-2-yl methyl esters 25a-25i were subjected to 




in situ by dissolving Na metal in anhydrous isopropanol and stirring with anhydrous 
guanidine hydrochloride. The reactions proceeded to completion after approximately 16 h, 
forming a single product with only minor side products observed by TLC analysis. The 
crude residues were purified by preparative rp-HPLC to afford the acylguanidines as TFA 
salts after lyophilisation. The TFA salts were then stirred with 0.1 N HCl in acetonitrile to 
yield the targets 26a-26i as hydrochloride (HCl) salts. All compounds were 
comprehensively characterised and their structures confirmed by spectroscopic analysis. 1H 
and 13C APT NMR data and interpretations are provided for representative acylguanidine 


















Table 6.4 Conversion of methyl esters 25a-25i to target acylguanidines 26a-26i. 
 
 
The 1H NMR spectrum of 26b showed the expected signals. Addition of a 
guanidine group to replace the methyl ester in 25b was evidenced by loss of the methyl 
ester CH3 signal of 25b at δ 3.79 ppm and the appearance of three new downfield signals 
corresponding to the guanidine NH groups. When the spectrum was recorded in methanol-
d4, the guanidine NH signals disappeared due to 1H-2H exchange. Analogous signal changes 




Analysis of the 13C APT NMR spectrum of 26b supported the assigned structure 
(Figure 6.4). As expected, an additional peak (relative to 25b) was observed at δ 156.8 ppm, 
corresponding to the newly introduced guanidine sp2 carbon and the methyl ester CH3 








Figure 6.4 1H (500 MHz, methanol-d4) and 13C APT spectra (125 MHz, methanol-d4) for 
26b. 
 
6.7 Synthesis of substituted 6-benzofuran-2-yl analogues 30a-30d using Sonogashira-
tandem cyclisation chemistry 
The relatively small number of commercially available substituted benzofuran-2-yl 
boronic acids (represented by the total number of analogues produced above) limited the 
depth of SAR information that could be obtained on modifications to the benzofuran ring 
and their effects on TB activity. To address this, alternative chemistry was needed for 
appending additional benzofurans to the amiloride 6-position. 
Searching the benzofuran literature revealed a common theme, where many 
publications reported benzofuran syntheses employing Sonogashira reactions coupled to a 




combinations to mediate couplings between 2-halophenols and terminal alkynes. Several of 
the procedures require a copper(I) co-catalyst (although some proceed completely copper-
free) and a base (usually an amine). A brief overview of representative literature examples 
of this chemistry is provided below. 
 
6.7.1 Palladium-catalysed heteroannulation with acetylenic compounds67  
A typical example of benzofuran-2-yl formation by palladium-catalysed 
Sonogashira-tandem cyclisation chemistry was reported by Kundu et al. in 1997. This 
method provides a general and convenient way of reacting terminal acetylenes with 
2-iodophenols to give benzofuran derivatives (Scheme 6.10). Use of the common palladium 
catalyst Pd(PPh3)2Cl2, copper(I)iodide and triethylamine in DMF gave the corresponding 
2-substituted benzo[b]furans in excellent yields. The reactions proceed well with a variety 
of terminal alkynes in molecules containing other hydroxyl, vinyl and aromatic groups. Use 
of Pd(OAc)2 as the catalyst led to poorer yields and addition of triphenylphosphine was 
found to hamper formation of benzofurans. 
 
 








6.7.2 Reactions of 2-hydroxyaryl and hydroxyheteroaryl halides with 1-alkynes57 
Arcadi et al. reported the use of palladium catalysts in Sonogashira-style reactions 
between 2-hydroxy(hetero)aryl halides and terminal alkynes to form benzofurans. The 
reactions were conducted under anaerobic and anhydrous conditions with a catalytic system 
consisting of bis(triphenylphosphine) palladium (II) diacetate (Pd(OAc)2(PPh3)2) and 
copper(I)iodide.  The base used was piperidine and the reactions were performed in DMF 
with either gentle or no heating (Scheme 6.11). An impressive variety of functional groups 
were tolerated in the phenolic and alkyne reaction partners. 
 
 
Scheme 6.11 Sonogashira-tandem benzofuran cyclisations using Pd(OAc)2(PPh3)2 and CuI 
under mild conditions. 57  
 
6.7.3 One-pot Sonogashira-tandem benzofuran cyclisations under ligand- and copper-
free aerobic conditions68 
Another example of the palladium-catalysed Sonogashira-tandem benzofuran 
cyclisation was reported by Ranu et al. in 1997. Their method uses in situ-generated 
palladium nanoparticles in the absence of copper co-catalysts to couple and then cyclise 2-
iodophenols and aryl acetylenes into benzofurans (Scheme 6.12). In contrast to other 
procedures, the reactions could be carried out in water under aerobic conditions, making it 




generated in situ by reduction of Na2PdCl4 by sodium dodecyl sulphate (SDS) in water 
while heating at reflux. A nanoparticle loading of 4 mol% and the use of triethylamine as 
base were found to be optimal. Several 2-iodophenol derivatives and functionalised aryl 
acetylenes smoothly underwent the reaction, producing a library of functionalised 2-
arylbenzofurans in 75-86% yields. 
 
 
Scheme 6.12 Synthesis of benzofurans using palladium nanoparticles in water under 
ligand- and copper-free aerobic conditions (SDS = sodium dodecyl sulfate).68  
 
6.7.4 Pd-Tetraphosphine-Catalysed Coupling of 2-Halophenols with Alkynes69 
In 2014, a new one-pot synthesis yielding 2-substituted benzofurans from 2-
halophenols was described by Zhou et al. (Scheme 6.13). This method employed a highly 
efficient catalyst system consisting of [Pd(η3-C3H5)Cl]2 and the tetraphosphine ligand 
N,N,N’,N’-tetra(diphenyl-phosphinomethyl)pyridine-2,6-diamine (L), with Cs2CO3 present 
as base. The reaction tolerated a wide range of functional groups on the halophenol and 






Scheme 6.13 One-pot synthesis of benzofurans reported by Zhou et al.69  
 
6.7.5 Visible light-induced Sonogashira-tandem benzofuran cyclisations in water70 
In 2012, Ghosh et al. reported an environmentally friendly, visible light-induced 
one-pot palladium-catalysed Sonogashira-tandem cyclisation procedure that furnished 2-
alkyl/aryl benzofurans (Scheme 6.14). 2-Iodo/bromo phenols and terminal alkynes were 
photo-irradiated in the presence of palladium(II) chloride, triphenylphosphine and 
triethylamine in water to give the desired products in practical yields without a copper (I) 











6.8 Synthetic strategy overview 
Based on the above literature precedents, the Sonogashira-tandem cyclisation 
approach was chosen as the method for accessing substituted 6-benzofuran-2-yl amiloride 
analogues that could not be obtained using the Suzuki-Miyaura coupling route. A 
significant advantage of the proposed method was its use of 2-iodophenols, a large number 
of which are commercially available, meaning that many analogues could potentially be 
produced for further study. A selection of four such analogues only were pursued here to 
validate the chemistry and support wider implementation, if required. 
The strategy for applying the Sonogashira-tandem cyclisation approach is outlined 
in Scheme 6.15. Commencing from the 6-chloropyrazine methyl ester 21, Sonogashira 
coupling of TMS acetylene would install a TMS-alkyne at the pyrazine 6-position to give 
27. TMS-deprotection of the alkyne with tetrabutylammonium fluoride (TBAF) would then 
give the terminal alkyne 28. Sonogashira-tandem cyclisations of the alkyne 28 with diverse 
2-iodophenols would then install the functionalised benzofurans and final conversion to 
acylguanidines would use the method described above. The proposed strategy was 
appealing due to its diversification at a late stage in the synthesis, allowing multiple 
acylguanidine analogues to be accessed from a single advanced common intermediate (i.e. 
terminal alkyne 28) in only 2-steps each. Divergent chemistry of this type is highly valued 
in medicinal chemistry SAR studies that aim to generate multiple analogues in practical 
timeframes. As described below, the chemistry could also be extended to use of o-iodo-






Scheme 6.15 General strategy for the synthesis of substituted 6-benzofuran-2-yl amiloride 
analogues using Sonogashira-tandem cyclisation chemistry. 
 
6.8.1 Sonogashira reaction to produce 6-TMS-alkynyl pyrazine methyl ester 27 
The 6-chloropyrazine methyl ester 21 was reacted with trimethylsilyl (TMS)-
acetylene in the presence of Pd(PPh3)Cl2 and CuI in THF, with triethylamine (TEA) or 
N,N-diisopropylethylamine (DIPEA) present as base. The solids were added first to THF 
and the mixture was stirred for 5 min at 60 °C, before adding the base and stirring for a 
further 30 min. TMS-acetylene was introduced and stirring continued at 60 °C for 6-7 h, 
with the reaction progress monitored by HRESI-MS. 
The first two attempts at the reaction performed on a small scale using TEA as the 
base afforded variable yields of 27 (50 and 15%) after 16 h. When the reaction was 
performed on a 5 mmol scale and the base was switched to DIPEA, a better yield (76%) 






Table 6.5 Sonogashira cross-coupling reactions of 6-chloropyrazine methyl ester 21 with 
TMS-acetylene to give 27. 
 
 
The initial step of the Sonogashira cross-coupling reaction involves oxidative 
insertion of the active palladium(0) catalyst into the C-Cl bond of pyrazine 21. The TMS-
acetylene is converted into a copper TMS-acetylide in the presence of CuI and base 
(DIPEA), which serves to deprotonate the TMS-acetylene. A transmetalation process 
ensues between the activated organopalladium (II) intermediate and the copper TMS-
acetylide to produce a TMS-acetylene/pyrazine palladium (II) complex. The final step that 
delivers the TMS-alkyne product involves reductive elimination, which returns the active 






Scheme 6.16 Mechanism for the Sonogashira cross-coupling reaction of TMS-acetylene 
with 6-chloropyrazine methyl ester 21 to give TMS-alkyne 27. 
 
The 1H spectrum of 27 (Figure 6.5, top) showed a diagnostic 9H singlet for the three 
chemically equivalent TMS-CH3 groups at δ 0.24 ppm. A singlet at δ 3.74 ppm with 
integration 3H corresponded to the methyl ester group. As the spectrum was recorded in 
methanol-d4, none of the NH signals appeared due to 1H-2H exchange. HRESI-MS showed 
the correct peak at m/z 265.1114 corresponding to the expected [C11H17N4O2Si]+ molecular 
ion.  
The 13C APT spectrum of 27 in DMSO-d6 (Figure 6.5, bottom) showed a (negative) 
carbonyl peak as the furthest downfield signal at δ 165.9 ppm. Two downfield negative 
peaks at δ 156.8 and δ 155.2 corresponded to the C5 and C3 pyrazine carbons directly 




to the two other pyrazine carbons at C2 and C6. Negative signals at δ 100.2 and δ 97.2 ppm 
were assigned to the two acetylene carbons. A positive peak at δ 51.2 ppm corresponded to 
the CH3 of the methyl ester and the furthest upfield signal at δ 0.17 ppm corresponded to 










6.8.2 Deprotection of 27 to give 6-ethynyl pyrazine methyl ester 28 
Desilylation of TMS-methyl ester 27 was attempted using tetrabutylammonium 
fluoride (TBAF) (5 eq), introduced as a 1.0 M solution in THF.72 The reaction mixture was 
stirred for 45 min at 0 °C and then quenched with H2O and stirred for further 1 h at room 
temperature. TLC monitoring showed that the reaction had gone to completion and the 
desired ester 28 was obtained in 79% yield after purification by silica gel column 
chromatography (Scheme 6.17). The reaction was completed 3 times to afford a total of 581 
mg of 28. 
 
 
Scheme 6.17 Desilylation of 27 using TBAF to give alkyne 28. 
 
The mechanism for the TMS cleavage proceeds via a pentavalent silicon 
intermediate formed during attack by the F-, present as the counterion in TBAF. The 
organic soluble tetrabutyl ammonium cation provides a means of solubilising F- in the THF 
solvent. Cleavage of the alkynyl C-Si bond ensues to form the deprotonated terminal alkyne 
and trimethylsilyl fluoride, a process driven by formation of the very strong Si-F bond (565 
kJ/mol).73 The anion is protonated upon workup (quenching with water) to give the desired 





Scheme 6.18 Mechanism for the desilyation of 27 using TBAF to give 28.  
 
Analysis of the 1H NMR spectrum of 28 (Figure 6.6) showed the expected loss of 
the terminal TMS methyl signal at δ 0.23 and the appearance of a terminal acetylene singlet 
at δ 4.36. Two singlets at δ 7.27 and δ 6.95, each showing integration 2H, were assigned to 
the two NH2 groups at positions 3 and 5 on the pyrazine ring. The singlet at δ 3.74 with 
integration 3H was assigned to the methyl ester CH3 group. HRESI-MS showed a peak at 
m/z 215.0539, corresponding to the expected [C8H8N4NaO2]+ molecular ion .  
The 13C APT spectrum of 28 (Figure 6.6) showed the methyl ester carbonyl as the 
furthest downfield signal at δ 165.9 ppm. Two negative peaks at δ 156.8 and δ 155.2 
corresponded to the pyrazine carbons at positions 3 and 5; i.e. directly attached to the 
amino groups. Two negative peaks at δ 112.6 and δ 112.4 ppm corresponded to carbons at 
positions 2 and 6 on the pyrazine ring, respectively, and the two negative peaks at δ 100.2 
and δ 97.2 ppm corresponded to the acetylene carbons. A positive peak at δ 51.2 ppm 
corresponded to the methyl ester CH3. Loss of the peak at δ 0.17 ppm in 27 confirmed 






Figure 6.6 1H (400 MHz, DMSO-d6) and 13C APT spectra (100 MHz, DMSO-d6) for 28. 
 
6.8.3 One-pot Sonogashira-tandem benzofuran cyclisations to synthesise 6-substituted 
pyrazine methyl esters 29a-29d 
The Sonogashira-tandem benzofuran cyclisation reaction was attempted using 
standard Sonogashira conditions that had been reported in related literature precedents, with 
minor modifications.74-76 The 6-ethynyl methyl ester 28, 2-iodophenol/o-




introduction of piperidine. The reaction mixtures were then heated at 60 °C until TLC (20% 
EtOAc in pet. spirit) and HRESI-MS analysis showed disappearance of the starting material 
28 (typically 1-1.5 h). Quenching by addition of water followed by extraction with n-
butanol and filtration over celite delivered the crude products, which were then purified by 
silica gel column chromatography. The quantities of cyclisation products prepared and the 
reaction yields are provided in Table 6.6. 
 
Table 6.6 Synthesis of 29a-29d using Sonogashira-tandem cyclisation reactions. 
 
 
Each of the reactions was performed once only to obtain the yields indicated. While 
the yields were only moderate (25-57%), performing the reactions on a (0.52−0.78) mmol 




target acylguanidines. All of the compounds were comprehensively characterised and their 
structures confirmed by 1H, 13C NMR and HRESI-MS analysis. 
The 1H NMR spectrum of the 4-furopyridine analogue 29a (Figure 6.7) in DMSO-
d6 showed a de-shielded doublet-of- doublets at d 8.51 ppm (J = 4.7, 1.2 Hz), which was 
assigned to the H17 proton next to the electron withdrawing pyridine nitrogen. A doublet at 
d 8.05 ppm (J = 8.3 Hz) was assigned to the H15 of the furopyridine.  A doublet-of-
doublets at d 7.33 (J = 8.3, 4.8 Hz) corresponded to H16 and a singlet at d 7.26 ppm was 
assigned to H12. A singlet peak at 3.82 ppm integrating for 3H corresponded to the methyl 
ester group.   
The 13C APT spectrum of 29a (Figure 6.7) showed the typical carbonyl peak as the 
furthest downfield signal at δ 166.2 ppm. The C5 and C3 signals of the pyrazine ring 
appeared as two negative signals at δ 156.9 and 155.5 ppm. Two negative peaks at δ 153.6 
and 146.8 ppm were assigned to the two carbons neighbouring the furanyl oxygen atom, i.e. 
C14 and C11, respectively. A negative peak at 147.8 ppm was assigned to the ring junction 
C13. The most de-shielded positive (CH) signal at δ 146.1 ppm arises from the carbon 
directly attached to the electron withdrawing pyridine nitrogen. Two other positive peaks at 
δ 118.9 and δ 118.3 ppm corresponded to the pyridine ring protons. Two negative peaks at 
δ 117.9 and δ 112.7 ppm were assigned to the C6 and C2 of the pyrazine ring and the most 
upfield positive aromatic ring signal at δ 103.3 ppm corresponded to the furan CH. The 









Figure 6.7 1H (400 MHz, DMSO-d6) and 13C APT spectra (100 MHz, DMSO-d6) for 4-
furopyridine methyl ester 29a. 
 
6.8.4 Mechanism of the one-pot Sonogashira-tandem cyclisation reaction77 
The mechanism of the one-pot Sonogashira-tandem benzofuran cyclisation reaction 
is outlined in Scheme 6.19, exemplified with the formation of 4-furopyridine methyl ester 
66. The first step involves oxidative insertion of the active palladium(0) catalyst into the 
aryl iodide bond of o-iodohydroxypyridine, leading to formation of a square planar Pd (II)-




presence of CuI and piperidine, which serves to deprotonate the acetylide. A 
transmetalation process ensues between the activated organopalladium (II) intermediate and 
the copper acetylide to produce a palladium (II) arylacetylide complex II, which then 
undergoes reductive elimination to deliver the intermediate 2-(arylethynyl)-
hydroxypyridine and return the active palladium (0) catalyst ready for the next cycle. The 
2-(arylethynyl)-hydroxypyridine enters a second catalytic cycle by coordination with the 
palladium. Intramolecular attack of the phenol onto the activated alkyne leads to formation 
of a benzofuran-bound palladium complex III. Final reductive elimination then delivers the 
furopyridine product IV and returns the active palladium (0) catalyst (Scheme 6.19).  
 
Scheme 6.19 Mechanism for the Sonogashira-tandem cyclisation reaction of acetylene 28 









6.8.5 Guanidinylation reactions on methyl esters 29a-29d to produce acylguanidines 
30a-30d 
Methyl esters 29a-29d were submitted to the typical guanidinylation procedure. The 
free base guanidine was generated in situ as usual by dissolving Na metal in anhydrous 
iPrOH and stirring for 40 min at 40 °C before adding anhydrous guanidine.HCl. The 
reaction mixtures were stirred for further 1 h at room temperature to give a white 
precipitate of NaCl. The mixture was filtered to give a clear solution of free base guanidine 
that was directly added to the methyl esters in refluxing iPrOH and stirred for 2-16 h.  After 
concentrating the reaction mixtures, the crude residues were purified by preparative rp-
HPLC to give the acyguanidine TFA salts after lyophilisation. The TFA salts were stirred 
with HCl 0.1N in acetonitrile to yield the targets 30a-30d as hydrochloride (HCl) salts in 
21-78% yields. The acylguanidine products were all fully characterised and their structures 
confirmed by HRESI-MS and spectroscopic analysis. Spectroscopic data for the 4-



















Table 6.7 Conversion of methyl esters 29a-29d to acylguanidines 30a-30d. 
 
 
The 1H NMR spectrum in DMSO-d6 of 30a (Figure 6.8) showed the expected 
signals. Additional of a guanidine group to 29a was evidenced by loss of the methyl ester 
signal at δ 3.82 ppm and appearance of three new downfield signals at δ 10.52, 8.74, 8.38 
ppm, corresponding to the protons of the newly introduced guanidine group. Similar signal 
changes were observed with the three other analogues.  
Analysis of the 13C APT NMR spectrum of 30a (Figure 6.8) showed an additional 
peak (relative to 29a) at δ 155.1 ppm, corresponding to the new guanidine carbon, as well 
as loss of the methyl ester carbonyl signal. All other signals observed for the methyl ester 







Figure 6.8 1H (500 MHz, DMSO-d6) and 13C APT spectra (125 MHz, DMSO-d6) for 4-
furopyridine acylguanidine 30a . 
 
 
6.9 Biological Evaluation 
6.9.1 Anti-TB and Eukaryotic Cell Cytotoxicity Testing 
Acylguanidines 20, 24a-24l, 26a-26k and 30a-30d were submitted to Prof Gregory 




antibacterial activity against M. tuberculosis. The compounds were tested against M. 
tuberculosis mc26230, a strain obtained by the Cook Lab from Howard Hughes Medical 
Institute, Department of Microbiology and Immunology, Albert Einstein College of 
Medicine (USA).  
 In addition to screening for anti-TB activity, selected compounds were counter-
screened against HepG2 hepatocellular carcinoma cells to track eukaryotic cell cytotoxicity. 
Promising drug candidates would be expected to show greater than 100-fold selectivity for 
TB cells over their human cell counterparts. This testing was carried out by Associate 
Research Fellow Dr Benjamin Buckley at the Illawarra Health and Medical Research 
Insitute (IHMRI) and University of Wollongong. A summary of the HepG2 assay 
procedures performed by Dr Buckley is provided in section 7.1.4. 
 
6.9.2 Activity of analogues HM2-16F 20 and 24a-24k 
 When tested under the above conditions, HM2-16F 20 showed an MIC of 4 µg/mL 
(Table 6.8). The single atom change introduced by converting the benzofuran to a 
benzothiophene 24a caused an 8-fold drop in potency against MTB. Replacing the 6-
benzofuran with a p-CF3-phenyl group led to a dramatic loss of activity (MIC = 512 µM). 
Similar losses were observed with all other 6-membered aryl rings (compounds 24c-24f, 
24k). Removal of the fused benzene ring in the benzofuran to give a 2-furanyl substituent 
24g also greatly reduced potency (256 µM). The drop in potency was slightly less when the 
attachment point on the furan was moved to the 3-position 24h (64-128 µM). Other 5-
membered heteroaromatics thiophene 24i and N-methylimidazole 24j showed similarly 




with other (hetero)aryl groups suggests this group plays a central role in the mode of 
activity of the 6-substituted amiloride class. 
 When tested for HepG2 cytotoxicity, the parent compound HM2-16F 20 showed an 
IC50 value of 31 µM, indicating that the compound exhibits 8-fold higher selectivity for 
MTB cells. The MTB inactive p-methoxypyrimidine derivative 24d showed no effects 
against HepG2 cells (IC50 > 100 µM). Due to their low MTB activity, none of the other 




















Table 6.8 MICs of 20, 24a-24k against MTB cells and IC50 values of selected analogues 





6.9.3 Activity of analogues 26a-26i 
 The apparent requirement of a benzofuran at the pyrazine 6-position was the main 
driver for exploring benzofuran-2-yl analogues carrying substituents in the 6-membered 
ring. Choice of target analogues was based exclusively on commercial availability of the 
substituted benzofuran-2-yl boronic acid required for the synthesis. 
 Addition of methyl 26a or electron donating methoxy 26b groups to the benzofuran 
5-position led to an 8-fold drop in potency (MIC = 32 µM) relative to HM2-16F 20. 
Addition of an electron withdrawing nitrile at the same position 26c resulted in greater loss 
of activity (MIC > 128 µM). Addition of halogen atoms to the 5-position was also 
detrimental, with the smallest loss (4-fold relative to HM2-16F 20) occurring with 5-chloro 
analogue 26e. The 6-methoxy-substituted 26g (MIC = 32 µM) showed the same activity as 
its 5-methoxy counterpart 26b. Shifting the pyrazine attachment point of the benzofuran 
around to the 5-position (26i) led to a total loss of activity, as did inclusion of a 
dihydrobenzofuran linked via its 7-position (26h). The losses in potency observed with 
these analogues suggested that all benzofuran modifications are detrimental to activity. 
 The most potent member of this series, 5-chloro analogue 26e, was tested for 
HepG2 cytotoxicity, where it returned an IC50 of 9 uM. This value was lower than its MIC 
against MTB, indicating the compound shows no selectivity for mycobacterial cells over 
human cells. The nitrile-substituted 26c, which showed no activity against MTB, was also 
inactive against on HepG2 cells. These findings were worrying signs that MTB activity 
may be tracking with HepG2 cytotoxicity. This was a concern because it hints towards a 
non-specific mode of cytotoxicity for the 6-substituted amiloride class in all cells rather 




Table 6.9 MICs of 26a-26i against MTB cells and IC50 values of selected analogues against 
human HepG2 cells. 
 
 
6.9.4 Activity of analogues 30a-30d 
 The four modified benzofuran analogues 30a-30d, accessed using the Sonogashira-
tandem benzofuran cyclisation chemistry, were tested for both TB and HepG2 activity. The 




the electron deficient pyridine ring would be expected to lower oxidative hepatic 
metabolism compared to an electron rich benzofuran. This would be desirable in 
downstream drug development as it should increase the half-life of the compound in vivo. 
Drugs with longer half-lives can be dosed less frequently resulting in better patient 
compliance. Unfortunately, both furopyridines showed very low activity against TB. The 5-
tert-butyl benzofuran analogue 30c showed moderate activity (MIC 32 µM) but the 5-7-
difluro 30d showed only low activity. 
When tested against HepG2 cells, the two furopyridines showed no activity, 
consistent with the above trend where activity against TB appears to track with HepG2 
activity. In further support of this, the relatively higher TB potency of tert-butyl-substituted 
30c was paralleled by an increase in toxicity towards HepG2. The difluoro analogue 30d, 
however, showed a reversal in this trend, where 21-fold higher toxicity was observed 


















6.10 Summary and Conclusion Remarks  
 This chapter explored the synthesis and anti-TB structure-activity relationships 
around the preliminary lead 6-substituted amiloride HM2-16F 20. In the first (24a-24k) and 
second (26a-26i) series, the benzofuran-2-yl located at the 6-position in 20 was replaced by 
(hetero)aryl groups or substituted benzofurans, introduced onto the pyrazine scaffold using 
Suzuki-Miyaura Pd-catalysed coupling chemistry. While Suzuki-Miyaura couplings have 
previously been reported on pyrazines (see 6.1), this type of chemistry has not been 
reported on the highly functionalised amiloride scaffold. Indeed, at the outset of the project 
there was a paucity of reports on either the synthesis or biological evaluation of any 6-




amiloride chemistry and the 6-substituted analogues produced represent a new amiloride 
sub-class. 
 In the third series, a novel application of Sonogashira-tandem benzofuran 
cyclisation chemistry was developed to obtain additional substituted benzofuran derivatives 
that could not be accessed using the Suzuki-Miyaura chemistry due to the required 
benzofuran-2yl boronic acid reagents being unavailable commercially. Formation of 
benzofurans using this type of chemistry had been previously reported in the literature (see 
6.8), however, this was the first demonstration of the chemistry on a polyfunctionalised 
pyrazine-based scaffold, like amiloride. While only four examples were synthesised, the 
generality of the chemistry was evident. Thus, as the medicinal chemistry program 
advances and further structure-activity information comes to hand, multiple other 
benzofuran substituents could potentially be investigated, if needed, by deploying the very 
large number of commercially available 2-iodophenols in the Sonogashira-tandem 
benzofuran cyclisation reaction. 
 All of the 6-substituted amilorides synthesised showed lower MTB activity than the 
parent lead HM2-16F 20. While a disappointing result, the structure-activity insights gained 
will help to guide future selection of analogues for synthesis and biological evaluation on 
route to eventually identifying a more potent and selective lead amiloride analogue for 
detailed evaluation in TB, including mechanism of action studies. At this stage, the 
mechanism is still unclear and it is not known if TB ATP synthase is involved (see 5.6.2 
and 5.7). A key parameter that must be optimised before a truly useful probe compound is 
obtained is mammalian cell cytotoxicity, monitored in this work using HepG2 cells. 




selectivity for TB over HepG2 cells, TB activity appeared to track with HepG2 cytotoxicity. 
Monitoring of cytotoxicity will be critical in the future to establish whether the trend is 
class-wide, or if analogues with the 100-fold or greater TB cell selectivity required for drug 
development can be identified and therefore prioritised.  
 My PhD efforts represented part of a wider medicinal chemistry effort in the Kelso 
Lab at UOW exploring anti-TB structure-activity relationships in 6-substituted amilorides 
and related compounds. While completing my studies, chemists from the Kelso Lab and 
biologists from the Cook Lab at the University of Otago identified four promising 
analogues that showed MICs in the range 4-16 µM. The structures of the compounds and 
their MICs are shown in Table 6.11. MICs for BB2-50F 19, HM2-16F 20 and TB drugs 
isoniazid (INH) and bedaquiline (BDQ) were (re)measured in parallel alongside the four 
new leads to facilitate direct activity comparisons. 
 
Table 6.11 Structures and MTB MIC values of 6-substituted amiloride leads developed by 
other Kelso Lab members at UOW. Structures and MICs for BB2-50F 19, HM2-16F 20 
and TB drugs isoniazid (INH) and bedaquiline (BDQ) are also shown. 






























 Two of the new compounds, AA2-137 and RSB1-41, retained a benzofuran at the 




CF3-phenyl group. The good potency of AA1-49 and AA3-97 was interesting as in my 
work the amiloride derivative substituted with a p-CF3-phenyl group at the 6-position (i.e. 
compound 36) was essentially inactive (MIC 512 µM).  It was notable that the pyrrolidine 
group appeared as a promising substituent at the pyrazine 5-position. 
 The compounds in Table 6.11 were next tested in parallel using most probable 
number (MPN) assays. The logMPN parameter serves as a proxy for colony forming 
units/mL (cfu/mL) and was developed by the Cook Lab to assess viability of slow-growing 
MTB cells in shorter and more practical timeframes (7 days). Briefly, ten-fold serial 
dilutions of M. tuberculosis mc26260, compound treated and untreated, were prepared in 
96 well microtitre plates in triplicate in 7H9 medium supplemented with OADC and 0.05% 
Tyloxapol. The plates were incubated at 37 °C for 7 days and visible bacterial growth was 
monitored and logMPN values calculated using the published statistical methods.78  
 The logMPN experiments showed that INH and BDQ reduce MTB viability to the 
same extent (~4logMPN) after 7 days, although a faster initial reduction is observed with 
INH. BB2-50F 19 showed a similar rate and extent of reduction as INH and BDQ over the 
first 6 days but was able to sterilise the cultures after Day 7. HM2-16F 20 showed the same 
reduction in viability as INH and BDQ after 7 days but the rate of reduction in viability was 






Figure 6.9 LogMPN assay results with leading amiloride analogues and TB drug controls 
isoniazid (INH) and bedaquiline (BDQ). The compound indicated in each panel 
corresponds to the data in orange. The 6-substituted amiloride analogues were all present at 
40 µM. INH and BDQ were present at 2 µM and 0.2 µM, respectively. Data for IND and 





The p-CF3-phenyl derivative carrying a hexamethylene group at the 5-position (AA1-49) 
appeared as the most active compound in the series, causing sterilisation of cultures after 
just 4 days. Changing the hexamethylene group to a 5-membered pyrrolidine whilst 
retaining the p-CF3-phenyl group at position 6 (AA3-97) produced a compound with 
activity that directly mirrored BDQ throughout the course of the experiment. Adding a 
nitrile group to the benzofuran 5-position of BB2-50F (i.e. AA2-137) produced little 
change in logMPN despite the compound showing a 4-fold lower MIC (Table 6.11). 
Replacing the hexamethylene ring of BB2-50F with a pyrrolidine (i.e. (RSB1-41) produced 
the lowest logMPN reduction within this compound set. Overall these data highlight the 
exciting potential of this class and support further medicinal chemistry investigations. 
Current efforts in the Kelso Lab are focusing on finding isosteric replacements for the 
acylguanidine as pharmacokinetic data obtained from collaborators shows that hydrolytic 
metabolism of this group is occurring rapidly in mice. A more stable group will need to be 




















Part B: Experimental and references 
7.1 Experimental Procedures - Chemistry 
7.1.1 Chemistry – General  
Tetrakis(triphenylphosphine)- palladium(0) was prepared by the reaction of 
triphenylphosphine and palladium chloride under nitrogen gas.79  
Products and compounds were weighed using a Sartorius Extend 220g balance. 
Solvents were removed under reduced pressure (in vacuo) at (25-40°C) with a Büchi rotary 
evaporator 70 attached to a vacuubrand CVC2 pump (Vacuubrand GmbH, Wertheim, 
Germany). Solvent residues were removed in vacuo using a Javac Vector RD-90 double 
stage high vacuum pump. Fractions collected from preparative HPLC purifications were 
freeze-dried using a Christ Alpha 1-4 LOC-1M (MartinChrist GmBH, Osterode am Harz, 
Germany) or Christ Alpha 1-2 LD plus instrument. Analytical thin layer (TLC) monitoring 
of reactions was performed using aluminum plates coated with silica gel (Merck 60 F254).  
Compounds were purified to more than 95% purity for testing using a Waters 
PLC/DSC Prep LC150 System with detection at 254 nm. Purification was performed using 
gradient elutions with solvents A (100% H2O, 0.1% TFA) and B (90% ACN, 10% H2O, 0.1 
TFA) on a SunfireTM PREP C18 OBMTM (5µM) steel jacketed column run at 20 mL.min-1. 
The analyses were performed using gradient elutions with solvents A and B on a 





7.1.2 Characterisation and Data Collection 
Low resolution electron impact (EI+) mass spectra were obtained on a Shimadzu 
QP- 5000 mass spectrometer by direct insertion with a 70-eV electron beam. Low 
resolution electrospray (ES+) mass spectra were obtained on a micromass Z-path (LCZ) 
platform spectrometer. EI High Resolution Mass Spectra (HRMS) were obtained on a 
Fisons/VG Autospec spectrometer using perfluorokerosene as internal standard. ES HRMS 
were obtained on a Waters QTof Ultima spectrometer using polyethylene glycol or 
polypropylene glycol as internal standard.  
Many compounds in this study contain several exchangeable protons bound to 
nitrogens. The 1H chemical shifts of these protons were highly solvent, temperature and 
concentration dependent.  
7.1.3 Anti-TB Testing Procedures 
Briefly, mycobacteria were grown in Middlebrook 7H9 medium (Difco, Sparks, 
MD) supplemented with 10% (v/v) OADC enrichment (Difco), 0.2% (v/v) glycerol, 0.05% 
(v/v) tyloxapol, and pantothenate (50 mg/L). Cultures were grown at 37 °C with 
shaking. After the cultures were harvested by centrifugation at 4,000 rpm for 10 min, the 
supernatant was removed and the cell pellet resuspended in PBS to optical density 1.0 at 
600 nm. The central 80 wells of a 96 well plate was set up to contain, in triplicate, a 2-fold 
dilution series of test compound in 50 μL 7H9 medium. Culture suspension (50 μL) was 
then added to the central 80 wells to give a final assay volume of 100 μL. Rows A and H 
contained 200 μL of sterile distilled water to minimise evaporation from culture wells 
during incubation. Wells B-F of column 1 contained 100 μL of PBS. Wells B-F of column 




The plates were placed inside plastic bags and double contained inside a plastic box to 
further minimise evaporation. The plates were incubated for 7 days at 37 °C with shaking 
(150 rpm), after which the minimal inhibitory concentration (MIC) was determined by 
recording the concentration of test compound that produced no visible pellet. 
 
7.1.4 Eukaryotic Cell Cytotoxicity Testing Procedures 
HepG2 (ATCC HB-8065) cells were cultured at 37 °C, 95% humidity, and 5% (v/v) 
CO2 in a Thermo Scientific Heracell 150i CO2 incubator and maintained in DMEM/Hi 
glucose culture medium supplemented with 10% heat-inactivated foetal calf serum. 
Adherent cells were passaged via the addition of trypsin/0.05% EDTA solution, followed 
by centrifugation and resuspension in fresh media using a 5 mL Luerlock syringe fitted 
with an 18-gauge needle. Cultures were routinely tested for the presence of mycoplasma 
infection. Sub-confluent cells (∼70−80% confluence, passage no. 3-15) were harvested and 
dissociated into a single cell suspension. Cells were seeded at a density of 7,500 cells/well 
(final volume 90 μL) into a Greiner CELLSTAR 96-well plate via multichannel pipette and 
incubated for 18 h prior to addition of compounds. Compounds were serially diluted from 
20 to 50 mM DMSO stocks in culture media in a separate 96-well plate under sterile 
conditions to give 10× stocks (10 nM to 1 mM) on the day of compound addition. 10 μL of 
the 10× compound/media stocks or matched vehicle/media solutions (for vehicle controls; 
final vehicle concentration 0.2% v/v) were transferred via multi-channel pipette into the 
assay plate containing 90 μL of cell suspension to give the treated assay plate at the final 1× 
drug concentrations (1 nM to 100 μM, n = 4 wells at each concentration). Drug blanks or 




intrinsic colour of compounds and phenol red containing media. 200 μL media was added 
to outside wells to minimise evaporation. After incubation for 48 h, plates were removed 
from the incubator and 20 μL of CellTiter 96 Aqueous One solution cell proliferation assay 
was added to each well. Plates were incubated for a further 2 h prior to reading at 490 nm 
using a SpectraMax Plus 384-well plate reader. IC50 values (defined as the concentration of 
each treatment causing 50% inhibition of maximal cell viability) were determined using a 
logarithmic sigmoidal dose response curve in GraphPad Prism v7.0. 
 
7.2 Synthesis of 6-substituted methyl esters 23a-23l by Suzuki cross-coupling reaction  
7.2.1 General Method 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (1eq) was combined with aryl 
boronic acid (1.5 eq), (tetrakis(triphenylphosphine)- palladium(0) (0.05 eq) and K2CO3 (10 
eq) in an oven-dried round bottom flask under Ar. To the dry mixture was added methanol 
and toluene (1:4), a reflux condenser was attached and the reaction heated at 80 °C.  
 
Synthesis of methyl 3,5-diamino-6-(benzofuran-2-yl)pyrazine-2-carboxylate 23a 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (250 
mg, 1.23 mmol) was combined with benzofuran-2-
ylboronic acid (300 mg, 1.8 mmol), 
tetrakis(triphenylphosphine)-palladium(0) (71.3 mg, 61.7 
µmol) and K2CO3 (1.705 g, 12.3 mmol) in a 100 mL oven-dried round bottom flask under 
Ar was added dry mixture methanol and toluene (18:4.5 mL), a reflux condenser attached 




spirit:EtOAc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of EtOAc:MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a gradient (10 → 40% EtOAc/Pet. Spirit) with 5% of CH3Cl, to give 
23a (200 mg, 57%) as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.62; Mp 
188-190 ºC; 1H NMR (400 MHz, DMSO) δ 7.66 (m, 2H, H17, H18), 7.29 (dt, J = 24.3, 7.1 
Hz 2H, H15, H16), 7.19 (s, 1H, H12), 3.81 (s, 3H, H21); 13C NMR (125 MHz, DMSO) δ 
166.8 (C7), 155.8 (C5), 154.1 (C14), 153.8 (C11), 153.8 (C3), 128.7 (C6), 124.5 (C15), 
123.6 (C16), 121.3 (C17), 119.3 (C13), 112.7 (C2), 111.8 (C18), 103.5 (C12), 51.7 (C21); 
IR (neat) ν 3405.1, 3345, 1718.7, 1611.6, 1533.5, 1295.3, 767.7, 734.0 cm-1; HRESI-MS: 
m/z calculated for C14H12N4O3Na [M + H]+  307.0802, found 307.0819. 
 
Synthesis of methyl 3,5-diamino-6-(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate 23b 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (500 
mg, 2.46 mmol) was combined with benzo[b]thiophen-2-
yldimethylborane (659 mg, 3.70 mmol), 
tetrakis(triphenylphosphine)palladium(0) (143 mg, 0.12 
mmol) and K2CO3 (3.413 g, 24.6 mmol) in a 100 mL oven-dried round bottom flask under 
Ar was added dry mixture methanol and toluene (30:7.5 mL), a reflux condenser attached 
and the reaction heated at 80 °C with stirring for 1.5 h while monitoring by TLC (Pet. 
spirit:EtOAc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of EtOAc:MeOH, 




chromatography using a gradient (0 → 40% EtOAc/Pet. Spirit) to give 23b (146 mg, 20%) 
as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.40; Mp 188-190 ºC; 1H NMR 
(400 MHz, DMSO) δ 7.92 (m, 1H, H18), 7.80 (d, J = 1.67 Hz, 1H, H15), 7.78 (s, 1H, H12), 
7.34 (m, 2H, H16, H17), 7.21 (s, 2H, NH2), 7.09 (s, 2H, NH2), 3.80 (s, 3H, H21); 13C NMR 
(100 MHz, DMSO) δ 166.8 (C7), 155.5 (C5), 153.7 (C3), 142.8 (C13), 141.3 (C14), 139.0 
(C11), 124.9 (C17), 124.7 (C16), 124.2 (C15), 123.4 (C6), 122.4 (C12), 120.3 (C18), 112.0 
(C2), 51.8 (C21); IR (neat) ν 3371.7, 3155.6, 1683.9, 1539.2, 741.6, 723.34 cm-1; HRESI-
MS: m/z calculated for C14H13N4O2S [M + H]+ 301.0754, found 301.0763. 
 
Synthesis of methyl 3,5-diamino-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxylate 
23c 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (250 
mg, 1.23 mmol) was combined with 4-
(trifluoromethyl)phenyl-2-ylboronic acid (352 mg, 1.8 
mmol), tetrakis(triphenylphosphine)palladium(0) (71.3 mg, 
0.06 mmol) and K2CO3 (1.705 g, 12.3 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and toluene (30:7.5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 3 h while monitoring by TLC 
(Pet. spirit:EtOAc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture EtOAc:MeOH, 50:50 
(2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a gradient (0 → 35% EtOAc/Pet. Spirit) to give 23c (280 mg, 73%) 




(500 MHz, DMSO-d6) δ 7.77 (apparent singlet, 2H, H12, H16), 7.64 (d, J = 8.4 Hz, 2H, 
H13, H15), 7.12 (s, 2H, NH2), 6.78 (s, 2H, NH2), 3.74 (s, 3H, H21); 13C NMR (125 MHz, 
DMSO) δ 167.3 (C7), 156.3 (C5), 154.8 (C3), 141.9 (J = 8.2 Hz, C14), 129.4 (C12, C16), 
128.5 (C11), 128.4 (J = 18.5 Hz, C17), 128.3 (C6), 126.0 (J = 3.2 Hz, C13, C15), 112.4 
(C2), 51.8 (C21); IR (neat) ν 3502.8, 3364.9, 3174, 1683.9, 1650.1, 1595, 1243, 857.4, 
803.4, 689.5 cm-1; HRESI-MS: m/z calculated for C13H12N4O2F3 [M + H]+ 313.0907, found 
313.0909. 
 
Synthesis of methyl 3,5-diamino-6-(4-(methylthio)phenyl)pyrazine-2-carboxylate 23d 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (250 
mg, 1.2 mmol) was combined with 4-
(methylthio)phenylboronic acid (311.1 mg, 1.8 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.07 mg, 0.06 
mmol) and K2CO3 (1.7 g, 12.3 mmol) in a 100 mL oven-dried round bottom flask under Ar 
was added dry mixture methanol and toluene (30:7.5 mL), a reflux condenser attached and 
the reaction heated at 80 °C with stirring for 2 h while monitoring by TLC (Pet. 
spirit:EtOAc, 70:30). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of CHCl3: EtOAc, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a gradient (0 → 30% EtOAc/Pet. Spirit) to give 23d (208 mg, 58%) 
as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.48; Mp 228-230 ºC; 1H NMR 
(500 MHz, DMSO-d6) δ 7.49 (d, J = 8.1 Hz, 2H, H13, H15), 7.32 (d, J = 8.2 Hz, 2H, H12, 




NMR (125 MHz, DMSO) δ 167.3 (C7), 155.9 (C5), 154.5 (C3), 138.0 (C11), 134.2 (C14), 
129.6 (C6), 129.0 (C12, C16), 126.0 (C13, C15), 111.6 (C2), 51.4 (C21), 15.1 (C17); IR 
(neat) ν 3445.9, 3325.4, 3126.7, 1680, 1647.2, 15894, 719.4 cm-1; HRESI-MS: m/z 
calculated for C13H15N4O2S [M + H]+ 291.0910, found 291.0920. 
 
Synthesis of methyl 3,5-diamino-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxylate 
23e 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (500 
mg, 2.4 mmol) was combined with (2-methoxypyrimidin-
5-yl)boronic acid (569 mg, 3.6 mmol), 
tetrakis(triphenylphosphine)palladium(0) (71 mg, 0.12 mmol) and K2CO3 (1.705 g, 24.6 
mmol) in a 100 mL oven-dried round bottom flask under Ar was added dry mixture 
methanol and toluene (40:10 mL), a reflux condenser attached and the reaction heated at 
80 °C with stirring for 3.5 h while monitoring by TLC (EtOAc). The reaction mixture was 
cool down to room temperature and added H2O (50 mL) with stirring for 1h. The mixture 
was filtrated by using Buchner funnel, the product left on filter paper and washed with 
EtOAc (1 × 50 mL) and dried in vacuo, and give pure 23e (609 mg, 89%) as a yellow-white 
solid. TLC Rf (EtOAc) = 0.56; Mp 242-244 ºC; 1H NMR (500 MHz, DMSO-d6) δ 8.67 (s, 
2H, H11, H13), 7.13 (s, 2H, NH2), 6.88 (s, 2H, NH2), 3.97 (s, 3H, H16), 3.74 (s, 3H, H21); 
13C NMR (125 MHz, DMSO) δ 167.1 (C7), 164.72 (C15), 159.4 (C11, C13), 156.4 (C5), 
155.2 (C3), 125.8 (C12), 124.7 (C6), 111.9 (C2), 55.1 (C16), 51.5 (C21); IR (neat) ν 3444, 
3359, 3144, 2296, 2256, 1691, 1597, 1556, 1531, 1249 799 cm-1; HRESI-MS: m/z 




Synthesis of methyl 3,5-diamino-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-
carboxylate 23f 
Methyl-3,5-diamino-6-chloropyrazine-2-carboxylate (500 
mg, 2.4 mmol) was combined with (2,4-
dimethoxypyrimidin-5-yl)boronic acid (681 mg, 3.7 
mmol), tetrakis(triphenylphosphine)palladium(0) (71.3 mg, 0.12 mmol) and K2CO3 (1.705 
g, 24.6 mmol) in a 100 mL oven-dried round bottom flask under Ar was added dry mixture 
methanol and toluene (30:7.5 mL), a reflux condenser attached and the reaction heated at 
80 °C with stirring for 2 h while monitoring by TLC (EtOAc). The reaction mixture was 
cool down to room temperature and filtrated by Celite ® using Buchner funnel and washed 
with a mixture of MeOH:EtOAc, 50:50 (2 × 100 mL) dried in vacuo. The solvent was 
evaporated, and the crude residue was purified by silica gel column chromatography using 
a gradient (50 → 100% EtOAc/Pet. Spirit) to give 23f (412 mg, 54%) as a white solid. TLC 
Rf (EtOAc) = 0.51; Mp 238-241 ºC; 1H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H, H13), 
3.95 (s, 3H, H18), 3.88 (s, 3H, H16), 3.71 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 
169.0 (C15), 167.2 (C7), 165.1 (C11), 159.7 (C13), 156.7 (C5), 155.7 (C3), 124.2 (C6), 
113.0 (C12), 111.0 (C2), 55.0 (C18), 54.2 (C16), 51.4 (C21); IR (neat) ν 3459.4, 3341.8, 
3133.5, 1676.2, 1651, 1588.4, 1248, 721.4 cm-1; HRESI-MS: m/z calculated for 







Synthesis of methyl 3,5-diamino-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxylate 
23g 
Methyl-3,5-diamino-6-chloropyrazine-2-carboxylate (150 
mg, 0.74 mmol) was combined with (2,6-
dimethoxypyridin-3-yl)boronic acid (183 mg, 1.1 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.04 mg, 0.03 
mmol) and K2CO3 (1.022 g, 7.4 mmol) in a 100 mL oven-dried round bottom flask under 
Ar was added dry mixture methanol and toluene (30:7.5 mL), a reflux condenser attached 
and the reaction heated at 80 °C with stirring for 2 h while monitoring by TLC (Pet. 
spirit:EtOAc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of CHCl3: EtOAc, 
50:50 (2 × 100 mL) dried in vacuo. The solvent was evaporated, and the crude residue was 
purified by silica gel column chromatography using a gradient (0 → 35% EtOAc/Pet. Spirit) 
to give 23g (107 mg, 47%) as a white-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 
0.26; Mp 260-262 ºC; 1H NMR (500 MHz, DMSO-d6) δ 7.52 (d, J = 8.0 Hz, 1H, H13), 6.97 
(s, 2H, NH2), 6.49 (s, 2H, NH2), 6.44 (d, J = 8.0 Hz, 1H, H14), 3.91 (s, 3H, H18), 3.86 
(s,3H, H16), 3.69 (s,3H, H21); 13C NMR (125 MHz, DMSO) δ 167.5 (C7), 163.1 (C11), 
160.3 (C15), 156.5 (C5), 155.5 (C3), 143.8 (C14), 127.7 (C6), 112.1 (C12), 111.0 (C2), 
101.6 (C13), 53.9 (C18), 53.7 (C16), 51.5 (C21); IR (neat) ν 3459.4, 3341.8 3133.5, 1676.2, 
1651, 1588.4, 1248.9, 721.4 cm-1; HRESI-MS: m/z calculated for C13H16N5O4 [M + H]+ 






Synthesis of methyl 3,5-diamino-6-(furan-2-yl)pyrazine-2-carboxylate 23h  
Methyl-3,5-diamino-6-chloropyrazine-2-carboxylate (250 mg, 
1.2 mmol) was combined with furan-2-ylboronic acid (206 mg, 
1.8 mmol), tetrakis(triphenylphosphine)palladium(0) (71.1 mg, 
0.24 mmol) and K2CO3 (1.702 g, 12.3 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and benzene (30:7.5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 2 h while monitoring by TLC 
(Pet. spirit:EtOAc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel, the product left on filter paper and washed with 
EtOAc:MeOH, 90:10 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica 
gel column chromatography using a gradient (0 → 40% EtOAc/Pet. spirit) to give 23h (201 
mg, 69%) as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.37; Mp 185-187 ºC; 
1H NMR (400 MHz, DMSO-d6) δ 7.72 (dd, J = 1.8, 0.8 Hz, 1H, H11), 7.13 (s, 2H, NH2), 
6.93 (s, 2H, NH2), 6.76 (dd, J = 3.4, 0.8 Hz, 1H, H13), 6.60 (dd, J = 3.4, 1.8 Hz, 1H, H12), 
3.76 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 166.9 (C7), 155.5 (C5), 153.2 (C3), 
151.6 (C14), 142.6 (C11), 120.5 (C6), 112.0 (C12), 111.6 (C2), 107.8 (C13), 51.6 (C21); 
IR (neat) ν 3437.3, 3313.8, 3154.8, 1683.9, 1653, 1648.2, 1600, 1257.6, 697.3 cm-1; 
HRESI-MS: m/z calculated for C10H11N4O3 [M + H]+ 235.0826, found 235.0818. 
 
Synthesis of methyl 3,5-diamino-6-(furan-3-yl)pyrazine-2-carboxylate 23i  
Methyl-3,5-diamino-6-chloropyrazine-2-carboxylate (500 mg, 
2.4 mmol) was combined with 2-(furan-3-yl)-4,4,5,5-




tetrakis(triphenylphosphine)- palladium(0) (142.7 mg, 0.12 mmol) and K2CO3 (3.413 g, 
24.6 mmol) in a 100 mL oven-dried round bottom flask under Ar was added dry mixture 
methanol and toluene (30:7.5 mL), a reflux condenser attached and the reaction heated at 
80 °C with stirring for 1.5 h while monitoring by TLC (Pet. spirit:EtOAc, 80:20). The 
reaction mixture was cool down to room temperature and filtrated by Celite ® using 
Buchner funnel and washed with a mixture of EtOAc:MeOH, 50:50 (2 × 100 mL) dried in 
vacuo. The residue was purified by silica gel column chromatography using a gradient (0 
→ 30% EtOAc/Pet. spirit) to yield 23i (490 mg, 85%) as an off-yellow solid. TLC Rf (Pet. 
spirit:EtOAc, 60:40) = 0.43; Mp 166-168 ºC; 1H NMR (400 MHz, DMSO-d6) δ 8.08 (dd, J 
= 1.4, 0.9 Hz, 1H, H11), 7.72 (m, 1H, H14), 6.81 (dd, J = 1.8, 0.8 Hz, 1H, H13), 6.72 (s, 
2H, NH2), 3.75 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 167.2 (C7), 155.4 (C5), 154.3 
(C3), 143.0 (C14), 139.9 (C11), 123.1 (C6), 123.0 (C12), 111.5 (C2), 110.2 (C13), 50.9 
(C21); IR (neat) ν 3443, 3363, 3111.3, 1669.4, 1602.9, 1527.6, 804.3, 735.8, 700.1 cm-1; 
HRESI-MS: m/z calculated for C10H11N4O3 [M + H]+ 235.0826, found 235.0821. 
 
Synthesis of methyl 3,5-diamino-6-(thiophen-2-yl)pyrazine-2-carboxylate 23j 
Methyl-3,5-diamino-6-chloropyrazine-2-carboxylate (500 mg, 
2.468 mmol) was combined with thiophen-2-ylboronic acid 
(474 mg, 3.7 mmol), tetrakis(triphenylphosphine)palladium(0) 
(142.7 mg, 0.12 mmol) and K2CO3 (3.413 g, 24.6 mmol) in a 100 mL oven-dried round 
bottom flask under Ar was added dry mixture methanol and toluene (30:7.5 mL), a reflux 
condenser attached and the reaction heated at 80 °C with stirring for 3 h while monitoring 




temperature and filtrated by Celite ® using Buchner funnel and washed with a mixture of 
EtOAc:MeOH, 50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica 
gel column chromatography using a gradient (0 → 40% EtOAc/Pet. Spirit 60:40) to give 
23j (146 mg, 24%) as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.32; Mp 
185-187 ºC; 1H NMR (400 MHz, DMSO-d6) δ 7.72 (dd, J = 2.8, 1.3 Hz, 1H, H11), 7.61 
(dd, J = 5.0, 2.9 Hz, 1H, H13), 7.39 (dd, J = 5.3, 1.2 Hz, 1H, H12), 7.05 (s, 2H, NH2), 6.71 
(s, 2H, NH2), 3.75 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 167.2 (C7), 155.7 (C5), 
154.5 (C3), 138.6 (C14), 128.6 (C11), 126.3 (C12), 126.0 (C6), 123.4 (C13), 111.2 (C2), 
51.5 (C21); IR (neat) ν 3437.3, 3313.8, 3154.8, 1683.9, 1653, 1648.2, 1600, 1257.6, 697.3 
cm-1; HRESI-MS: m/z calculated for C10H11N4O2S [M + H]+  251.0597, found 251.0611. 
 
Synthesis of methyl 3,5-diamino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylate 
23k 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (200 
mg, 0.9 mmol) was combined with (1-methyl-1H-pyrazol-4-
yl)boronic acid (187 mg, 1.4 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.05 mg, 0.04 mmol) and K2CO3 (1.364 g, 9.8 
mmol) in a 100 mL oven-dried round bottom flask under Ar was added dry mixture 
methanol and toluene (18:4.5 mL), a reflux condenser attached and the reaction heated at 
80 °C with stirring for 3.5 h while monitoring by TLC (EtOAc). The reaction mixture was 
cool down to room temperature and filtrated by Celite ® using Buchner funnel and washed 
with a mixture of MeOH: EtOAc, 50:50 (2 × 100 mL) dried in vacuo. The crude residue 




spirit) to give 23k (149 mg, 61%) as an off-yellow solid. TLC Rf (EtOAc) = 0.24; Mp 213-
215 ºC; 1H NMR (500 MHz, DMSO-d6) δ 8.00 (s, 1H, H15), 7.70 (s, 1H, H13), 6.94 (s, 2H, 
NH2), 6.62 (s, 2H, NH2), 3.87 (s, 3H, H16), 3.74 (s, 3H, H21); 13C NMR (125 MHz, 
DMSO) δ 167.2 (C7), 155.3 (C5), 154.2 (C3), 137.8 (C13), 129.7 (C15), 124.0 (C6), 118.6 
(C14), 111.0 (C2), 51.4 (C21), 38.9 (C16); IR (neat) ν 3474.9, 3327.3, 3159.5, 1653, 
1600.9, 1559.5, 800.4 cm-1; HRESI-MS: m/z calculated for C10H13N6O2 [M + H]+ 249.1095, 
found 249.1100. 
 
Synthesis of methyl 3,5-diamino-6-phenylpyrazine-2-carboxylate 23l 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (500 mg, 
2.4 mmol) was combined with phenylboronic acid (360 mg, 3.7 
mmol), tetrakis(triphenylphosphine)palladium(0) (71.3 mg, 
0.12 mmol) and K2CO3 (1.705 g, 24.6 mmol) in a 100 mL 
oven-dried round bottom flask under Ar was added dry mixture methanol and toluene 
(30:7.5 mL), a reflux condenser attached and the reaction heated at 80 °C with stirring for 2 
h while monitoring by TLC (Pet. spirit:EtOAc, 60:40). The reaction mixture was cool down 
to room temperature and filtrated by Celite ® using Buchner funnel and washed with a 
mixture of CHCl3: EtOAc, 50:50 (2 × 100 mL). The crude residue was purified by silica gel 
column chromatography using a gradient (0 → 30% EtOAc/Pet. Spirit) to give 23l (412 mg, 
68%) as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.35; Mp 194-196 ºC; 1H 
NMR (500 MHz, DMSO-d6) δ 7.54 (s, 2H, H12, H16), 7.44 (s, 2H, H13, H15), 7.37 (s, 1H, 
H14), 7.08 (s, 2H, NH2), 6.66 (s, 2H, NH2), 3.74 (s, 3H, H21); 13C NMR (125 MHz, 




128.5 (C12, C16), 128.1 (C14), 111.7 (C2), 51.4 (C21); IR (neat) ν 3435.3, 3319.6, 3160.5, 
2948-2852, 1684.9, 1650.1, 1595.2, 1246.1, 708.2, 646.1 cm-1; HRESI-MS: m/z calculated 
for C12H13N4O2 [M + H]+ 245.1033, found 245.1051. 
 
7.3 Synthesis of 6-Substituted Amiloride Analogues 
7.3.1 General method 
General method A: Sodium (2 eq) in dry iPrOH (10 mL) was stirred under N2 
atmosphere until the mixture had completely dissolved with a gentle heat. Guanidine 
hydrochloride (2 eq) was added and stirred for 30 min while the resultant NaCl was formed 
and filtered off to combine free guanidine. The filtrate was added to methyl ester (1 eq). 
The mixture was heated at reflux 2-4 h before cooling and concentrating in vacuo. The 
residue was taken up in DMSO (2 mL) for purification by preparative HPLC using a 
gradient from 0% to 100% B over 30 mins. The collected fractions containing purified 
product were investigated with MS spectra and concentrated by freeze-drying.   
Method B: Sodium (2 mmol) in dry MeOH (6 mL) was stirred under Ar 
atmosphere until the mixture had completely dissolved at room temperature. Guanidine 
hydrochloride (5 mmol) was added and stirred for 20 min while the resultant NaCl was 
formed and filtered off to combine free guanidine. The filtrate was concentrated to (2-3 mL) 
and added to methyl ester (1 mmol). The mixture was heated at 70 C° for overnight while 
monitory by TLC. The mixture was quenched with H2O (5 mL) and the precipitate was 







The compound was produced by General Method A 
using methyl ester (200 mg, 0.70 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 20 (134 mg, 
61%) as a yellow powder. Mp 231-233 °C; 1H NMR (400 MHz, DMSO) δ 7.63 (m, 2H, 
H17, H18), 7.26 (m, 2H, H15, H16), 7.08 (s, 1H, H12), 6.59 (s, 2H, NH2); 13C NMR (100 
MHz, DMSO) δ 174.4 (C7), 162.9 (C9), 155.5 (C5), 155.2 (C14), 153.9 (C11), 152.1 (C3), 
129.0 (C6), 123.9 (C15), 123.5 (C16), 122.7 (C13), 120.9 (C17), 117.1 (C2), 111.6 (C18), 
101.8 (C12); IR (neat) ν 3356.2, 3309, 3101.6, 2988.8, 1684.8, 1654, 1559.5, 720 cm-1; 





The compound was produced by General Method A 
using methyl ester (136 mg, 0.45 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24a (77 mg, 
52%) as a yellow powder. Mp 267-269 °C; 1H NMR (500 MHz, DMSO) δ 10.38 (s, 1H, 
H8), 8.83 (s, 2H, H10’), 8.54 (s, 2H, H10), 7.97 (m, 1H, H18), 7.87 (m, 2H, H12, H15), 



























(C9), 140.7 (C13), 139.9 (C14), 139.4 (C11), 125.3 (C17), 124.9 (C16), 124.6 (C15), 124.2 
(C6), 122.9 (C12), 122.4 (C18), 111.1 (C2); IR (neat) ν 3310, 3096, 1674, 1642, 1508, 
1432 1090, 947 cm-1; Anal HPLC (tr 11.1 min); HRESI-MS: m/z calculated for 




The compound was produced by General Method A 
using methyl ester (247 mg, 0.85 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24b (90 mg, 
34%) as a yellow powder. Mp 196-198°C; 1H NMR (500 MHz, DMSO) δ 10.59 (s, 1H, 
H8), 8.78 (s, 2H, H10’), 8.36 (s, 2H, H10), 7.90 (d, J = 8.1 Hz, 2H, H12, H16), 7.82 (d, J = 
8.4 Hz, 2H, H13, H15), 7.43 (s, 2H, NH2), 7.24 (s, 1H, NH2); 13C NMR (125 MHz, DMSO) 
δ 166.0 (C7), 156.0 (C5), 155.4 (C3), 154.9 (C9), 140.1 (J = 8.1 Hz, C14), 129.4 (C12, 
C16), 128.6 (C11), 128.4 (J = 18.2 Hz, C17), 128.1 (C6), 125.3 (J = 3.6 Hz, C13, C15), 
110.5 (C2); IR (neat) ν 3386, 3287, 3195, 3038, 1687, 1550, 1321, 1225, 1068, 745, 728 
cm-1; Anal HPLC (tr 10.5 min); HRESI-MS: m/z calculated for C13H13N7OF3 [M + H]+ 









The compound was produced by General Method A 
using methyl ester (300 mg, 1.03 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24c (71 mg, 
22%) as a yellow powder. Mp 284-286 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H, 
H8), 8.81 (s, 2H, H10'), 8.45 (s, 2H, H10), 7.63 (d, J = 7.7 Hz, 2H, H12, H16), 7.35 (d, J = 
8.0 Hz, 2H), H13, H15), 2.52 (s, 3H, H17); 13C NMR (100 MHz, DMSO) δ 166.0 (C7), 
155.6 (C5), 155.4 (C3), 155.0 (C9), 138.3 (C14), 132.5 (C11), 130.0 (C6), 129.0 (C12, 
C16), 125.8 (C13, C15), 110.0 (C2), 14.6 (C17); IR (neat) ν 3364, 3326, 3087, 3023, 1682, 
1554, 1224 cm-1; Anal HPLC (tr 9.9 min); HRESI-MS: m/z calculated for C13H16N7OS [M 
+ H]+ 318.1132, found 318.1122. 
 
Synthesis of 3,5-diamino-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-
carboxamide 24d  
The compound was produced by General Method B 
using methyl ester (261 mg, 1.0 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24d (235 mg, 82%) as a yellow powder. Mp 241-
243°C; 1H NMR (400 MHz, DMSO) δ 8.70 (s, 1H, H11, H13), 6.27 (s, 2H, NH2), 3.96 (s, 
3H, H16); 13C NMR (100 MHz, DMSO) δ 164.2 (C15), 159.0 (C11, C13), 155.4 (C5), 




1239 cm-1; Anal HPLC (tr 7.9 min); HRESI-MS: m/z calculated for C11H14N9O2 [M + H]+ 




The compound was produced by General Method A 
using methyl ester (104 mg, 0.34 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24e (52 mg, 
46%) as a yellow powder. Mp 223-225 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.30 (s, 1H, 
H13), 7.06 (s, 2H, H19), 3.95 (s, 3H, H18), 3.89 (s, 3H, H16); 13C NMR (100 MHz, DMSO) 
δ 182.3 (C15), 169.0 (C11), 165.3 (C7), 160.1 (C13), 156.8 (C9), 151.5 (C5), 129.4 (C6), 
128.2 (C12), 112.3 (C2), 55.1 (C18), 54.3 (C16); IR (neat) ν 3320, 3181, 1595, 1556, 1386, 
1234, 801 cm-1; Anal HPLC (tr 7.3 min); HRESI-MS: m/z calculated for C12H16N9O3 [M + 




The compound was produced by General Method A 
using methyl ester (73 mg, 0.23 mmol). The crude 
was taken up in DMSO (1 mL) for purification by 
preparative HPLC to afford guanidine 24f (14 mg, 




7.0 Hz, 1H, H14), δ 6.47 (d, J = 8.0 Hz, 1H, H14), 3.91 (s, 3H, H18), 3.86 (s, 3H, H16); 
13C NMR (100 MHz, DMSO) δ 166.1 (C7), 162.7 (C11), 159.8 (C15), 156.2 (C5), 156.1 
(C3), 155.4 (C9), 143.8 (C14), 143.6 (C6), 110.8 (C12), 109.5 (C2), 101.3 (C13), 53.4 
(C18), 53.2 (C16); IR (neat) ν 3364.9, 3326.3, 1696.4, 1647.2, 817.8 cm-1; Anal HPLC 
(tr 7.8 min); HRESI-MS: m/z calculated for C13H17N8O3 [M + H]+ 333.1418, found 
333.1414. 
 
Synthesis of 3,5-diamino-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide 24g 
The compound was produced by General Method A using 
methyl ester (234 mg, 1.0 mmol). The crude was taken up 
in DMSO (2 mL) for purification by preparative HPLC to 
afford guanidine 24g (108 mg, 41%) as a yellow powder. 
Mp > 300 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.69 (s, 1H, H8), 9.12 (s, 2H, H10'), 8.55 
(s, 2H, H10), 7.75 (dd, J = 1.7, 0.8 Hz, 1H, H11), 7.60 (d, J = 3.1 Hz, 2H, H13), 6.65 (dd, J 
= 3.4, 1.8 Hz, 1H, H12); 13C NMR (100 MHz, DMSO) δ 165.8 (C7), 155.2 (C5), 155.1 
(C3), 153.7 (C9), 150.8 (C14), 142.4 (C11), 120.5 (C6), 111.8 (C12), 109.9 (C2), 109.6 
(C13); IR (neat) ν 3300, 3108, 1615, 1512, 1238 cm-1; Anal HPLC (tr 8.4 min); HRESI-MS: 
m/z calculated for C10H12N7O2 [M + H]+  262.1047, found 262.1062. 
 
Synthesis of 3,5-diamino-N-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide 24h 
The compound was produced by General Method A using 
methyl ester (252 mg, 1.01 mmol). The crude was taken 




to afford guanidine 24h (145 mg, 52%) as a yellow powder. Mp 234-236 °C; 1H NMR (500 
MHz, DMSO) δ 10.42 (s, 1H, H8), 8.75 (s, 2H, H10’), 8.31 (s, 2H, H10), 8.20 (dd, J = 0.8 
Hz, 1H, H11), 7.81 (t, J = 1.6 Hz, 1H, H14), 7.32 (s, 2H, NH2), 7.16 (dd, J = 0.8 Hz, 1H, 
H13); 13C NMR (125 MHz, DMSO) δ 166.2 (C7), (C9), 155.7 (C5), 155.2 (C3), 143.8 
(C14), 141.4 (C11), 123.7 (C6), 122.2 (C12), 111.1 (C13), 110.2 (C2); IR (neat) ν 3316.7, 
3141.2, 1683.9, 1669.4, 1559.5, 799.5 cm-1; Anal HPLC (tr 7.7 min); HRESI-MS: m/z 
calculated for C10H12N7O2 [M + H]+  262.1047, found 262.1053. 
 
Synthesis of 3,5-diamino-N-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide 
24i 
The compound was produced by General Method A using 
methyl ester (389 mg, 1.5 mmol). The crude was taken up 
in DMSO (3 mL) for purification by preparative HPLC to 
afford guanidine 24i (149 mg, 35%) as a yellow powder. Mp 200-202 °C; 1H NMR (400 
MHz, DMSO) δ 10.61 (s, 1H, H8), 8.94 (s, 2H, H10’), 8.51 (s, 2H, H10), 8.01 (dd, J = 2.8, 
1.3 Hz, 1H, H11), 7.71 (dd, J = 5.0, 1.3 Hz, 1H, H13), 7.65 (dd, J = 5.0, 2.8 Hz, 1H, H12); 
13C NMR (100 MHz, DMSO) δ 166.4 (C7), 155.8 (C5), 155.7 (C3), 155.6 (C9), 137.4 
(C14), 129.1 (C13), 126.7 (C6), 126.4 (C12), 125.0 (C11), 110.2 (C2); IR (neat) ν 3405.4, 
3292.6, 3190.4,3068.8, 2508.5, 1683.9, 1700.3, 1696.4, 737.8 cm-1; Anal HPLC (tr 7.92 









The compound was produced by General Method A 
using methyl ester (135 mg, 0.54 mmol). The crude 
was taken up in DMSO (2 mL) for purification by 
preparative HPLC to afford guanidine 24j (105 mg, 70%) as a yellow powder. Mp 226-
228 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H, H8), 8.73 (s, 2H, H10'), 8.45 (s, 2H, 
H10), 8.17 (s, 1H, H15), 8.00 (s, 1H, H13), 7.27 (s, 2H, NH2), 7.11 (s, 2H, NH2), 3.89 (s, 
3H, H16); 13C NMR (100 MHz, DMSO) δ 166.3 (C7), 155.7 (C5), 155.6 (C3), 155.3 (C9), 
138.8 (C13), 130.3 (C15), 124.8 (C6), 117.6 (C14), 109.8 (C2), 39.1 (C16); IR (neat) ν 
3446.9, 3312.8, 3149.8, 1675.2, 1654, 739.7 cm-1; Anal HPLC (tr 7.93 min); HRESI-MS: 
m/z calculated for C10H14N9O [M + H]+ 276.1316, found 276.1322. 
 
Synthesis of 3,5-diamino-N-carbamimidoyl-6-phenylpyrazine-2-carboxamide 24k 
The compound was produced by General Method A using 
methyl ester (302 mg, 1.23 mmol). The crude was taken 
up in DMSO (2 mL) for purification by preparative HPLC 
to afford guanidine 24k (278 mg, 83%) as a yellow 
powder. Mp 205-207 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.55 (d, J = 5.9 Hz, 1H, H8), 
8.79 (s, 2H, H10'), 8.35 (m, 2H, H10), 7.66 (s, 2H, H12, H16), 7.49 (t, J = 6.4 Hz, 2H, H13, 
H15), 7.43 (m, 1H, H14), 7.36 (s, 2H, NH2), 7.08 (s, 2H, NH2) 13C NMR (125 MHz, 
DMSO) δ 166.1 (C7), 155.8 (C5), 155.4 (C3), 155.0 (C9), 136.0 (C11), 130.4 (C6), 128.6 




1638, 1515, 1223, 733 cm-1; Anal HPLC (tr 8.3 min); HRESI-MS: m/z calculated for 
C12H14N7O [M + H]+ 272.1254, found 272.1251. 
 
7.4 Synthesis of substituted benzofuran methyl esters 25a-25i by Suzuki cross-
coupling reaction 
Synthesis of methyl 3,5-diamino-6-(5-methylbenzofuran-2-yl)pyrazine-2-carboxylate 
25a 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(200 mg, 0.98 mmol) was combined with (5-
methylbenzofuran-2-yl)boronic acid (260 mg, 1.4 
mmol), (tetrakis(triphenylphosphine) palladium(0) (57 
mg, 49.2 µmol) and K2CO3 (1.361 g, 9.8 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and toluene (20:5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 6 h while monitoring by TLC 
(DCM:MeOH, 80:10). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of DCM: MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a gradient (0 → 5% MeOM/DCM) to give 25a (103 mg, 35%) as an 
off-yellow solid. TLC Rf (DCM:MeOH, 85:15) = 0.58; Mp 206-208 ºC; 1H NMR (500 
MHz, DMSO-d6) δ 7.63 (d, J = 8.4 Hz, 1H, H18), 7.53 (s, 1H, H12), 7.45 (m, 1H, H15), 
7.31 (s, 2H, H19), 7.2 (s,2H, H20), 7.20 (m, 2H, H12, H17), 3.90 (s, 3H, H21), 2.41 (s, 3H, 
H22); 13C NMR (125 MHz, DMSO) δ 166.8 (C7), 155.8 (C5), 154.0 (C3), 153.7 (C11), 




111.4 (C18), 103.3 (C12), 51.8 (C21), 21.4 (C22); IR (neat) ν 3460, 3355, 3147, 1666, 
2995, 2958, 1640, 1255, 800 cm-1; HRESI-MS: m/z calculated for C15H15N4O3 [M + H]+ 
299.1139, found 299.1149.  
 
Synthesis of methyl 3,5-diamino-6-(5-methoxybenzofuran-2-yl)pyrazine-2-carboxylate 
25b 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(200 mg, 0.98 mmol) was combined with (5-
methoxybenzofuran-2-yl)boronic acid (227 mg, 1.4 
mmol), (tetrakis(triphenylphosphine)- palladium(0) (57 
mg, 49.2 µmol) and K2CO3 (1.361 g, 9.8 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and toluene (25:5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 1.5 h while monitoring by TLC 
(Pet. spirit:E2O 20:80). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of EtAOc: MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a gradient (50→100 pet. spirit:E2O) to give 25b (185 mg, 60%) as 
an off-yellow solid. TLC Rf (Pet. spirit:E2O 20:80) = 0.71; Mp 186-188 ºC; 1H NMR (500 
MHz, DMSO) δ 7.55 (d, J = 8.9 Hz, 1H, H18), 7.15 (d, J = 2.6 Hz, 1H, H15), 7.10 (d, J = 
0.7 Hz, 1H, H12), 6.90 (dd, J = 9.7, 4.9 Hz, 1H, H17), 3.80 (s, 3H, H22), 3.79 (s, 3H, H21); 
13C NMR (125 MHz, DMSO-d6) δ 166.8 (C7), 156.3 (C16), 155.8 (C5), 154.7 (C14), 153.7 
(C3), 149.0 (C11), 129.3 (C13), 119.4 (C6), 113.1 (C17), 112.6 (C2), 112.4 (C18), 103.7 




1668, 1606, 1253, 791cm-1; HRESI-MS: m/z calculated for C15H14N4O4Na [M + Na]+  
337.0907, found 337.0910.  
 
Synthesis of methyl 3,5-diamino-6-(5-cyanobenzofuran-2-yl)pyrazine-2-carboxylate 
25c  
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(250 mg, 1.2 mmol) was combined with (5-
cyanobenzofuran-2-yl)boronic acid (253 mg, 1.3 
mmol), tetrakis(triphenylphosphine)- palladium(0) (71 
mg, 61.5 µmol) and K2CO3 (1.7023 g, 12.3 mmol) in a 100 mL oven-dried round bottom 
flask under Ar was added dry mixture methanol and toluene (20:5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 3 h while monitoring by TLC 
(MeOH:DCM, 5:95). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of DCM: MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a (MeOH:DCM, 5:95) to give 25c (223 mg, 56%) as an off-yellow 
solid. TLC Rf (MeOH:DCM, 5:95) = 0.42; Mp 288-290 ºC; 1H NMR (400 MHz, DMSO) δ 
8.19 (d, J = 1.4 Hz, 1H, H15), 7.87 (d, J = 8.5 Hz, 1H, H18), 7.74 (dd, J = 8.5, 1.6 Hz, 1H, 
H17), 7.32 (s, 2H, H19), 7.25 (s, 1H, H12), 7.24 (s, 2H, H20), 3.81 (s, 3H, H21); 13C NMR 
(100 MHz, DMSO) δ 166.6 (C7), 156.1 (C14), 156.0 (C5), 155.9 (C3), 153.9 (C11), 129.5 
(C13), 128.1 (C17), 126.3 (C15), 119.8 (C22), 118.1 (C6), 113.4 (C2), 113.1 (C18), 106.5 




1256, 1098, 827cm-1; HRESI-MS: m/z calculated for C15H11N5O3Na [M + Na]+  332.0754, 
found 332.0769. 
 
Synthesis of methyl 3,5-diamino-6-(5-fluorobenzofuran-2-yl)pyrazine-2-carboxylate 
25d 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (460 
mg, 2.2 mmol) was combined with (5-fluorobenzofuran-
2-yl)boronic acid (449 mg, 2.4 mmol), 
(tetrakis(triphenylphosphine)- palladium(0) (131.1 mg, 
0.1 mmol) and K2CO3 (3.138 g, 22.7 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and toluene (40:10 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 4 h while monitoring by TLC 
(MeOH:DCM, 5:95). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of DCM: MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a (MeOH:DCM, 1:99) to give 25d (344 mg, 50%) as an off-yellow 
solid. TLC Rf (MeOH:DCM, 5:95) = 0.51; Mp 161-163 ºC; 1H NMR (400 MHz, DMSO-d6) 
δ 7.69 (dd, J = 8.9,  0.9 Hz, 1H, H18), 7.45 (dd, J = 8.9,  2.7 Hz, 1H, H15), 7.20 (s, 2H, 
NH2), 7.15 (m, 2H, H12, H17), 3.81 (s, 1H, H21); 13C NMR (100 MHz, DMSO) δ 166.7 
(C7), 160.4 (C16), 158.1(C5), 155.9 (C11), 153.7 (C3), 150.5 (C14), 129.7 (C13), 118.7 
(C6), 112.9 (d, J = 10.3 MHz, C18), 111.8 (d, J = 28.1 MHz, C17), 106.5 (d, J = 25.7 MHz, 




1246, 802, 862 cm-1; HRESI-MS: m/z calculated for C14H12N4O3F [M + H]+ 303.0888, 
found 303.0882. 
 
Synthesis of methyl 3,5-diamino-6-(5-chlorobenzofuran-2-yl)pyrazine-2-carboxylate 
25e  
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(200 mg, 0.98 mmol) was combined with (5-
chlorobenzofuran-2-yl)boronic acid (290 mg, 1.4 mmol), 
(tetrakis(triphenylphosphine)- palladium(0) (57 mg, 49.2 
µmol) and K2CO3 (1.361 g, 9.8 mmol) in a 100 mL oven-dried round bottom flask under Ar 
was added dry mixture methanol and toluene (20:5 mL), a reflux condenser attached and 
the reaction heated at 80 °C with stirring for 6 h while monitoring by TLC (EtOAc:DCM, 
10:90). The reaction mixture was cool down to room temperature and filtrated by Celite ® 
using Buchner funnel and washed with a mixture of DCM: MeOH, 50:50 (2 × 100) dried in 
vacuo. The crude residue was purified by silica gel column chromatography using a 
gradient (0 → 5% EtOAc:DCM, 5:95) to give 25e (107 mg, 34%) as a yellowish solid. 
TLC Rf (EtOAc:DCM 5:95) = 0.31; Mp 207-209 ºC; 1H NMR (500 MHz, DMSO-d6) δ 7.71 
(dd, J = 4.4, 2.2 Hz, 1H, H15), 7.69 (d, J = 8.7 Hz, 1H, H18), 7.32 (dd, J = 4.4, 2.2 Hz, 1H, 
H17), 7.21 (s, 2H, NH2), 7.14 (dd, J = 8.1, 0.8 Hz, 1H, H12), 3.8 (s, 3H, H21); 13C NMR 
(125 MHz, DMSO) δ 165.8 (C7), 155.5 (C11), 155.2 (C5), 153.3 (C3), 152.2 (C14), 129.9 
(C13), 127.5 (C16), 123.8 (C17), 120.1 (C15), 118.0 (C6), 113.0 (C18), 112.6 (C2), 102.3 




801, 700 cm-1; HRESI-MS: m/z calculated for C14H11N4O3NaCl [M + Na]+ 341.0412, found 
341.0421.  
 
Synthesis of methyl 3,5-diamino-6-(5-bromobenzofuran-2-yl)pyrazine-2-carboxylate 
25f  
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(200 mg, 0.98 mmol) was combined with (5-
bromobenzofuran-2-yl)boronic acid (261 mg, 1.08 
mmol), (tetrakis(triphenylphosphine)- palladium(0) (57 
mg, 49.2 µmol) and K2CO3 (1.361 g, 9.8 mmol) in a 100 mL oven-dried round bottom flask 
under Ar was added dry mixture methanol and toluene (20:5 mL), a reflux condenser 
attached and the reaction heated at 80 °C with stirring for 5 h while monitoring by TLC 
(MeOH:DCM, 5:95). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of MeOH:DCM, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a (MeOH:DCM, 1:99) to give 25f (175 mg, 49%) as an off-yellow 
solid. TLC Rf (MeOH:DCM, 5:95) = 0.53; Mp 224-226 ºC; 1H NMR (400 MHz, DMSO) δ 
7.86 (m, 1H, H15), 7.65 (d, J = 8.7 Hz, 1H, H18), 7.44 (dd, J = 8.7, 2.1 Hz, 1H, H12), 7.32 
(s, 2H, H19), 7.21 (s, 2H, H20), 7.14 (dd, J = 6.1, 0.9 Hz, 1H, H17), 3.81 (s, 3H, H21); 13C 
NMR (100 MHz, DMSO) δ 166.7 (C7), 155.9 (C5), 155.4 (C3), 153.8 (C11), 153.0 (C14), 
131.0 (C13), 127.0 (C17), 123.6 (C15), 118.6 (C6), 116.0 (C16), 113.9 (C18), 112.9 (C2), 




1104, 801, 473 cm-1; HRESI-MS: m/z calculated for C14H12N4O3Br [M + H]+  363.0087, 
found 363.0086.  
 
Synthesis of methyl 3,5-diamino-6-(6-methoxybenzofuran-2-yl)pyrazine-2-carboxylate 
25g 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate 
(250 mg, 1.2 mmol) was combined with (6-
methoxybenzofuran-2-yl)boronic acid (260 mg, 1.3 
mmol), (tetrakis(triphenylphosphine)- palladium(0) 
(71 mg, 61.5 µmol) and K2CO3 (1.7023 g, 12.3 mmol) in a 100 mL oven-dried round 
bottom flask under Ar was added dry mixture methanol and toluene (20:5 mL), a reflux 
condenser attached and the reaction heated at 80 °C with stirring for 3.5 h while monitoring 
by TLC (Et2O). The reaction mixture was cool down to room temperature and filtrated by 
Celite ® using Buchner funnel and washed with a mixture of DCM: MeOH, 50:50 (2 × 100 
mL) dried in vacuo. The crude residue was purified by silica gel column chromatography 
using a (Pet. spirit: Et2O, 80→100) to give 25g (212 mg, 55%) as an off-yellow solid. TLC 
Rf (Et2O) = 0.42; Mp 175-177 ºC; 1H NMR (400 MHz, DMSO) δ 7.52 (d, J = 8.5 Hz, 1H, 
H15), 7.30 (d, J = 1.9 Hz, 1H, H12), 7.23 (s, 2H, H19), 7.12 (s, 2H, H20), 7.11 (d, J = 0.7 
Hz, 1H, H18), 6.90 (dd, J = 8.5, 2.2 Hz, 1H, H16), 3.82 (s, 3H, H22), 3.80 (s, 3H, H21); 
13C NMR (100 MHz, DMSO) δ 166.9 (C7), 158.1 (C17), 155.7 (C5), 155.2 (C14), 153.6 
(C3), 152.9 (C11), 121.8 (C15), 121.5 (C13), 119.8 (C6), 112.6 (C16), 112.3 (C2), 103.6 




1602, 1256, 808 cm-1; HRESI-MS: m/z calculated for C15H14N4O4Na [M + Na]+  337.0907, 
found 337.0927.  
 
Synthesis of methyl 3,5-diamino-6-(2,3-dihydrobenzofuran-7-yl)pyrazine-2-
carboxylate 25h 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (200 mg, 
0.9 mmol) was combined with (2,3-dihydrobenzofuran-5-
yl)boronic acid (219 mg, 1.35 mmol), 
(tetrakis(triphenylphosphine)- palladium(0) (71 mg, 61.5 µmol) 
and K2CO3 (1.7023 g, 12.3 mmol) in a 100 mL oven-dried round bottom flask under Ar 
was added dry mixture methanol and toluene (25:5 mL), a reflux condenser attached and 
the reaction heated at 80 °C with stirring for 1 h while monitoring by TLC (Pet. 
spirit:EtAOc, 60:40). The reaction mixture was cool down to room temperature and 
filtrated by Celite ® using Buchner funnel and washed with a mixture of CHCl3: MeOH, 
50:50 (2 × 100 mL) dried in vacuo. The crude residue was purified by silica gel column 
chromatography using a (80→100 Pet. spirit:EtAOc) to give 25h (138 mg, 49%) as an off-
yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.30; Mp 235-237 ºC; 1H NMR (500 
MHz, DMSO) δ 7.26 (d, J = 7.1 Hz, 1H, H15), 7.08 (d, J = 7.5 Hz, 1H, H17), 6.90 (t, J = 
7.4 Hz, 1H, H16), 6.45 (s, 2H, H19), 4.55 (t, J = 8.6 Hz, 2H, H11), 3.71 (s, 3H, H21), 3.22 
(t, J = 8.6 Hz, 2H, H12); 13C NMR (125 MHz, DMSO) δ 167.3 (C7), 157.4 (C14), 156.2 
(C5), 154.8 (C3), 129.7 (C15), 128.3 (C18) 127.7 (C6), 125.2 (C17), 120.8 (C16), 119.4 




2969, 2946, 2881, 1680, 1536, 1433, 1244, 736 cm-1 HRESI-MS: m/z calculated for 
C14H14N4O3Na [M + Na]+  309.0958, found 309.0966.  
 
Synthesis of methyl 3,5-diamino-6-(benzofuran-5-yl)pyrazine-2-carboxylate 25i 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (250 mg, 
1.2 mmol) was combined with (benzofuran-5-yl)boronic acid 
(194 mg, 1.1 mmol), (tetrakis(triphenylphosphine)- palladium(0) 
(57 mg, 49.2 µmol) and K2CO3 (1.36 g, 9.8 mmol) in a 100 mL 
oven-dried round bottom flask under Ar was added dry mixture methanol and toluene (25:5 
mL), a reflux condenser attached and the reaction heated at 80 °C with stirring for 1 h while 
monitoring by TLC (Pet. spirit:EtAOc, 60:40). The reaction mixture was cool down to 
room temperature and filtrated by Celite ® using Buchner funnel and washed with a 
mixture of DCM: MeOH, 50:50 (2 × 100 mL) dried in vacuo. The crude residue was 
purified by silica gel column chromatography using a (Pet. spirit:EtAOc, 0→50) to give 25i 
(194 mg, 55%) as an off-yellow solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.33; Mp 223-
225 ºC; 1H NMR (400 MHz, DMSO) δ 7.96 (d, J = 2.2 Hz, 1H, H18), 7.82 (dd, J = 1.8, 0.5 
Hz, 1H, H12), 7.63 (m, 1H, H16), 7.49 (dd, J = 8.5, 1.7 Hz, 1H, H15), 6.99 (dd, J = 2.2, 1.0 
Hz, 1H, H17), 3.78 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 167.4 (C7), 156.0 (C5), 
154.8 (C14), 154.3 (C3), 146.9 (C18), 132.6 (C11), 130.6 (C6), 127.8 (C13), 125.4 (C16), 
121.6 (C12), 111.7 (C15), 111.4 (C2), 107.5 (C17), 51.4 (C21); IR (neat) ν 3484, 3316, 
3144, 2951, 1683, 1524, 1432, 1253, 1091 cm-1; HRESI-MS: m/z calculated for 





7.5 Synthesis of Substituted benzofuran amiloride Analogues 
Method C: Sodium (4.6 g, 0.2 mol) in dry MeOH (100 mL) was stirred under Ar 
atmosphere until the mixture had completely dissolved at room temperature. Guanidine 
hydrochloride (19.1 g, 0.2 mol) was added and stirred for 1h min while the resultant NaCl 
was formed and filtered off to combine (2 M) solution of free guanidine. The filtrate had 




The compound was produced by General Method 
C using methyl ester (100 mg, 0.33 mmol) with (3 
mL) of free guanidine. The reflux condenser was 
attached, and the mixture was heated to 50 °C for 
overnight. The crude was diluted with (20 mL) of EtOAc and filtrated then the residue was 
washed by cold H2O followed wash by cold EtOAc and dried the product. The crude was 
taken up in DMSO (2 mL) for purification by preparative HPLC in a gradient from 0% to 
100% B over 30 mins (tr = 12.29). The collected fractions containing purified product were 
concentrated by freeze-drying to afford guanidine 26a (53 mg, 49%) as a yellow solid. Mp 
231-233°C; 1H NMR (500 MHz, DMSO-d6) δ 10.55 (s, 1H, H8), 8.75 (s, 2H, H10'), 8.44 (s, 
2H, H10), 7.58 (d, J = 8.4 Hz, 1H, H18), 7.54 (d, J = 0.9 Hz, 1H, H12), 7.46 (m, 1H, H15), 
7.16 (dd, J = 8.4, 1.7 Hz, 1H, H17), 2.42 (s, 3H, H22); 13C NMR (125 MHz, DMSO) δ 
165.4 (C7), 155.3 (C5), 154.6 (C9), 154.1 (C3), 152.8 (C11), 152.2 (C14), 132.4 (C16), 




20.8 (C22); IR (neat) ν 3317, 3188, 1675, 1514, 1418, 1238 cm-1; Anal HPLC (tr 12.3 min); 




The compound was produced by General Method 
C using methyl ester (112 mg, 0.35 mmol) with (3 
mL) of free guanidine. The reflux condenser was 
attached, and the mixture was heated to 50 °C for 
overnight. The solvent was removed and added (10 mL) of H2O with stirred for 5 min and 
followed wash by cold EtOAc and dried the product. The crude was taken up in DMSO (2 
mL) for purification by preparative HPLC in a gradient from 0% to 100% B over 30 mins 
(tr = 11.6). The collected fractions containing purified product were concentrated by freeze-
drying to afford guanidine 26b (41 mg, 34%) as a white-yellow solid. Mp 241-243 °C; 1H 
NMR (500 MHz, Methanol-d4) δ 7.47 (d, J = 9.0 Hz, 1H, H18), 7.45 (s, 1H, H15), 7.12 (s, 
1H, H12), 6.93 (d, J = 8.9 Hz, 1H, H17), 3.84 (s, 3H, H22); 13C NMR (125 MHz, CD3OD) 
δ 167.2 (C7), 158.1 (C16), 157.3 (C5), 156.8 (C9), 156.2 (C14), 155.3 (C3), 150.8 (C11), 
130.2 (C13), 121.5 (C6), 114.6 (C17), 112.7 (C12), 112.3 (C2), 105.8 (C18), 104.2 (C15), 
56.2 (C22); IR (neat) ν 3421, 3300, 1674, 1511, 1221, 1196 cm-1; Anal HPLC (tr 11.6 min); 







The compound was produced by General Method 
C using methyl ester (50 mg, 0.16 mmol) with 
(1.5 mL) of free guanidine. The reflux condenser 
was attached, and the mixture was heated to 
50 °C for overnight. The crude was diluted with (10 mL) of EtOAc and filtrated then the 
residue was washed by cold H2O followed wash by cold EtOAc and dried the product. The 
crude was taken up in DMSO (2 mL) for purification by preparative HPLC in a gradient 
from 0% to 100% B over 30 mins (tr = 11.6). The collected fractions containing purified 
product were concentrated by freeze-drying to afford guanidine 26c (17 mg, 31%) as a 
yellow solid. Mp 261°C decom; 1H NMR (500 MHz, Methanol-d4) δ 9.00 (s, 1H, H15), 8.67 
(d, J = 8.9 Hz, 1H, H18), 8.53 (d, 2H, H12, H17); 13C NMR (125 MHz, CD3OD) δ 167.0 
(C7), 157.1 (C14), 157.0 (C8), 156.7 (C5), 156.2 (C3), 155.8 (C11), 130.2 (C13), 129.4 
(C17), 127.3 (C15), 120.7 (C22), 119.5 (C6), 114.7 (C18), 108.0 (C16), 105.2 (C12); IR 
(neat) ν 3397, 3304, 3183, 3104, 2231, 1673, 1621, 1545, 1517, 1416 cm-1; Anal HPLC 









The compound was produced by General Method C 
using methyl ester (50 mg, 0.16 mmol) with (1.5 mL) 
of free guanidine. The reflux condenser was attached, 
and the mixture was heated to 50 °C for overnight. 
The reaction was quenched by addition of butanol (20 mL) and the mixture was diluted 
with H2O (25 mL) and, combined organic fractions were washed brine, dried over 
anhydrous MgSO4 and concentrated to afford guanidine 26d (41 mg, 75 %) as a white-
yellow solid. Mp 248-250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.06 (s, 1H, H12), 7.71 
(dd, J = 8.9, 4.2 Hz, 1H, H18), 7.41 (dd, J = 8.8, 2.6 Hz, 1H, H15), 7.16 (td, J = 9.3, 2.7 Hz, 
1H, H17); 13C NMR (100 MHz, DMSO) δ 166.1 (C7), 160.1 (C16), 157.7 (C5), 155.5 
(C11), 155.1 (C9), 154.0 (C3), 150.2 (C14), 129.1 (C13), 118.7 (C2), 112.9 (d, J = 10.1 
MHz, C18), 111.8 (d, J = 27.2 MHz, C17), 106.1 (d, J = 25.2 MHz, C15), 105.0 (C12); IR 
(neat) ν 3301, 3177, 1641, 1510, 1443, 1232, 1096, 1035, 779 cm-1; Anal HPLC (tr 11.6 




The compound was produced by General Method C 
using methyl ester (55 mg, 0.17 mmol) with (1.5 
mL) of free guanidine. The reflux condenser was 




overnight. The reaction was quenched by addition of butanol (10 mL) and the mixture was 
diluted with H2O (15 mL) and, combined organic fractions were washed brine, dried over 
anhydrous MgSO4 and concentrated to afford guanidine 26e (22 mg, 37%) as a white-
yellow solid. Mp 238-240 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.87 (s, 1H, H12), 7.72 (d, 
J = 8.7 Hz, 1H, H18), 7.70 (d, J = 2.1 Hz, 1H, H15), 7.56 (s, 2H, NH2), 7.35 (dd, J = 8.7, 
2.2 Hz, 1H, H17); 13C NMR (100 MHz, DMSO) δ 165.6 (C7), 155.5 (C11), 155.0 (C5), 
154.6 (C9), 154.3 (C3), 152.4 (C14), 129.7 (C13), 127.9 (C16), 124.2 (C17), 120.1 (C15), 
118.6 (C6), 113.4 (C18), 111.4 (C12), 104.1 (C2); IR (neat) ν 3560, 3450, 3319, 3089, 
1512, 1231, 1108, 796 cm-1; Anal HPLC (tr 12.7 min); HRESI-MS: m/z calculated for 
C14H13N7O2Cl [M + H]+ 346.0814, found 346.0829. 
 
Synthesis of 3,5-diamino-6-(5-bromobenzofuran-2-yl)-N-carbamimidoylpyrazine-2-
carboxamide 26f  
The compound was produced by General Method C 
using methyl ester (77 mg, 0.21 mmol) with (2 mL) 
of free guanidine. The reflux condenser was 
attached, and the mixture was heated to 50 °C for 
overnight. The solvent was removed and added (10 mL) of H2O with stirred for 5 min and 
followed wash by cold EtOAc and dried the product. The crude was taken up in DMSO (2 
mL) for purification by preparative HPLC in a gradient from 0% to 100% B over 30 mins 
(tr = 13.1). The collected fractions containing purified product were concentrated by freeze-
drying to afford guanidine 26f (18 mg, 22%) as a white-yellow solid. Mp 228-230°C; 1H 




7.88 (d, J = 1.9 Hz, 1H, H15), 7.68 (d, J = 8.7 Hz, 1H, H18), 7.58 (s, 1H, H12), 7.49 (dd, J 
= 8.7, 2.0 Hz, 1H, H17); 13C NMR (125 MHz, DMSO) δ 165.5 (C7), 155.6 (C5), 155.1 
(C9), 154.7 (C3), 154.4 (C11), 152.7 (C14), 130.2 (C13), 127.0, (C17) 123.1 (C15), 118.5 
(C6), 115.9 (C16), 113.9 (C18), 111.3 (C2), 103.5 (C12); IR (neat) ν 3313, 3192, 3121, 
1672, 1512, 1238, 1132, 720 cm-1; Anal HPLC (tr 13.1 min); HRESI-MS: m/z calculated 




The compound was produced by General Method 
C using methyl ester (117 mg, 0.37 mmol) with (3 
mL) of free guanidine. The reflux condenser was 
attached, and the mixture was heated to 50 °C for 
overnight. The solvent was removed and added (10 mL) of H2O with stirred for 5 min and 
followed wash by cold EtOAc and dried the product. The crude was taken up in DMSO (2 
mL) for purification by preparative HPLC in a gradient from 0% to 100% B over 30 mins 
(tr = 11.8). The collected fractions containing purified product were concentrated by freeze-
drying to afford guanidine 26g (25 mg, 20%) as a white-yellow solid. Mp 230-232°C; 1H 
NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H, H8), 8.75 (s, 2H, H10'), 8.44 (s, 2H, H10), 
7.56 (d, J = 8.6 Hz, 1H, H15), 7.53 (d, J = 0.9 Hz, 1H, H12), 7.50 (s, 2H, NH2), 7.34 (d, J = 
2.0 Hz, 1H, H18), 6.94 (dd, J = 8.6, 2.3 Hz, 1H, H16), 3.83 (s, 3H, H22); 13C NMR (100 
MHz, DMSO) δ 165.5 (C7), 157.8 (C17), 155.4 (C5), 155.0 (C9), 154.7 (C14), 154.2 (C3), 




96.4 (C18), 55.5 (C22); IR (neat) ν 3314, 3180, 3149, 1674, 1621, 1417, 1196 cm-1; Anal 





The compound was produced by General Method C using 
methyl ester (99 mg, 0.34 mmol) with (1.5 mL) of free 
guanidine. The reflux condenser was attached, and the 
mixture was heated to 50 °C for overnight. The solvent 
was removed and added (10 mL) of H2O with stirred for 5 min and followed wash by cold 
EtOAc and dried the product. The crude was taken up in DMSO (2 mL) for purification by 
preparative HPLC in a gradient from 0% to 100% B over 30 mins (tr = 8.9). The collected 
fractions containing purified product were concentrated by freeze-drying to afford 
guanidine 26h (47 mg, 43%) as a white-yellow solid. Mp 270°C decomp; 1H NMR (500 MHz, 
DMSO-d6) δ 10.52 (s, 1H, H8), 8.67 (s, 2H, H10'), 8.34 (s, 2H, H10), 7.31 (d, J = 6.4 Hz, 
1H, H15), 7.16 (d, J = 7.5 Hz, 1H, H17), 6.95 (t, J = 7.5 Hz, 1H, H16), 4.56 (t, J = 8.7 Hz, 
2H, H11), 3.22 (t, J = 8.5 Hz, 2H, H12); 13C NMR (125 MHz, DMSO) δ 166.1 (C7), 157.4 
(C14), 156.2 (C5), 155.6 (C3), 154.9 (C9), 129.4 (C15), 128.1 (C18), 125.3 (C17), 120.5 
(C16), 118.0 (C13), 109.7 (C2), 71.1 (C11), 29.1 (C12); IR (neat) ν 3338, 1667, 1647, 1196, 
1138, 800 cm-1; Anal HPLC (tr 8.9 min); HRESI-MS: m/z calculated for C14H16N7O2 [M + 






carboxamide 26i  
The compound was produced by General Method C 
using methyl ester (64 mg, 0.22 mmol) with (1 mL) 
of free guanidine. The reflux condenser was attached, 
and the mixture was heated to 50 °C for overnight. 
The solvent was removed and added (10 mL) of H2O with stirred for 5 min and followed 
wash by cold EtOAc and dried the product. The crude was taken up in DMSO (2 mL) for 
purification by preparative HPLC in a gradient from 0% to 100% B over 30 mins (tr = 9.5). 
The collected fractions containing purified product were concentrated by freeze-drying to 
afford guanidine 26i (47 mg, 67%) as a white-yellow solid. Mp 221-223°C; 1H NMR (400 
MHz, DMSO-d6) δ 10.60 (s, 1H,H8), 8.81 (s, 2H, H10'), 8.49 (s, 2H, H10), 8.06 (d, J = 2.1 
Hz, 1H, H18), 7.93 (d, J = 1.3 Hz, 1H, H12), 7.68 (d, J = 8.5 Hz, 1H, H16), 7.58 (d, J = 8.5 
Hz, 1H, H15), 7.03 (d, J = 2.9 Hz, 1H, H17); 13C NMR (100 MHz, DMSO) δ 166.1 (C7), 
155.9 (C5), 155.7 (C9), 155.1 (C14), 154.2 (C3), 146.6 (C18), 131.0 (C11), 131.0 (C6), 
127.4 (C13), 125.3 (C16), 121.7 (C12), 111.3 (C15), 109.8 (C2), 107.1 (C17); IR (neat) ν 
3304, 3175, 1673, 1515, 1245, 1128, 750 cm-1; Anal HPLC (tr 9.5 min); HRESI-MS: m/z 









7.6 Cyclization of benzofuran amiloride  
7.6.1 Synthesis of methyl 3,5-diamino-6-((trimethylsilyl)ethynyl)pyrazine-2-
carboxylate 27 
Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (1,013 g, 
5.0 mmol) was combined with (tetrakis(triphenylphosphine)-
palladium dichloride (175 mg, 5 mol%) and copper (I) iodide 
(133 mg, 14 mol%) in a 100 mL oven-dried round bottom 
flask under Ar was added dry DMF (10 mL). The mixture was stirred for 5 min at 60 °C 
until dissolved completely. DIPEA (15 mL, 3 eq) was then added at 60 °C and stirred for 
further 30 min, followed trimethylsilyl acetylene (2.2 mL, 3 eq) was added and stirred for 
1.5 h at the same temperature while monitoring by TLC (Pet. spirit:EtOAc, 60:40). The 
solvent was evaporated and the residue re-dissolved in EtOAc (50 mL). The organic layer 
was washed successively with water and brine, dried over anhydrous Na2SO4 and 
concentrated. The crude residue was purified by silica gel column chromatography using a 
gradient (0 → 20% EtOAc/Pet. Spirit) to give 27 (1,012g, 76%) as yellow solid. TLC Rf 
(Pet. spirit:EtOAc, 60:40) = 0.62; Mp 192-194 ºC; 1H NMR (400 MHz, DMSO) δ 3.74 (s, 
3H, H21), 0.23 (s, 9H, H10); 13C NMR (100 MHz, DMSO) δ 165.9 (C7), 156.8 (C5), 155.2 
(C3), 112.6 (C2), 112.4 (C6), 100.2 (C8), 97.2 (C9), 51.2 (C21), 0.1 (C10); IR (neat) ν 
3406, 3377, 3324, 3188, 2950, 2147, 1687, 1649, 1247, 1093, 840 cm-1 HRESI-MS: m/z 







7.6.2 Synthesis of methyl 3,5-diamino-6-ethynylpyrazine-2-carboxylate 28 
To a stirring solution of TMS-acetylide 27 (264 mg, 1 mmol) 
in anhydrous THF (20 mL) in a 50 mL oven-dried round 
bottom flask under Ar was added TBAF (5 mL, 5 mmol). The 
reaction stirred at 0 °C while monitoring by TLC (Pet. spirit:EtOAc, 60:40). After 40 min 
the reaction was quenched by addition of water (20 mL) and allowed to warm to room 
teamperature with stirring for further 1 h. The mixture was extracted with EtOAc (3 x 30 
mL). The combined organic layers were washed with water and brine, dried over anhydrous 
MgSO4 and concentrated. The crude residue was purified by silica gel column 
chromatography using pet. spirit:EtOAc 60:40 to yield 28 (581 mg, 79%) as an yellow 
solid. Rf (pet. spirit:EtOAc, 60:40) = 0.65; Mp 204-206 ºC; 1H NMR (400 MHz, DMSO) δ 
7.27 (s, 2H, NH2), 6.95 (s, 2H, NH2), 4.35 (s, 1H, H10), 3.73 (s, 3H, H21); 13C NMR (100 
MHz, DMSO) δ 165.9 (C7), 157.0 (C5), 155.3 (C3), 112.2 (C2), 112.1 (C6), 83.4 (C8), 
79.1 (C9), 51.2 (C21); IR (neat) ν 3471, 3441, 3362, 3225, 2985, 2090, 1672, 1598, 1249, 
1094,  cm-1; HRESI-MS: m/z calculated for C8H8N4NaO2 [M + Na]+ 215.0539, found 
215.0575.  
 
7.6.3 One-Pot Sonogashira-tandem cyclisations 
Synthesis of methyl 3,5-diamino-6-(furo[3,2-b]pyridin-2-yl)pyrazine-2-carboxylate 29a 
To a stirring solution of methyl 3,5-diamino-6-
ethynylpyrazine-2-carboxylate 65 (100 mg, 0.52 mmol), 2-
iodopyridin-3-ol (230 mg, 1.04 mmol), 




mg, 5 mol%) and copper(I) iodide (4.9 mg, 5 mol%) in anhydrous DMF (12 mL) in a 50 
mL oven-dried round bottom flask under Ar was added piperidine (154 µL, 1.56 mmol). 
The reaction stirred at 60 °C for 1 h while monitoring by TLC (EtOAc). The reaction was 
quenched by addition of water (20 mL) and extracted with 1-butanol (2 x 15 mL). The 
combined organic layers were washed with water and brine, dried over anhydrous MgSO4 
and concentrated. The crude residue was purified by silica gel column chromatography 
using a gradient (50 → 80% EtOAc/Pet. Spirit) to yield 29a (60 mg, 40%) as a yellow solid. 
Rf (EtOAc) = 0.34; Mp 260-262 ºC; 1H NMR (400 MHz, DMSO-d6) δ 8.51 (dd, J = 4.7, 1.2 
Hz, 1H, H17), 8.05 (d, J = 8.3 Hz, 1H, H15), 7.33 (dd, J = 8.3, 4.8 Hz, 1H, H16), 7.26 (s, 
1H, H12), 3.82 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 166.2 (C7), 156.9 (C5), 155.5 
(C3), 153.6 (C11), 147.8 (C13), 146.8 (C14), 146.1 (C17), 118.9 (C16), 118.3 (C15), 117.9 
(C6), 112.7 (C2), 103.3 (C12), 51.4 (C21); IR (neat) ν 3543, 3413, 2936, 1681, 1260, 1109 
cm-1; HRESI-MS: m/z calculated for C13H12N5O3 [M + H]+ 286.0935, found 286.0940. 
 
Synthesis of methyl 3,5-diamino-6-(furo[3,2-c]pyridin-2-yl)pyrazine-2-carboxylate 29b 
To a stirring solution of methyl 3,5-diamino-6-
ethynylpyrazine-2-carboxylate 28 (100 mg, 0.52 mmol), 3-
iodopyridin-4-ol (138 mg, 0.62 mmol), 
(tetrakis(triphenylphosphine)-palladium dichloride (18.2 mg, 
5 mol%) and copper (I) iodide (4.9 mg, 5 mol%) in anhydrous DMF (12 mL) in a 50 mL 
oven-dried round bottom flask under Ar was added piperidine (154 µL, 1.5 mmol). The 
reaction stirred at 60 °C for 1 h while monitoring by TLC (EtOAc). The reaction was 




combined organic layers were washed with water and brine, dried over anhydrous MgSO4 
and concentrated. The crude residue was purified by silica gel column chromatography 
using a gradient (EtOAc: pet. spirit 50 → 80%) to yield 29b (69 mg, 46%) as a yellow solid. 
Rf (EtOAc) = 0.3; Mp 261-263 ºC; 1H NMR (500 MHz, DMSO-d6) δ 8.95 (s, 1H, H18), 
8.46 (s, 1H, H16), 7.71 (d, J = 5.4 Hz, 1H, H15), 7.26 (d, J = 0.9 Hz, 1H, H12), 7.19 (s, 2H, 
NH2), 3.80 (s, 3H, H21); 13C NMR (125 MHz, DMSO) δ 166.2 (C7), 157.9 (C14), 155.5 
(C5), 153.9 (C11), 153.6 (C3), 144.1 (C16), 143.7 (C18), 125.7 (C13), 118.0 (C6), 112.5 
(C2), 107.3 (C15), 101.0 (C12), 51.4 (C21); IR (neat) ν 3486, 3397, 3155, 2937, 1671, 
1645, 1442, 1260, 820 cm-1; HRESI-MS: m/z calculated for C13H12N5O3 [M + H]+ 
286.0935, found 286.09336.   
 
Synthesis of methyl 3,5-diamino-6-(5-(tert-butyl)benzofuran-2-yl)pyrazine-2-
carboxylate 29c 
To a stirring solution of methyl 3,5-diamino-6-
ethynylpyrazine-2-carboxylate 28 (150 mg, 0.78 mmol), 
4-(tert-butyl)-2-iodophenol (258 mg, 0.93 mmol), 
(tetrakis(triphenylphosphine)-palladium dichloride 
(27.4 mg, 5 mol%) and copper(I) iodide (7.4 mg, 5 mol%) in anhydrous DMF (15 mL) in a 
50 mL oven-dried round bottom flask under Ar was added piperidine (200 µL, 2.3 mmol). 
The reaction stirred at 60 °C for 1.5 h while monitoring by TLC (pet. spirit:EtOAc, 40:60). 
The reaction was quenched by addition of water (25 mL) and extracted with 1-butanol (2 x 
20 mL). The combined organic layers were washed with water and brine, dried over 




chromatography using a gradient (0 → 30% EtOAc/Pet. spirit with 5% CH2Cl2) to yield 
29c (66 mg, 25%) as a yellow solid. Rf (EtOAc) = 0.3; Mp 161-162 ºC; 1H NMR (400 MHz, 
CDCl3) δ 7.59 (d, J = 1.8 Hz, 1H, H18), 7.41 (d, J = 8.7 Hz, 1H, H15), 7.36 (dd, J = 8.7, 
1.9 Hz, 1H, H16), 7.26 (m, 1H, H12), 3.95 (s, 3H, H21), 1.38 (s, 9H, H23); 13C NMR (100 
MHz, CDCl3) δ 166.8 (C7), 155.0 (C5), 153.9 (C11), 152.7 (C3), 152.5 (C14), 146.6 (C17), 
128.0 (C13), 122.4 (C16), 120.7 (C6), 117.3 (C18), 114.3 (C2), 110.3 (C15), 104.4 (C12), 
52.1 (C21), 31.8 (C23); IR (neat) ν 3398, 3363, 3189, 2950, 1685, 1636, 1436, 1113, 803 
cm-1; HRESI-MS: m/z calculated for C18H21N4O3 [M + H]+ 341.1608, found 341.1614. 
 
Synthesis of methyl 3,5-diamino-6-(5,7-difluorobenzofuran-2-yl)pyrazine-2-
carboxylate 29d 
To a stirring solution of methyl 3,5-diamino-6-
ethynylpyrazine-2-carboxylate 65 (100 mg, 0.52 mmol), 
2,4-difluoro-6-iodophenol (265 mg, 1.04 mmol), 
(tetrakis(triphenylphosphine)-palladium dichloride (18.2 
mg, 5 mol%) and copper (I) iodide (4.9 mg, 5 mol%) in anhydrous DMF (12 mL) in a 50 
mL oven-dried round bottom flask under Ar was added piperidine (154 µL, 1.5 mmol). The 
reaction stirred at 60 °C for 1 h while monitoring by TLC (EtOAc). The reaction was 
quenched by addition of water (20 mL) and extracted with 1-butanol (2 x 15 mL). The 
combined organic layers were washed with water and brine, dried over anhydrous MgSO4 
and concentrated. The crude residue was purified by silica gel column chromatography 
using a gradient (20 → 40% EtOAc/Pet. spirit with 5% CH2Cl2) to yield 29d (95 mg, 57%) 




(dd, J = 6.8, 2.3 Hz, 1H, H18), 7.28 (m, 1H, H16), 7.24 (d, J = 2.3 Hz, 1H, H12), 7.08 (s, 
2H, H19), 3.80 (s, 3H, H21); 13C NMR (100 MHz, DMSO) δ 166.2 (C7), 156.8 (d, J = 9 
MHz, C17), 155.7 (C11), 155.6 (C5), 153.6 (C3), 145.0 (d, J = 15.1 MHz, C15), 137.1 
(C14), 131.8 (d, J = 13.1 MHz, C13), 117.9 (C6), 112.5 (C2), 104.2 (d, J = 6 MHz, C12), 
102.7 (d, J = 28.2 MHz, C18), 99.8 (d, J = 51.5 MHz, C16), 51.4 (C21); IR (neat) ν 3542, 
3433, 3176, 2954, 1680, 1530, 1109 cm-1; HRESI-MS: m/z calculated for C14H11F2N4O3 [M 
+ H]+ 321.0794, found 321.0799.   
 
7.7 Synthesis of benzofuran amiloride analogues 30a-30d   
Synthesis of 3,5-diamino-N-carbamimidoyl-6-(furo[3,2-b]pyridin-2-yl)pyrazine-2-
carboxamide 30a 
The compound was produced by General Method C 
using methyl ester (50 mg, 0.17 mmol) with (3 mL) 
of free guanidine. The reflux condenser was attached, 
and the mixture was heated to 50 °C for overnight. 
The reaction was quenched by addition of 1-butanol (10 mL) and the mixture was diluted 
with H2O (15 mL) and, combined twice organic fractions were washed brine, dried over 
anhydrous MgSO4 and concentrated to afford guanidine 30a (28 mg, 51%) as a yellow 
solid. Mp 203-205 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.52 (s, 1H, H8), 8.74 (s, 2H, 
H10'), 8.55 (dd, J = 4.8, 1.3 Hz, 1H, H17), 8.38 (s, 2H, H10), 8.09 (dd, J = 8.3, 1.1 Hz, 1H, 
H15), 7.83 (d, J = 0.8 Hz, 1H, H12), 7.62 (s, 2H, NH2), 7.37 (dd, J = 8.3, 4.8 Hz, 1H, H16); 
13C NMR (125 MHz, DMSO) δ 165.8 (C7), 157.4 (C13), 156.1 (C5), 155.1 (C9), 154.8 




(C2), 104.6 (C12); IR (neat) ν 3302, 3192, 1670, 1625, 1209, 1126, 795 cm-1; Anal HPLC 





The compound was produced by General Method C 
using methyl ester (51 mg, 0.17 mmol) with (3 mL) of 
free guanidine. The reflux condenser was attached, and 
the mixture was heated to 75 °C for 2 h. The reaction 
was quenched by addition of 1-butanol (10 mL) and the mixture was diluted with H2O (15 
mL) and, combined twice organic fractions were washed brine, dried over anhydrous 
MgSO4 and concentrated to afford guanidine 30b (47 mg, 85%) as a yellow solid. Mp 239-
240 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.65 (s, 1H, H8), 9.27 (s, 1H, H18), 8.75 (s, 2H, 
H10'), 8.70 (d, J = 6.0 Hz, 1H, H16), 8.61 (s, 2H, H10), 8.11 (d, J = 6.1 Hz, 1H, H15), 7.84 
(s, 1H, H12); 13C NMR (125 MHz, DMSO) δ 165.5 (C7), 159.9 (C14), 156.2 (C11), 155.7 
(C5), 154.8 (C9), 154.5 (C3), 140.0 (C16), 139.9 (C18), 126.4 (C13), 117.1 (C6), 112.1 
(C2), 109.4 (C15), 102.1 (C12); IR (neat) ν 3500, 3363, 3311, 2303, 1672, 1179, 1132, 798 
cm-1; Anal HPLC (tr 7.6 min); HRESI-MS: m/z calculated for C13H13N8O2 [M + H]+ 






Synthesis of 3,5-diamino-6-(5-(tert-butyl)benzofuran-2-yl)-N-carbamimidoyl 
pyrazine-2-carboxamide 30c 
The compound was produced by General Method 
C using methyl ester (59 mg, 0.17 mmol) with (3 
mL) of free guanidine. The reflux condenser was 
attached, and the mixture was heated to 80 °C for 
3 h. The reaction was quenched by addition of 1-butanol (10 mL) and the mixture was 
diluted with H2O (15 mL) and, combined twice organic fractions were washed brine, dried 
over anhydrous MgSO4 and concentrated to afford guanidine 30c (34 mg, 53%) as a white-
yellow solid. Mp 236-238 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H, H8), 8.75 (s, 
2H, H10'), 8.48 (s, 2H, H10), 7.63 (d, J = 1.9 Hz, 1H, H18), 7.61 (d, J = 8.7 Hz, 1H, H15), 
7.56 (d, J = 2.9 Hz, 1H, H12), 7.53 (s, 2H, NH2), 7.42 (dd, J = 8.7, 2.0 Hz, 1H, H16), 1.35 
(s, 9H, H23); 13C NMR (125 MHz, DMSO) δ 165.4 (C7), 155.3 (C5), 154.6 (C9), 154.2 
(C3), 152.8 (C11), 152.0 (C14), 145.9 (C17), 127.4 (C13), 122.2 (C16), 119.3 (C6), 116.6 
(C18), 110.9 (C15), 110.7 (C2), 104.5 (C12), 34.3 (C22), 31.4 (C23); IR (neat) ν 3311, 
3183, 2960, 1696, 1515, 1134, 800 cm-1; Anal HPLC (tr 14 min); HRESI-MS: m/z 









 The compound was produced by General Method C 
using methyl ester (93 mg, 0.29 mmol) with (3 mL) 
of free guanidine. The reflux condenser was attached, 
and the mixture was heated to 80 °C for 2.5 h. The 
reaction was quenched by addition of 1-butanol (10 mL) and the mixture was diluted with 
H2O (15 mL) and, combined twice organic fractions were washed brine, dried over 
anhydrous MgSO4 and concentrated to afford guanidine 30d (37 mg, 37%) as a yellow 
solid. Mp 252-254 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.31 (dd, J = 8.5, 2.2 Hz, 1H, 
H18), 7.22 (dt, J = 12.2, 2.4 Hz, 1H, H16), 7.14 (d, J = 2.9 Hz, 1H, H12), 6.50 (s, 2H, NH2); 
13C NMR (100 MHz, DMSO) δ 173.6 (C7), 158.1 (d, J = 9.1 MHz, C17), 157.5 (C11), 
156.8 (d, J = 10.1 MHz, C9), 154.9 (C5), 151.9 (C3), 144.9 (d, J = 15.1 MHz, C15), 136.7 
(d, J = 11.1 MHz, C14), 132.1 (d, J = 18.1 MHz, C13), 122.7 (C6), 102.9 (d, J = 20.2 MHz, 
C18), 102.4 (d, J = 4 MHz, C12), 99.6 (d, J = 20.2 MHz, C16); IR (neat) ν 3303, 3184, 
3100, 1672, 1601, 1519, 1174, 1125 cm-1; Anal HPLC (tr 13.7 min); HRESI-MS: m/z 
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The legend explaining HMBC spectrum of 23i in DMSO-d6. 
